CCRL2, A PUTATIVE CHEMOTACTIC RECEPTOR, PARTICIPATES IN THE LUNG DENDRITIC CELL TRAFFICKING by S. GONZALVO FEO
   UNIVERSITÀ DEGLI STUDI DI MILANO 
SCIENZE BIOMEDICHE CLINICHE E SPERIMENTALI 
DIPARTIMENTO DI MEDICINA TRASLAZIONALE 
 
  
CORSO DI DOTTORATO 
PATOLOGIA E NEUROPATOLOGIA SPERIMENTALE 
CICLO XXIII 
 
 
 
CCRL2, A PUTATIVE CHEMOTACTIC RECEPTOR, PARTICIPATES 
IN THE LUNG DENDRITIC CELL TRAFFICKING 
Settore scientifico disciplinare: MED/04 
 
 
 
 
 
Dottorando: Safiyé Gonzalvo Feo 
 
 
 
 
Tutore: Prof. Antonio Sica 
Coordinatore del dottorato: Prof. Alberto Mantovani 
 
 
 
 
 
A.A. 2009-2010 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A mis brujas del más acá y el más allá 
Acknowledgments 
 
I thank all those who have positively influenced my life in these five years. Even to 
those who have welcomed me with a magical “Buongiorno” on a typical cloudy day in 
Milan. 
A special thanks to Annunciata and Annalisa, who taught me everything 
wholeheartedly with much patience. Thanks for always being present not only at work. I 
thank Silvano for showing me that an iron hand can help (not always) to improve 
oneself. Thanks also for accepting me in your group, not only for the professional 
opportunity... Finally, I have to thank my ex-boss, Macias, I’ll never forget his proof of 
friendship in  critical moments between the past and the present. 
Of course, (and fortunately!) I don’t have to say: Thank you, only to “I capi”. I have 
a very special Thanks for the 3 “streghette”: Nadia, Marina and Barbara. Strict and 
sweet at the same time, always maternal. To Garlanda’s group (new and old), the group 
that adopted me…. Really they had no choice, it was the result of a random spatial 
distribution… but it worked: Ragazzi, tout le plaisir a été pour moi. To my real group, 
“I ragazzi di Brescia” for always being available. 
Thanks also to my roomates of Via Sardegna, 7, some of them are now more than 
roomates, and all of them have been great company in the long and cold Milan nights. 
To my friends, the old ones, who have always been close no matter how far. To my new 
friends who have made me understand that it is possible to find a home anywhere. Last 
but not least, I thank all my family members , including those I have just rediscovered 
here. A special thanks to my wonderful mum, who taught me that happiness and respect 
for others are sacred obligations, and of course, to “mi Juanito”. 
 
Summary 
Summary  
 
CCRL2 (chemokine CC motif receptor-like 2) is an orphan heptahelic serpentine 
receptor that is rapidly induced in dendritic cells (DC) during maturation. CCRL2 
shares the highest homology with the inflammatory chemokine receptors CCR1 and 
CCR5 and the ligand, chemerin, with the chemotactic receptor ChemR23. Although 
both CCRL2 and ChemR23 are expressed by DC, they show an opposite regulation 
during DC maturation. In addition, CCRL2 is apparently unable to signal in response to 
chemerin and was shown to function as a presenting protein of chemerin to ChemR23-
expressing cells. 
In order to evaluate the biological relevance of this receptor, we used CCRL2 
deficient mice in an established model of allergen-induced airway inflammation in 
which DC are known to play a crucial role. CCRL2-/- mice were protected in a model 
of OVA-induced airway inflammation with reduced leukocyte recruitment in the BAL 
(eosinophils and mononuclear cells) and reduced production of the Th2 cytokines IL-4 
and IL-5 and chemokines CCL11 and CCL17. CCRL2-/- mice showed normal 
recruitment of circulating DC into the lung but a defective trafficking of antigen-loaded 
lung DC to mediastinal lymph nodes. This defect was associated to a reduction in lymph 
node cellularity and reduced priming of Th2 response. Chemerin was expressed by 
mouse lung vascular endothelial cells and by lymphatic endothelial cells and was found 
to be upregulated by retinoic acid. Retinoic acid stimulated endothelial cells (EC) 
promoted the transmigration of DC in a ChemR23-dependent manner, suggesting a role 
for membrane associated chemerin.  
The results here reported define chemerin as a new relevant protein for DC 
trafficking across lymphatic and blood endothelial barriers. In addition, these results 
highlight a nonredundant role for CCRL2 in the migration of lung DC and in the 
induction of Th2-polarized airway allergic inflammation. Altogether, this study 
proposes the CCRL2/chemerin axis as a new potential target for therapeutic strategies 
aimed at controlling lung hypersensitivity. 
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1. Introduction 
 
1.1. Cell migration 
Migration represents a crucial cellular function contributing to many important 
physiological and pathological processes. It plays a fundamental role during 
embryogenesis, and defects in this process can result in pathological outcomes such as 
congenital neurological defects. In the adult, cell migration is a key player in the 
organization of an effective immune response, in the repair of injured tissues and in 
angiogenesis, to cite a few examples. Deregulation of migration can lead to many types 
of pathological disorders including cardiovascular illnesses, chronic inflammatory 
diseases and metastasis 1, 2. An important aspect of cell motility is the ability of cells to 
respond to directional cues with oriented movement. Gradients of diffuse chemicals 
give rise to directional cell migration, a phenomenon known as chemotaxis 3, 4. 
Continuous trafficking of cells of immune cells throughout the body requires not only 
locomotion and chemotaxis, but also the ability to move out of the circulation toward 
target tissues where they exert their effector functions. 
 
1.1.1. Extravasation  
The vascular and lymphatic circulatory systems are lined by monolayers of 
endothelial cells (EC) that grow on an ablumenal layer of extracellular matrix (the 
basement membrane); these cells form organized intercellular junctional zones that 
include adhesion junctions, tight junctions and gap junctions 5-7 In this way, the 
endothelium serves as the principal barrier between the circulation and the underlying 
tissues. Leukocytes have to cross these barriers to reach its target tissues by a process 
known as extravasation. 
 
1.1.1.1. Leukocyte extravasation across vascular endothelium 
An inflammatory response is initiated by the extravasation of leukocytes across the 
blood vessel wall. This process involves a multistep cascade of successive interactions 
of adhesion receptors between leukocytes and EC 8, 9. 
Circulating leukocytes in the bloodstream have to establish a contact (tethering) with 
the vascular wall and adhere to it, while withstanding the haemodynamic shear force. 
Tethering is largely mediated by selectins, a type 1 transmembrane glycoproteins. 
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Although interaction of endothelial E and P-selectin (expressed on EC and activated by 
proinflammatory stimuli) with their corresponding ligands on the leukocytes (L-
selectin, PSGL1 (P-Selectin glycoprotein ligand-1)) are of low affinity, the high 
frequency of association-dissociation of interactions allows them to mediate labile and 
transient tethers between leukocytes and the endothelium 10, 11. Tethering slows down 
the velocity of leukocytes in the bloodstreams and allows them to roll over the 
endothelial surface. 
The slow rolling leukocytes encounter chemokines bound to glycosaminoglycans on 
the apical endothelial surface. Chemokines act by signaling via the G protein coupled 
receptor (GPCR) located in the microvilli of the leukocyte, inducing multiple 
conformational changes in leukocyte integrins 12-15, a family of heterodimeric receptors 
that actively changes their adhesive properties, leading to firm adhesion to the 
endothelium 15, 16. The most relevant integrins for leukocyte adhesion to the 
endothelium are LFA-1 (lymphocyte function-associated antigen 1), Mac-1 and VLA-4 
(very late antigen 4), while its main ligands on EC are VCAM-1 (vascular cell adhesion 
molecule 1) and ICAM-1 (intercellular adhesion molecule 1), both members of the 
immunoglobulin superfamily 17, 18. ICAM-1 is scarcely expressed on the quiescent 
endothelium, whereas the expression of both molecules is induced after cell activation 
by proinflammatory cytokines 19, 20. The presence of specific chemokines in different 
vascular beds helps orchestrate the selective recruitment of different leukocyte 
subpopulations to the inflammatory foci or to the secondary lymphoid organs 21. 
After activation the integrins regulate different effectors of myosin contractility, actin 
remodeling GTPases, and molecules implicated in the regulation of the microtubule 
network leading to a marked morphological change. The rounded circulating cells are 
transformed into cells with polarized morphology, in which at least two regions can be 
identified: the cell front and the cellular uropod 22. The polarization of the leukocytes 
allows the cell to coordinate the intracellular forces to produce the necessary cell 
crawling during the extravasation process 23. Lymphocytes undergo ICAM-1 dependent 
lateral migration on the luminal surface of the endothelium, a movement that seems to 
allow then to sek out sites that are permissive for diapedesis (passage through intact 
capillary walls) 24, 25. Once the leukocytes have reached an appropriate site for 
transmigration (preferably the intercellular junctions), they deploy exploratory 
pseudopods between two adjacent EC. The pseudopods then transform into a lamella 
that moves across the open space of the monolayer. During this process the LFA-1 
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molecule has a predominant role. This molecule is quickly relocalized to form a ring-
shaped cluster at the contact interface between the leukocyte and endothelium, where it 
interacts with ICAM-1 26 or JAM-A (junctional adhesion molecule A) 27. When the 
transmigration process is over LFA-1 is finally concentrated in the uropod 27. Other 
proteins localized at EC contacts, implicated in the transmigration process are ICAM-2, 
JAM-B, JAM-C, PECAM-1 (platelet endothelial cell adhesion molecule-1), ESAM 
(endothelium selective adhesion molecule) and CD99, many of which are able to 
interact both homophilically and heterophilically maintaining the interendothelial 
junctions or leukocyte-endothelial interactions 28, 29. 
Diapedesis can occur also via the formation of a transcellular pore directly through 
an individual EC (transcellular diapedesis). This process takes place preferentially in the 
microvasculature, the blood brain barrier, or high endothelial venules (HEV) of the 
secondary lymphoid organs rather than in macrovasculature 30-32. 
 
1.1.1.2. Leukocyte extravasation across lymphatic endothelium 
During leukocyte trafficking they encounter also lymphatic endothelial barriers. A 
classical example is represented by the migration of dendrititc cells (DC) from 
peripheral tissues to draining lymph nodes. Current knowledge of the mechanisms 
involved in leukocyte trans-lymphatic migration is extremely sparse, however the few 
evidences available indicate that key events in the process are mediated by the same 
adhesion molecules that regulate blood vascular transmigration.  
E-selectin is transiently upregulated on the surface of inflamed lymphatic 
endothelium 33. E-selectin could have some role in the initial interaction between 
leukocytes and lymphatic endothelium, however since has been calculated that a 
leukocyte only has to contend with a shear stress of approximately 0.08 dynes/cm2 (as 
opposed to 1–4 dynes/cm2 in blood capillaries 34, 35 and considering that its engagement 
can trigger signals in selectin-expressing cell and the ligand-expressing cell (e.g. 
integrin’s activation), the primary role of lymphatic E-selectin seems to be related to 
this second function, been a necessary prerequisite for VCAM-1 and ICAM-1 mediated 
adhesion. Similar to blood vascular endothelium, resting lymphatic EC express low 
levels of both ICAM-1 and ICAM-2, but not VCAM-1 33. However, after stimulation 
with TNF-  (tumor necrosis factor), both ICAM-1 and VCAM-1 are both upregulated. 
Also in lymphatic EC ICAM-1 and VCAM-1 mediate leukocyte adhesion steps 33 
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DC show a relatively slow rate of transmigration across lymphatic EC by comparison 
with blood vessel endothelium (requiring hours rather than minutes) and a delay (1–3 h) 
between initial adhesion and the onset of transmigration 33. Furthermore, the early 
stages of adhesion are insensitive to blockade by ICAM-1 and VCAM-1 antibodies. 
Possible explanations for these phenomena include pre-binding to other receptors, such 
as ICAM-2, successive rounds of transmigration events by DC or a lag period due to a 
requirement for chemokine-induced activation of integrins expression on DC 33, 36 
Similar observations for intercellular diapedesis across lymphatic and vascular EC 
have been reported, although in the case of lymphatic EC, both ICAM-1 and VCAM-1 
appear to be present on both surfaces, whereas they are more polarized to the apical 
surface in blood EC 33. Some studies suggests that leukocytes utilize also the 
transcellular pathway to transmigrate across lymphatic vessels, however it is not yet 
known whether it occurs in vivo 37, 38. 
Despite the commonalities between endothelial lymphatic and vascular cells in terms 
of molecules expressed and the fact that they are morphologically indistinguishable, 
they are nevertheless specialized and adapted for their distinct functions, expressing 
some molecules characteristic of each kind of endothelium. Some lymphatic 
endothelial–specific receptors with a possible roles in regulating leukocyte adhesion and 
transmigration are mannose receptor, podoplanin and LYVE-1 (lymphatic vessel 
endothelial receptor 1) 
Mannose receptor is expressed in lymphatic endothelium and in lymph node sinuses, 
where they have been shown to bind leukocyte-expressed L-selectin. Thus, this receptor 
may assist in adhesion of L-selectin+ lymphocytes prior to transmigration into afferent 
lymphatic vessels. Prodoplanin represents one of the most highly expressed genes in 
lymphatic endothelium 11, 12. It contributes to the active recruitment of mononuclear 
leukocytes by lymphatic EC through its predominant expression on the basolateral 
surface, where it forms a complex with CCL21 that is subsequently shed into the 
stroma, thus establishing a peri-lymphovascular CCL21 gradient 39 . The key role that 
podoplanin plays in cell adhesion, migration, and vessel formation have been indicated 
by studies on podoplanin−/− mice, which exhibited cutaneous lymphedema, dilated 
cutaneous intestinal lymphatic vessels, and impaired lymphatic transport 40. 
Furthermore, overexpression of podoplanin in vascular EC has been shown to promote 
the formation of elongated cell extensions and to increase cell adhesion, migration and 
tube formation 40. The mechanisms through which podoplanin performs these functions 
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appear to be dependent upon interactions between a juxtamembrane cluster of basic 
amino acids in the short cytoplasmic tail of podoplanin and members of the ERM (ezrin, 
radixin, moesin)family 41. ERM family proteins in turn bind to the cortical actin 
cytoskeleton and participate in a RhoA GTPase signal transduction pathway that 
regulates cell motility and adhesion. As podoplanin expression is concentrated at actin-
rich microvilli and plasma membrane projections and can stimulate actin rearrangement, 
it is possible that this small membrane mucin may also play a role in regulating 
transcellular transmigration of cells across a monolayer of podoplanin-expressing cells, 
such as lymphatic endothelia. LYVE-1 is another abundant surface component of 
lymphatic EC 42, 43. The similarity in amino acid sequence with the inflammatory 
homing receptor CD44 suggests that LYVE-1 might play an analogous role in 
lymphatic homing. Confocal microscopic observation that LYVE-1 is concentrated 
within the cleft-like openings of overlapping interendothelial junctions in initial 
lymphatics and only sparse within adjacent tight junction structures 5 is consistent with 
a role for the receptor in maintaining some aspect of junctional permeability.  
  
1.1.2. Chemotactic factors 
Every tissue site appears to be unique in its chemotactic property for immune cells. 
The chemotactic property of a tissue site is determined by its expression profile of 
chemotactic molecules. Chemotactic molecules include the chemokine protein family, 
inflammatory lipid mediators such as leukotrienes and prostaglandins, antimicrobial 
peptides such as defensins and chemerin, and cytokines. Also, microbial products such 
as N-formilmetionil-leucil-fenilalanina (fMLP) and complement proteins such as C3a 
and C5a can act as potent chemoattractants. Together, these chemotactic molecules 
form the greater chemotactic network important for precise and robust immune cell 
trafficking.  
 
1.1.2.1. Chemokines 
Chemokines are chemotactic cytokines that activate specific receptors expressed on 
cellular membranes. Chemokine receptors sense a chemical gradient and direct cells 
toward the gradient direction. The principal targets of chemokines are leukocytes and, 
as motility is an essential part of their function, chemokines play pivotal roles in 
coordinating leukocyte navigation. However, chemokines are not only simple 
chemotactic factors.  
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Accumulating evidence suggests that chemokines are important regulators in 
development, homeostasis and pathophysiological processes associated with 
osteoporosis 44, obesity and insulin resistance 45, viral infections 46, immune responses 
47
, mobilization of progenitors to the bone marrow 48, autoimmune encephalomyelitis. 
Moreover, nonhematopoietic elements, including epithelial cells, fibroblasts, and 
vascular elements have been shown to express receptors for and respond to CC 
chemokines. 
The chemokine family comprises about 50 members (Table. 1); most are low 
molecular weight molecules (8-10 kDa), all consisting of roughly 70-130 amino acids, 
with four conserved cysteines 49-53. Two main subfamilies, CXC and CC chemokines 
are distinguished, according to the position of the first two cysteines, which are 
separated by one amino acid (CXC) or adjacent (CC). The cysteines form two disulfide 
bonds, which confer to the chemokines their characteristic three-dimensional folding, 
with a flexible N-terminal loop connected to the more structured core of the molecule 
(3β-sheets) and a terminal α-helix. The CXC chemokine family can be further 
subdivided according to the presence or absence of a conserved tripeptide motif 
glutamic acid-leucine-arginine (ELR) at the N-terminus of the protein, before the CXC 
domain. This motif is not simply structural but seems to be linked to function, giving 
specificity for neutrophil chemotaxis and angiogenesis. The two members of the C (γ) 
family, lymphotactin-α (XCL1) and lymphotactin-β (XCL2), have two instead of the 
usual four conserved cysteines and fractalkine (CX3CL1) has three amino acids 
between the first two cysteines, giving rise to the one-member CX3C (δ) subfamily. 
There are differences in the genomic organization of the chemokine families. Many 
of the genes for the CXC chemokines, which act on neutrophils are located on 
chromosome 4, while the majority of the genes for the CC chemokines, which act on 
monocytes are clustered on chromosome 17 54. These genes may have arisen by 
duplication and divergence from primordial chemokine genes but remained in clusters, 
supporting the idea that their functions are to some extent related. The remaining 
chemokines have a different chromosomal locations with respect to these two main 
clusters. These genes are more conserved between species and have highly specific 
functions, suggesting that they are older in evolutionary terms 54. 
Like cytokines, chemokines are secreted proteins; only two of them, CXCL16 and 
CX3CL1 are synthesized with a typical transmembrane sequence, which anchors them 
to the cell membrane.
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Table 1. Chemokine structural classification (adapted from Allavena et al, 2005) 
Chemokine Ligands 
 
Other Names 
 
Chemokine Receptors 
 
CXC Subfamily 
CXCL1 
CXCL2 
CXCL3 
CXCL4 
CXCL5 
CXCL6 
CXCL7 
CXCL8 
CXCL9 
CXCL10 
CXCL11 
CXCL12 
CXCL13 
CXCL14 
CXCL15 
CXCL16 
C Subfamily 
XCL1 
XCL2 
CX3C Subfamily 
CX3CL1 
CC Subfamily 
CCL1 
CCL2 
CCL3 
CCL4 
CCL5 
CCL6 
CCL7 
CCL8 
CCL9/10 
CCL11 
CCL12 
CCL13 
CCL14 
CCL15 
CCL16 
CCL17 
CCL18 
CCL19 
CCL20 
CCL21 
CCL22 
CCL23 
CCL24 
CCL25 
CCL26 
CCL27 
CCL28 
 
GROα/MGSA-α 
GROβ/MGSA-β 
GROγ/MGSA-γ 
PF4 
ENA-78 
GCP-2 
NAP-2 
IL-8 
Mig 
IP-10 
I-TAC 
SDF1 α/β 
BCA-1 
BRAK/bolekine 
Murine lungkine 
Bonzo ligand 
 
Lymphotactin/SCM-1α/ATAC 
SCM-1β 
 
Fractalkine 
 
I-309 
MCP-1/MCAF/TDCF 
MIP-1α/LD78α 
MIP-1β 
RANTES 
C10 
MCP-3 
MCP-2 
MIP-1γ 
Eotaxin 
Murine MCP-5 
MCP-4 
HCC-1 
HCC-2/Lkn-1/MIP-1δ 
HCC-4/LEC/LCC-1 
TARC 
DC-CK1/PARC/AMAC-1 
MIP-3β/ELC/exodus-3 
MIP-3α/LARC/exodus-1 
6Ckine/SLC/exodus-2 
MDC/STCP-1 
MPIF-1/CKβ8-1 
Eotaxin-2/MPIF-2 
TECK 
Eotaxin-3 
CTACK/ILC 
MEC 
 
CXCR2  
CXCR2R 
CXCR2 
CXCR3B 
CXCR2 
CXCR1, CXCR2 
CXCR2 
CXCR1, CXCR2 
CXCR3A 
CXCR3A 
CXCR3A 
CXCR4/ CXCR7 
CXCR5 
Unknown 
Unknown 
CXCR6 
 
XCR1 
XCR1 
 
CX3CR1 
 
CCR8 
CCR2 
CCR1, CCR5 
CCR5, CCR8 
CCR1, CCR3, CCR5 
CCR1 
CCR1, CCR2, CCR3, CCR5 
CCR1, CCR2, CCR3, CCR5 
CCR1 
CCR3 
CCR5 
CCR1, CCR2, CCR3 
CCR1, CCR5 
CCR1, CCR3 
CCR1 
CCR4, CCR8 
Unknown 
CCR7 
CCR6 
CCR7 
CCR4 
CCR1 
CCR3 
CCR9 
CCR3 
CCR10 
CCR10 
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Chemokines can also be grouped according to their function; in fact, they can be 
produced by leukocytes and tissue cells either constitutively or after induction, thus a 
former classification grouped chemokines into the functional subfamilies termed 
“inflammatory” and “homeostatic” (Fig. 1). Homeostatic chemokines usually guide the 
trafficking of leukocytes under steady state conditions, during immune surveillance of 
healthy peripheral tissues and control the architecture of secondary lymphoid organs; by 
contrast, inflammatory chemokines are produced and control the recruitment of effector 
leukocytes under conditions of inflammation, immune reactions, tissue injury and 
tumors 55. 
 
Constitutive
Normal
traffick Neoplasia
Infection
Inflammation
Immunity
CCL14
CCL16
CCL21
CCL25
CCL27
CCL18
CCL15
CCL17
CCL19
CCL20
CCL22
CCL2
CCL3L1 CCL4
CCL3
CCL1
CCL5 CCL7 CCL8
CCL11 CCL13
CCL23
CCL28 CCL24CCL26
CXCL12
CXCL13
CX3CL1
XCL1 XCL2 CXCL1
CXCL2 CXCL3CXCL5
CXCL8 CXCL7
CXCL9
CXCL11
CXCL10
CCL2
Inducible
 
 
Figure 1. Chemokine functional classification. Chemokines can be classified as 
constitutive, regulating normal leukocyte trafficking, or inducible, associated to 
inflammatory and immune responses. Chemokine production by tumor cells may reflect 
constitutive gene expression or activation by autocrine/paracrine loops (Adapted from 
Locati et al, 2002)55 
 
Many chemokines have broad target cell selectivity. In particular, expression of 
inducible chemokines can be elicited by almost any stimulus that alters cellular 
homeostasis; they can be thought of as vertebrate cellular “SOS response” that recruits 
leukocytes to areas of tissue injury. Recent findings, however, indicate that several 
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chemokines cannot be assigned unambiguously to either one of the two functional 
categories and therefore are referred to as “dual function” chemokines 56. Dual function 
chemokines participate in immune defense functions (e.g. are upregulated under 
inflammatory conditions, examples include the interferon (IFN)-inducible chemokines 
CXCL9, CXCL10, CXCL11) and also target non-effector leukocytes, including 
precursors and resting mature leukocytes, at sites of leukocyte development and 
immune surveillance (for instance CCL1, CCL25, CXCL16) 56. Many dual function 
chemokines are highly selective for lymphocytes and have a role in T-cell development 
in the thymus, as well as in T-cell recruitment to inflammatory sites. Remarkably, dual-
function and homeostatic chemokines usually bind to a single receptor, expressed 
mainly on lymphoid cells, in contrast to inflammatory chemokines, which bind to 
multiple receptors. 
In general, different chemokine classes tend to exhibit different ranges of leukocyte 
specificity; schematically, CXC-ELR+ chemokines (ELR is a highly conserved amino 
acid motif: Glu-Leu-Arg) are the major chemoattractants for neutrophils, whereas CXC-
ELR- chemokines attract lymphocytes and monocytes but have little or no action on 
neutrophils. Chemokines belonging to the CC family act primarily on monocytes, but 
they can also attract lymphocytes, natural killer (NK) cells, basophils and eosinophils. 
CX3C and C chemokines act on lymphoid cells (T cells and NK cells) and fractalkine is 
also active on monocytes. Despite this specificity, redundancy in the action on target 
cells is an intriguing feature of chemokines: no chemokine is uniquely active on one 
leukocyte population and usually a given leukocyte population has receptors for and 
responds to different chemokines. This confers robustness to the system, as variations in 
the amount or quality of any chemokine or receptor would have bearable consequences 
for basal trafficking of leukocytes 57-59. Moreover, the interaction of chemokines with 
their receptors is characterized by considerable promiscuity. Most ligands interact with 
more than one receptor and most known receptors have been reported to interact with 
multiple ligands; only CXCR4, CXCR5, CXCR6, CCR6, CCR9 and CX3CR1 bind to 
only one chemokine. Probably all cell types can produce chemokines under appropriate 
conditions and usually, a cell produces many chemokines concomitantly in response to 
the same stimulus (polyspeirism) Once again, this receptor promiscuity and 
polyspeirism contribute to the robustness of the chemokine network, essential features 
which act to retain the chemokine system function, even if genetic or epigenetic 
alterations affecting individual components occur. 
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1.1.2.2. Nonchemokine chemotactic factors 
A group of heterogeneous molecules different from chemokines has been described 
to present also chemotactic activity. These include bacterial components, bioactive 
lipids and signals of “tissue danger”. Among lipid mediators, leukotrienes 60 and 
prostaglandins 61 have been shown to induce directional migration of immune cells. 
Leukotriene B4 (LTB4), the most important chemoatractant produced during the early 
phases of inflammation is able to recruit neutrophils, eosinophils, Tcells and DC 19  
while prostaglandin D2 (PGD2) induces chemotaxis of eosinophils, basophils, and T-
helper type 2 (Th2) cells 62. Lysophospholipids, including lysophosphatidic acid and 
sphingosine 1-phosphate (S1P), also show direct chemotactic activity or modulate 
chemotaxis to other chemoattractants 22, 23. Some defensins (small cationic and Cys-rich 
peptides with molecular masses ranging from 3 to 5 kD), such as defensin-1 and 
defensin-2 produced by activated neutrophils, induce chemotaxis of T cells 63 and DC 
64
. Complement pathway products such as C3a and C5a are also chemotactic for 
leukocytes 65 e.g.. C5a promotes the recruitment of neutrophils and eosinophils. Some 
cytokines show chemotactic activity, e.g..interleukin-16 induces chemotaxis of CD4 T 
cells. Stem cell factor acts as a chemoattractant for mast cells and hematopoietic 
progenitor cells 66. Serotonin, a neurotransmitter and inflammatory mediator released by 
mast cells, can induce the chemotaxis of eosinophils 67. Chemerin is a recently 
identified protein with a chemotactic activity for DC, macrophages and NK cells 68-70. 
 
1.1.2.2.1. Chemerin 
Chemerin is a 163 aminoacids protein (Fig. 2) identified as the natural ligand of 
chemerin receptor (ChemR23), a GPCR related to chemokine receptors expressed in 
immature DC 70-72, macrophages 70 and the cytotoxic subset of NK cells 69. Chemerin 
acts as a chemoattractant protein for ChemR23+ cells 68-70. 
Chemerin mRNA (messenger RNA) is constitutively expressed at readily detectable 
levels in most tissues, primarily liver, lung, pituitary, and ovary. No chemerin 
transcripts are found in peripheral blood leukocyte populations 70 73. The liver, appears 
to be a primary source of chemerin, and is likely to be responsible for the high levels of 
this protein in blood 72. ChemR23 is also broadly distributed. ChemR23 transcripts have 
been found primarily in spleen, lymph nodes and lung 70. It have been also found in 
cardiovascular system, brain, kidney, gastrointestinal tissues, and myeloid tissues (Fig. 
2) 73. 
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Figure 2. Expression of human ChemR23 (A) and chemerin (B) (From Wittamer et 
al, 2003)70 
 
Chemerin is synthesized as a secreted 142 aminoacid precursor of low biological 
activity (prochemerin), which upon proteolytic cleavage of its C-terminal domain is 
converted into a potent and highly specific agonist of ChemR23 (Fig. 3 and 5) 70. 
Chemerin lacking the last six (chemerin 157) or seven (chemerin156) aminoacids are 
the sole bioactive forms of chemerin on ChemR23, the former being more active than 
the latter 74. Unlike chemerin, most chemokines are processed at their N-terminus. 
However the proteins closest structurally to prochemerin: cathelicidins (antibacterial 
peptides), cystatins (cysteine protease inhibitors), and the bradykinin precursor 
kininogen, are also activated by a C-terminal processing. 75-77  
A B
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Figure 3. Aminoacid sequence of human prochemerin. The signal peptide is in bold 
lowercase italic characters and underlined, the cleaved C-terminal peptide is in bold 
lowercase italics and cysteins are in bold characters. The putative disulfide bonds are 
indicated. (From Wittamer et al, 2004)74 
 
The production of chemerin is regulated both at transcriptional and posttranslational 
level. TIG2 (tazarotene-induced gene 2), chemerin encoding gene, has been found to be 
overexpressed in nonlesional psoriatic skin and at lower levels in psoriatic lesions, and 
to be up-regulated by the synthetic retinoid tazarotene in these lesions 78, 79. Induction of 
this gene was also shown in the osteoclastogenic mouse bone marrow stromal cell line 
ST2 after stimulation by 1,25-dihydroxy-vitamin D3 and dexamethasone 78. Therefore 
the transcriptional regulation of chemerin appears to vary according to cell types and 
tissue.  
The clotting-associated serine proteases, factors XIIa and VIIa, the fibrinolysis-
associated serine proteases plasmin and plasminogen activators, mast cell derived 
tryptase 80, serine proteases released from activated neutrophil azurophil granules 
(elastase (HLE) and cathepsin G (CG)) 80, 81 and Staphopain B, a cysteine protease 
secreted by Staphylococcus aureus 82 are all potent activators of chemerin. The 
activation of chemerin by different extracellular proteases associated with or induced by 
the clotting, fibrinolytic and inflammatory cascades, supports a role of chemerin in the 
recruitment of ChemR23+ cells to sites of tissue damage, infection or allergic 
inflammation to rapidly establish an appropriate immune response 72. 
Chemerin is not only positively regulated at posttranscriptional level, there are also 
proteolytic events that negatively control its chemotactic activity. Proteinase 3 (PR3), a 
serin protease known to be abundant in polymorphonuclear (PMN) granules, and mast 
cell chymase are involved in the generation of specific chemerin variants, which are 
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inactive on ChemR23. PR3 specifically converts prochemerin into an inactive chemerin 
form, lacking the last eight carboxy-terminal amino acids (chemerin-155), whereas mast 
cell chymase converts active chemerin-157 and to a lesser extent, chemerin-156 (but not 
prochemerin) into the inactive chemerin-154 form 83. 
In addition to transcriptional regulation, the post-translational processing by 
proteases constitutes an usual mechanism found also in the regulation of the biological 
activity of chemokines involved in inflammatory processes. Metalloprotease activity has 
been shown to lead to the inactivation of several chemokines e.g. the monocyte 
chemotactic proteins CCL2, 7, 8, and 13, and the general leukocyte attractant CXCL12 
84
. Proteolysis of CCL3/MIP-1  by HLE, CG, and PR3 inhibits its chemoattractant 
activity 85.  
Given its homology with cystatins and cathelicidin precursors, as well as the similar 
organization of their genes, it is likely that chemerin adopts the so-called cystatin fold 
70
. This fold is presumably stabilized by two disulfide bonds common to cystatins, and 
an additional bond specific to chemerin, but compatible with the cystatin fold. The C 
terminus of the protein, located after the last cysteine involved in the disulfide bond 
constitute an unstructured flexible domain crucial for the biological activity of the 
protein on ChemR23, with the aromatic residues Tyr149, Phe150, Phe154 and Phe156, 
as well as Gly152 playing a critical role in both ChemR23 binding and activation 74. 
The fact that the same region (C terminal) of chemerin is involved in both, binding 
and activation of ChemR23 (a one site model), greatly differentiates it from the family 
of chemokines in the region involved and the way they interact with their cognate 
receptors. In most chemokines the flexible domain is located at the N-terminal domain 
86
, playing a similar role as C-terminus of chemerin 87. Unlike chemerin, the interaction 
of chemokines with their receptors involves a two-site model: their binding involves 
first a high affinity binding site between the core of the chemokine and the N terminus 
and loops of the receptor, whereas activation of the receptor usually requires a second 
interaction between the flexible N terminus of the chemokine and the transmembrane 
helix bundle of the receptor 86. 
Chemerin and ChemR23 are relatively well conserved between mammalian species 
(Fig. 4). The six cysteins presumably involved in disulfide bridging are strictly 
conserved in all specie. Importantly, the C-terminal end of chemerin (YFPGQFAFS), 
which is essential for the activation of ChemR23, is particularly well conserved . It 
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appears therefore that the chemerin-ChemR23 system has been well conserved in 
evolution, suggesting important and stable functions all along the vertebrate lineage 88 
 
 
 
Figure 4. Dendogram of ChemR23 and prochemerin from different vertebrate 
species (From Luangsay et al, 2009) 88. 
 
Although chemerin was first described as a chemoatractant, recent observations 
suggest that it can also display angiogenic and anti-inflammatory properties that are 
absolutely depending on proteolytic processing and act via ChemR23. Kaur et al 89 have 
reported that chemerin acts on EC through ChemR23 (the receptor is expressed in 
human EC (micro (HMECs) and macro(HUVECs and EA.hy926)-vascular human EC) 
and upregulated by pro-inflammatory cytokines (TNF-α, IL-1β and IL-6)), is able to 
promote EC proliferation, migration and capillary tube formation; and activation of 
endothelial gelatinases (metalloproteinase (MMP) 2/9). 
Furthermore classically activated macrophages are capable of converting chemerin 
into the potent anti-inflammatory peptide C15 (140-AGEDPHGYFLPGQFA-154) (Fig. 
5) 90. C-15 enhances macrophage phagocytosis of microbial particles and apoptotic cells 
(efferocytosis) in a nonphlogistic manner.This is supported by in vivo studies where 
C15 ameliorated zymosan-induced peritonitis, reducing leukocyte recruitment by up to 
65%, with a concomitant suppression of inflammatory mediator expression and a 
quantifiable reduction in the level of apoptotic cells suggesting a role in resolution of 
inflammation 91.  
In addition, in a mouse model of acute lung injury chemerin instillation increased the 
mobilization of airway macrophages via ChemR23 and inhibited neutrophil recruitment 
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and the release of inflammatory cytokines (IL-6, TNF- , IL-1β) and chemokines 
(KC/CXCL1) 88 
Besides ChemR23, orphan receptor GPR1 (G protein-coupled receptor 1) and 
CCRL2 have been identified as spare receptors for chemerin 92, 93. However, only GPR1 
is capable to support chemerin-derived signal transduction, therefore at least some of 
the activities of chemerin may be mediated through GPR1. CCRL2 functions as a not 
signaling receptor for chemerin. It has been suggested that could act by concentrating 
bioactive chemerin and facilitate its presentation to adjacent cells. 
 
 
 
Figure 5. Regulation of the inflammatory response by chemerin. Prochemerin is 
processed by serin proteases at C-terminal region generating active chemerin, which 
induced cell migration through engagement of ChemR23 (1). Chemerin can binds also 
to CCRL2 by its N-terminal domain being presented in this way to adjacent ChemR23+ 
cells (2) Cystein protease processing of chemerin generates the anti-inflammatory 
peptide chemerin 15 which acts via ChemR23 inhibiting the generation of 
proinflammatory mediators (From Yoshimura and Oppenheim, 2008)94 
 
1.1.3. Chemotactic receptors 
The recruitment of different types of leukocyte subsets to tissues is governed by the 
regulated expression of chemotactic receptors. Signaling pathway of most 
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chemoattractant receptors is mediated by seven transmembrane domain GPCR. 
However an exception is represented by cytokines such as IL-16 and stem cell factor, 
which induce chemotaxis through CD4 and c-kit respectively 95, 96. 
 
1.1.3.1. Chemokine receptors 
Chemokines induce cell migration and activation by binding to specific seven 
transmembrane domain GPCR on target cells. Ten CC (CCR1-10), seven CXC 
(CXCR1-7), one CX3C (CX3CR1) and one XCR (XCR1) receptors have been 
identified (Fig.6) 51, 54. Receptor expression is a crucial determinant of the spectrum of 
action of chemokines. The profile of chemokine-receptor expression on an individual 
cell is determined by its lineage, stage of differentiation and microenvironmental 
factors, such as chemokine concentration, the presence of inflammatory cytokines and 
low oxygen tension. 
Some receptors are restricted to certain cells (e.g. CXCR1 is predominantly restricted 
to neutrophils); whereas others are more widely expressed (e.g. CCR2 is expressed on 
monocytes, T cells, NK, DC and basophils). Moreover, chemokine receptors can be 
constitutively expressed on some cells, whereas inducible in others (e.g. CCR1 and 
CCR2 are constitutively expressed on monocytes, but are expressed on lymphocytes 
only after IL-2 stimulation); again, the expression of some chemokine receptors can be 
restricted to a cell state of activation and differentiation (e.g. CXCR3 is expressed on 
activated T helper type 1 lymphocytes (Th1), whereas CCR3 is preferentially expressed 
on T helper type 2 lymphocytes (Th2) 97. 
Although initially studied on leukocytes, some chemokine receptors are also 
expressed in nonhematopoietic cells, including neurons, astrocytes, epithelial and 
endothelial cells. These observations suggest that the chemokine system has other roles 
in addition to leukocyte chemotaxis. 
As already pointed out for chemokines, the remarkable feature of the chemokine 
receptor family is their promiscuity as far as ligand binding is concerned; however, 
although relatively few receptors bind only one ligand, CC receptors bind only CC 
chemokines and CXC receptors bind only CXC chemokines. This ligand-receptor 
restriction may be related to structural differences between CC and CXC chemokines, 
which have similar primary, secondary and tertiary structures but different quaternary 
structures 98. 
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Figure. 6. Chemokine receptor family. Ligand specificity is represented, with 
many receptors binding more than one single ligand. (From Balkwill, 2004)99 
 
1.1.3.1.1. Chemokine receptor signaling. 
Although the details of the chemokine signalling pathways appear to vary depending 
on the cellular context, the general rule is that, upon chemokine binding, the G protein 
activated by Guanosine-5'-triphosphate (GTP) dissociates in α and βγ subunits, the 
latter activating the enzymes phospholipase C (PLC) 28 and phosphatidilinositol-3 
kinase γ (PI3Kγ). 
PLC catalyzes the cleavage of membrane bound phosphatydilinositol 4,5 
biphosphate (PIP2) yielding two second-messengers: inositol triphosphate (IP3) that 
triggers the release of calcium from intracellular stores and diacylglycerol (DAG) that 
activates several isoforms of protein kinase C (PKC). While the rise in the concentration 
of intracellular calcium has been widely used to test the responsiveness of chemokine 
receptors to different chemokines, activation of PKC isoenzymes is stimulated by 
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almost any surface receptor and therefore is not special for chemokine-induced signal 
transduction. However, PKC activation by chemokines contributes to receptor 
phosphorylation which leads to desensitization and inhibition of functional responses 
100
. 
PI3Kγ activation results in the generation of phosphatidylinositol-3,4,5-triphosphate 
(PIP3) that initiates the activation of protein kinase B (PKB) 101. PI3K, PKB and PIP3 
translocate to the leading edge of the cell where PP3 activate the small GTPase Rac, and 
all these mediators participate in local polymerization of the contractile protein 
filamentous actin (F actin), whereas the mediators of actomyosin contraction are 
recruited to the trailing edge 30 (Fig. 7). After chemotactic stimulation the phosphatase 
PTEN (phosphatase and tensin homolog, a PI3P phosphatase), which removes PIP3 by 
converting it back to PIP2, rapidly localizes to the cell membrane. Contrary to the 
former mediators PTEN localizes to the sides and rear of the cell, amplifying the 
intracellular PIP3 gradient 102. Another important player is also activated: Cdc42, a 
small GTPase, which is recruited to the leading edge, where it is involved in PTEN 
exclusion from the leading edge, being essential for directional cell migration. 103-105. 
Thus, upon chemokine stimulation, PI3K localizes anteriorly, whereas PTEN localizes 
posteriorly and this spatial and temporal regulation determines the polarity of the 
migrating cell 106.  
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Figure 7. Signalling through chemokine receptors. Different signalling components 
localize either in the leading edge or in the trailing edge, determining cell movement 
(adapted from Tanaka et al, 2005)107 
 
There are increasing evidence that chemokine receptors can also activate several 
intracellular effectors downstream of G coupling, including the low molecular weight 
protein Ras and Rho and the mitogen-activated protein kinase (MAPK) pathway 108, 109. 
Moreover, it has been suggested that, like cytokine receptors, chemokine receptors are 
also able to signal through the JAK-STAT pathway 110, 111. Upon ligand binding, the 
receptor dimerizes and catalyses the phosphorilation of the JAK kinases which in turn 
phosphorylate the receptor itself; this event brings to STAT molecule recruitment, 
dimerization and translocation to the nucleus where it triggers the expression of 
cytokine dependent genes. 
Gβγ 
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Chemokine receptor signalling is transient, and the rapid termination of receptor 
activity is achieved by three mechanisms: receptor inactivation, desensitization and 
internalization. Receptor inactivation is mediated by the intrinsic GTPase activity of the 
Gα subunit, which hydrolyzes GTP and reunites with Gβγ to return to the initial 
conformation of inactive heterotrimer. Desensitization is caused by receptor 
phosphorilation, through G-protein-coupled receptor kinases, among which PKC and 
finally internalization is caused by β-arrestin or adaptin-2 mediated receptor 
sequestration and internalization, through clathrin-coated pits or caveolae. The speed of 
response recovery is determined by the fate of internalized receptors, either lysosomal 
degradation or dephosphorylation and cell surface recycling; the pathway leading to 
either degradation or recycling following receptor internalization are determined by the 
guardians of all vesicular machinery, Rab GTPases 112 and by the rate of de novo 
chemokine receptor synthesis.  
Signal transduction downstream chemokine receptors is much more complicated than 
the one above described; indeed, a given receptor will activate signalling pathways 
influenced by those from other receptor systems.  
 
1.1.3.2. Atypical chemokine receptors  
Beside the conventional signalling chemokine receptors, other chemokine binding 
molecules with high structural similarity to chemokine receptors have been described, 
namely the Duffy antigen receptor for chemokines (DARC) 113-115, D6 114-116 and 
ChemoCentryx chemokine receptor (CCX-CKR) 117. These receptors do not elicit 
migration or conventional cellular responses, but still bind chemokines with high 
affinity. They are also referred to as “silent receptors” and have been suggested to favor 
transfer of chemokines across endothelial barriers and/or to act as decoy receptors 
which dampen inflammatory reactions 118. Of note, sequence motifs critical for G 
protein coupling and signaling functions of chemokine receptors, namely the 
DRYLAIV in the second intracellular loop and the TXP motif in the second 
transmembrane domain, are not conserved in these receptors. It have been recently 
reported that similar to silent receptors, CCRL2 is able to bind chemerin without 
inducing an intracellular signaling93. 
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1.1.3.2.1. C-C chemokine receptor-like 2 (CCRL2)  
CCRL2 (C-C chemokine receptor-like 2), also known as L-CCR (LPS-inducible CC 
Chemokine Receptor), is a 7-transmembrane GPCR described as potential leukocyte 
chemoattractant receptor. CCRL2 shares over 40% amino-acid identity with CC-
chemokine receptors and clusters on chromosome region 3p21-23 together with the 
most other CC-chemokine receptors (in particular, CCR1 and CCR5) 119. However 
CCRL2 possesses an uncharacteristic intracellular loop2 sequence in place of DRY 
motif, similar to nonsignaling chemotactic receptors, that makes it considered as a 
candidate decoy receptor 120. CCRL2 was originally cloned from the macrophage cell 
line RAW 264.7 121. Real time polymerase chain reaction (RT-PCR) and in situ 
hybridization experiments revealed CCRL2 mRNA expression by microglia, astrocytes 
and infiltrating macrophages in spinal cord and brain in a model of experimental 
autoimmune encephalomyelitis (EAE) 35-37. The expression of CCRL2 on glial cells 
resulted induced upon LPS stimulation both in vitro and in vivo 122. CCRL2 has been 
reported to be expressed in lung tissue and upregulated in macrophages and bronchial 
epithelium in a mouse model of ovalbumin (OVA) -induced airway inflammation 123. 
Recent observation shows that CCRL2 is constitutively expressed in mouse mast cells 
93
.  
Human CCRL2 counterpart is named HCR (human chemokine receptor) 124. Mouse 
and human CCRL2 genes share 51% homology, which is low comparing to the 
homology usually observed for other chemotactic receptors (usually > 80%). HCR 
mRNA expression has been found in human liver, spleen, heart, lung, kidney, and 
skeletal muscle leukocytes 125. In human blood and bone marrow CCRL2 is expressed 
at varying levels in all myeloid cells (monocyte, macrophages, PMN, and DC), 
lymphoid cells, and CD34+ myeloid precursors, with PMN expressing the highest 
levels. Unlike other lymphoid cells, B cells were initially reported to be negative for 
CCRL2 125. However a recent work demonstrates that HCR is clearly expressed on 
different B-cell types with a preferential expression in the early stages of differentiation 
and lack of expression in immature bone marrow B cells and IgM+-expressing B-cell 
lines 126. Interestingly, it is upregulated in human T cells after in vitro stimulation and in 
DC stimulated with LPS, poly (I:C), IFNγ or CD40L 125. In addition, human neutrophils 
constitutively express HCR 125, and its expression is shown to be upregulated in 
synovial neutrophils from rheumatoid arthritis patients 127, 128.  
CCRL2 is rapidly induced after LPS treatment: it is induced by 30 min. in 
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RAW264.7 cells, reaching a peak at 2h, and decreases thereafter 121. Similarly, in an 
OVA induced airway hyperesponsiveness model, CCRL2 is upregulated in the lung as 
early as 1-3 h after OVA challenge, returning to basal levels 6 h after 121, 123 
Recently it have been described the first biological function attributed to CCRL2 so 
far. Zabel et al found that mouse mast cells constitutively express CCRL2 93. Using 
CCRL2-deficient mice, they showed that the absence of CCRL2 did not affect the basic 
mast cell phenotype and function in vitro or T cell-mediated contact hypersensitivity in 
vivo. However, in a model of IgE-dependent passive cutaneous anaphylaxis in vivo, in 
which mast cells play a central role, they found that CCRL2-deficient mice had reduced 
inflammatory responses when a relatively low sensitization dose was used. The 
defective response was attributed to CCRL2 expression on mast cells, as mast cell-
deficient mice reconstituted with CCRL2-deficient bone marrow progenitor cells 
showed an impaired response compared to those reconstituted with WT (wild type) 
cells93. 
Due to its homology with CC chemokines receptor family, CCRL2 has been 
considered a putative chemokine receptor and several attempts have been performede to 
identify the putative ligands. Recently Biber and colleagues reported that HEK 293 cells 
transfected with mouse CCRL2 showed pertussis toxin (PTX) sensitive chemotaxis and 
intracellular calcium signal in response to the chemokines CCL2, CCL5, CCL7 and 
CCL8 129, suggesting that CCRL2 is a functional receptor. However these results remain 
controversial because radioligand binding of these chemokines to CCRL2-transfected 
cells could not induce any detectable signals and the results have never been confirmed 
(discussed by 120}. Recent reports suggest that CCRL2 is a non-signaling receptor, 
belonging to atypical silent/decoy receptors family 93, 128.  
Chemerin has been recently indicated as the natural non-signalling ligand for both 
human and mouse CCRL2. The binding affinity of chemerin for CCRL2 is similar to, if 
not slightly better than, chemerin binding to ChemR23 93. Leick et al 128 showed that 
CCL19 binds to CCRL2 with an affinity similar its classical receptor, CCR7, however 
this binding did not elicit any classical chemokine receptor response like MAPK 
phosphorylation, calcium mobilization or migration, confirming the ‘silent’ behavior of 
CCRL2. In spite of its phylogenetic homology with members of the CC chemokine 
receptor family, CCRL2 possesses an uncharacteristic intracellular loop 2 sequence in 
place of the DRYLAIV motif generally found in signaling chemokine receptors 
(QRYLVFL in human and QRYRVSF in mouse), a characteristic that might account for 
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its non-signaling characteristics after chemerin binding 130. The presence of a glutamine 
(Q) at position 127 instead of aspartic acid (D), replacing an acidic residue with a 
neutral one rends coupling to the Gi protein highly unlikely. 
Reports about CCRL2 internalization are conflicting. Zabel et al 93 have reported that 
CCRL2 show a low-level constitutive endocytosis and that chemerin binding does not 
trigger ligand internalization. On the other hand Leick et al have found that CCRL2 is 
constitutively recycled via clathrin-coated pits and quickly re-expressed at the cell 
surface and is able to internalize CCL19 as well as anti-CCRL2 antibodies 128. 
However, even whether CCRL2 internalizes CCL19, the process is less efficient than 
CCL19 internalization mediated by the scavenger receptor CCX-CKR. It is likely that 
CCRL2 could act more as chemokine presenter (like DARC) rather than a scavenger 
(like D6). Zabel et al have proposed that CCRL2 could be able to bind the 
chemoattractant and increase local concentrations of bioactive chemerin which then 
become available for interaction with ChemR23 on adjacent cells, thus providing a link 
between CCRL2 expression and inflammation via the cell-signalling chemerin receptor 
ChemR23. A similar reasoning could be doing for CCL19. The identification of 
chemerin as a non-signalling ligand for CCRL2 introduces a novel functionality for 
atypical receptors: concentration and presentation, as opposed to 
internalization/degradation 9341. Chemerin binds directly to the N-terminal domain of 
CCRL2 by its N-terminal region. The orientation of chemerin binding to CCRL2 leaves 
its critical cell-signaling C-terminus exposed, therefore available to bind to ChemR23 
(Fig 8). In this regard, it is interesting to note that the first 16 aminoacids of human and 
mouse CCRL2 share 81% identity, compared with just 17% shared identity in the 
remaining 24 aminoacids of the N-terminal domain 9341. In its role as a specialized 
molecule for concentrating extracellular chemerin, CCRL2 may operate like 
glycosaminoglycans, which are thought to bind, concentrate, and present chemokines to 
leukocytes and facilitate their chemotaxis. 
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Figure 8. Presentation of chemerin by CCRL2. (A) Chemerin binds to CCRL2 
leaving the C-terminal peptide sequence free to interact with adjacent ChemR23+ cells. 
(B) Alternatively, CCRL2 may concentrate the ligand for proteolytic processing, 
enhancing the local production of the active form which could then act as a 
chemoattractant after release from the cell surface. (From Zabel et al, 2008)93.  
 
1.1.4. Chemokines in physiology  
The eponymous function of chemokines and their receptors is to mobilize cells in a 
gradient direction. This biological function is particularly important in leukocyte 
recruitment at sites of inflammation, although it is now well known that many different 
cells express chemokine receptors and are therefore able to respond to different 
chemotactic stimuli. The trafficking of DC and lymphocytes through secondary 
lymphoid organs is finely regulated by chemokine receptors. DC can take up antigens in 
peripheral tissues and migrate to draining lymph nodes where they present antigen to 
naïve T cells, triggering the T cells to proliferate and differentiate. These activated T 
cells can then migrate to the inflamed tissues to perform their effectors functions. The 
movement of T cells and DC between lymph nodes and the periphery may be controlled 
by differential chemokine receptor expression 131, 132. 
Circulating monocytes and immature DC can express receptors for chemoattractants 
such as fMLP  and C5a as well as chemokine receptors including CXCR4, CCR1, 2, 3, 
4, 5 and 6 133, 134. Using these receptors, immature DC can migrate towards sites where 
there is a high concentration of inflammatory chemokines such as CCL2, CCL3 and 
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CCL5. Immature DC can also respond to constitutively expressed chemokines such as 
CXCL12, and this may be important for localizing DC in tissues under normal 
conditions. At sites of inflammation, immature DC are activated by inflammatory 
cytokines such as TNF-α and IL-1 135, which results in DC maturation. This process 
causes a switch in their chemokine receptor expression. Maturing DC lose their 
responsiveness to CCL3, 4, 5, 7 and 20 132, 136, 137, but concomitantly upregulate CCR7 
and gain responsiveness to CCL19 and CCL21 which are constitutively expressed in T 
cell rich areas of secondary lymphoid organs including lymph nodes, spleen and tonsils. 
Naïve T cells can express CXCR4 and CCR7, which may account for their 
localization in secondary lymphoid organs. Upon interaction with antigen-presenting 
DC, naïve T cells are activated and alter their chemokine receptor profile. Activated T 
cells can express CXCR3, CXCR4, CCR1, 2, 3, 4, 5, 6, 7 and 8 131, 138. Activated T cells 
can polarize to Th1 (expressing IFN-γ and IL- 12) or Th2 (expressing IL-4, IL-5 and IL-
13) subsets, which differ in their cytokine production and function during an immune 
response and also express different chemokine receptors. CCR5 and CXCR3 are 
preferentially expressed on Th1 cells, while Th2 cells preferentially express CCR3, 
CCR4 and CCR8 138, 139, although this differential chemokine receptor expression is not 
clear-cut. Finally, naïve B cells can express CXCR5 and CCR7 which direct them to the 
follicles of secondary lymphoid organs, where the ligands CXCL13, CCL19 and CCL21 
are expressed. Upon maturation to plasma cells, B cells down-regulate CXCR5 140 and 
CCR7 141, but have increased sensitivity to CXCL12 (through CXCR4) which regulates 
plasma cell positioning in the spleen and lodgement in the bone marrow.  
Several evidences suggest that chemokines have a role in the development of 
different biological responses that goes beyond cell recruitment. Chemokines have been 
shown to play a direct role also in definition of the cytokine milieu during both 
inflammatory and immune responses as well as in important mechanisms such as 
hematopoiesis. Thus, chemokines not only support differential leukocyte recruitment, 
but also directly affect target cell functions. Chip-based gene expression profile analysis 
in chemokine-activated monocytes revealed that CC chemokines induce specific 
transcriptional programs in target cells, demonstrating that chemokine effects on target 
cells include induction of transcriptional events 142.  
Chemokines not only attract T cells, but they may also have roles in regulating T 
cell biology, influencing Th1/Th2 polarization 143. CCL2 can suppress Th1 responses 
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and cause an increase in IL-4 (Th2 cytokine) production by activated and memory T 
cells in vitro 143, 144. The addition of CCL2 to macrophages cultured in vitro has been 
shown to decrease IL-12 (Th1 cytokine) production 145. CCL2 may therefore promote 
Th2 polarization both directly and indirectly by increasing IL-4 and decreasing IL-12 
production, respectively. In contrast, addition of CCL3 to in vitro cultures of activated T 
cells promoted the development of IFNγ-producing cells and hence Th1 differentiation. 
Similarly, CCL3, 4 and 5 production by monocyte-derived DC can promote the 
development of IFNγ-producing cells 146. However, experiments in mice deficient in the 
chemokines CCL2 and CCL3 and the chemokine receptors CCR1 and CCR2 resulted 
less conclusive, and in some instances gave opposite results, depending on the 
experimental protocols used 147-150. More work is required to further elucidate the role 
of chemokines in the differentiation of T cells, and also the contribution of chemokines 
produced by T cells themselves. This aspect may have implications for the use of 
chemokine receptor antagonists in the treatment of inflammatory disease.  
Chemokines play also an important role in hematopoiesis. Stem cells and 
hematopoietic progenitor cells in the bone marrow are subjected to the influence of a 
variety of different cytokines, resulting in either stimulation or inhibition of 
proliferation. Chemokine receptor expression by hematopoietic progenitor cells may 
regulate the homing of these cells within the bone marrow during differentiation and 
maturation, and their mobilization into the circulation. In particular, hematopoietic 
progenitor cells express CXCR4 and can migrate in response to CXCL12 151; therefore, 
this chemokine/receptor pair plays an important role in the balance between retention 
and mobilization of progenitor cells in the bone marrow and this function is 
accomplished through a mechanism of receptor desensitization and downregulation, 
with CXCL12 being constitutively produced in high amounts in bone marrow. 
Moreover, the CXCL12/CXCR4 axis can also be important for the retention of 
hematopoietic progenitor cells in the bone marrow, during B lymphopoiesis; retaining B 
cell precursors in the bone marrow would enable their regulated differentiation into 
mature B cells 152. Beside hematopoiesis, CXCR4 and CXCL12 are important in 
development and embryogenesis, as clearly demonstrated by knockout mice 153, 154. 
Both CXCR4 and CXCL12 deficient mice die in utero, pointing out their role in 
development and embryogenesis; this may also explain why CXCL12 is such a highly 
conserved chemokine. These mice have severely reduced numbers of B cell progenitors 
and myeloid progenitor cells, suggesting that the CXCL12/CXCR4 pair is responsible 
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for B cell lymphopoiesis and bone marrow myelopoiesis. Surprisingly, T cell 
lymphopoiesis is unaffected in these mice. They also have severe heart defects, 
including defective cardiac ventricular septum formation and a disorganized 
cerebellum. Evidences have been collected showing that mice deficient in either 
CXCR4 or CXCL12 have defective formation of the large blood vessels supplying the 
gastrointestinal tract, possibly due to defective regulation of vascular branching and/or 
remodeling processes in EC 153. 
 
1.1.5. Chemokines in Pathology 
The in vivo functions of chemokines are not limited to immunity and inflammation; 
given their broad spectrum activities, it is not surprising that they play a role in several 
types of human pathologies, including asthma, cardiovascular diseases, transplantation, 
neuroinflammation, HIV (human immunodeficiency virus)-associated diseases and 
neoplasia. 
Multiple sclerosis (MS) is a demyelinating autoimmune disease mediated by CD4+ T 
cells specific for one or more autoantigens expressed in the central nervous system, 
where a variety of destructive inflammatory mediators are produced. Beside auto-
reactive T lymphocytes, MS lesions contain a variety of cell types, including 
monocytes/macrophages and T cells which are subsequently recruited, activate 
microglia and cerebrovascular endothelium. During active MS attacks, significantly 
increased levels of CXCL9, CXCL10, and CCL5 are detected in cerebrospinal fluid 155 
and CCL2, CCL7 and CCL8 have been found immunohistochemically in MS lesions 
156
. Various chemokine receptors are also expressed in MS lesions: CCR2 and CCR5 
are found expressed on macrophages, microglia and T cells, and CCR3 is also found on 
reactive astrocytes 157. MS patients heterozygous or homozygous for the CCR5D32 
allele (which encodes a non-functional form of CCR5) show delayed disease onset of 
approximately 3 years compared with affected siblings 158. CXCR3 is expressed by 
more than 90 % of CD3+ T cells in cerebrospinal fluid, and >99 % of T cells in 
perivascular accumulations in active lesions 155. The presence of CXCL9 and CXCL10 
in MS lesions may account for the recruitment of CXCR3 positive T cells 159. CCR5 
and CXCR3 may represent a target for therapeutic intervention in MS  
Rheumatoid arthritis is characterized by the presence of a mixed inflammatory cell 
infiltrate into synovium-lined joints, in response to autoantigens. The success of anti-
TNF-based therapy has indicated the critical role played by this cytokine in arthritis, 
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presumably mediated by the induction of chemokines. Synovial fluid from pathological 
joints contains high levels of CCL2, CCL3, CCL5 and CXCL10 and both synovial-
lining cells and leukocytes are the source. Leukocytes are also the target, expressing 
CCR2, CCR5, CCR2 and CXCR3 160, 161. 
Accumulating evidence indicates that chemokines play a central role in 
cardiovascular disease and in particular in atherosclerosis, a chronic inflammatory 
disease of the blood vessel wall, characterized by the accumulation of mononuclear 
cells. Atherosclerosis is a multifactorial disease, with many risk factors including 
smoking, hypertension, hypercholesterolemia, family history and diabetes; however, 
there is consensus on the origin of atherosclerotic plaques from an inflammatory 
response occurring in the arterial damage, either because of hypercholesterolemia or 
shear stress. CCL2 has been found to be involved in this pathology. CCL2 and CCR2 
deficient mice show 60-85% less arterial lipid deposition than WT mice, in 
hypercholesterolemia models and this is consistent with the role of CCL2 in leukocyte 
recruitment. Recent evidence demonstrate that a broad spectrum CC-chemokine 
blockade reduces atherosclerosis in an Apo-E -/- mice 162, 163. Another important 
chemokine in atherosclerosis is CX3CL1 (fractalkine). This chemokine is produced by 
EC after inflammatory cytokine stimulation and can mediate leukocyte adhesion and 
infiltration into the vascular wall, as well as NK-cell-mediated endothelium injury. High 
levels of mRNA for CX3CL1 and other 16q13-chromosome-linked chemokines have 
been observed in human arteries with advanced atherosclerotic lesions 164. The ability to 
recruit leukocytes and its expression in vascular cells strongly suggest a pivotal role for 
fractalkine in the pathophysiology of atherosclerosis. 
Chemokines and their receptors are also involved in rejection of allogeneic 
transplants. In particular, after an early non specific release of inflammatory 
chemokines attracting neutrophils and monocytes, CXCR3 and CCR5 ligands appear, 
several days after the transplants, consisting with their orchestrating the movement of 
cells involved in acute rejection 165. Moreover, it has been demonstrated that CX3CL1 
expression is enhanced in rejecting cardiac allografts 166; in addition, the treatment of 
organ recipients with polyclonal anti-CX3CR1 blocking antibodies markedly prolonged 
survival of major histocompatibility complex (MHC)-mismatched heart allografts 166. 
As far as bone marrow transplant is concerned, CXCR4 and its ligand chemokine 
CXCL12 are very important. As comprehensible given their role in the balance between 
stem cell precursor retention and mobilization in the bone marrow, CXCR4/CXCL12 
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play a role in bone marrow engrafment of CD34+ cells and this may have clinical 
implications with regard to therapeutic stem cell transplantation. 
CD4 is the primary cell surface receptor used by HIV to penetrate T lymphocytes 
and macrophages. The chemokine receptors CXCR4 and CCR5 function as co-receptors 
which, along with CD4, allow viral envelope fusion and entry. A range of chemokine 
receptors have now been shown to have co-receptor activity in vitro, including CCR1, 
2, 3, 4, 5, 8, 9, CXCR2, 4, 5, 6 and CX3CR1 167, but so far only CXCR4 and CCR5 
have been shown to act as co-receptors in vivo, hence X4 tropic and R5 tropic viruses 
are described. Since chemokine receptors act as co-receptors for HIV entry, endogenous 
chemokine production can regulate HIV replication. In 1995, Cocchi et al published that 
CCL3, CCL4 and CCL5 have CD8+ T-cell-derived HIV inhibitory activity 168. 
Moreover, individuals homozygous for the D32 allele of CCR5, who are deficient in the 
cell surface expression of CCR5, can remain uninfected despite exposure to HIV 169, 170. 
These observations suggest that chemokines and their receptors, which are involved in 
HIV infection, are potential targets for the development of new drugs to treat HIV.  
Chemokines have also an important role in asthma, a disease detailed described in 
section 1.3 
 
1.1.5.1 Chemerin/ChemR23 axis in pathology 
Elevated levels of active chemerin have been found within the active range (33–358 
ng/ml, corresponding to 2–23 nM) in ascitic fluids resulting from ovary and liver 
cancer, from an ovary hyperstimulation syndrome, as well as in a pool of synovial fluids 
from arthritic patients. Therefore, it is likely that chemerin represents an important 
signal involved in the recruitment of ChemR23+ cells during inflammation and 
autoimmune diseases, and at tumor sites 70. 
Zheng et al 171 proposed a possible role for chemerin in the development of skin 
squamous cell carcinoma (SCC). Various stresses seem to activate prochemerin, which 
is highly expressed in normal epidermis 79 in the early stages of SCC. The bioactive 
chemerin could chemoattract antigen-presenting cells (DC and macrophages) to the 
target sites, resulting in immune responses and the release of cytokines and chemokines, 
which promote invasive tumors. Later, the transcription of TIG2 (chemerin codifying 
gene) is inhibited, resulting in the loss of chemerin in SCC. 
On the other hand TIG2 has been reported as one of the most differentially expressed 
genes reported as deregulated (underexpressed) in adrenocortical carcinoma 172, 173 and 
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has been shown to present excellent diagnostic accuracy for distinguishing benign from 
malignant adrenocortical tumors 174. 
ChemR23 has been found expressed, by immunohistochemistry, in inflammatory 
cells accumulating in the leptomeninges and in perivascular cuffs of MS lesions 
whereas chemerin was confined to vascular EC in the meninges and white matter 
lesions 175. Additionally, ChemR23 has shown an important contribution in the 
pathogenesis of EAE, with potential involvement in the regulation of DC dynamics and 
macrophage accumulation during central nervous system inflammation 176. A role for 
chemerin/ChemR23 axis has been suggested in the recruitment of inflammatory cells 
into the central nervous system in MS probably by the concerted action of other 
chemokines.  
Plasmacytoid DC (P-DC) are normally absent from the skin. However, they accumulate 
in some inflammatory dermatoses, where they organize local immune responses. The 
best characterized examples of these conditions are lupus erithematosus (LE) 177 and 
psoriasis 178.  
Psoriasis is a type I IFN-driven T cell–mediated disease characterized by the 
recruitment of P-DC into the skin 178, 179 . Prochemerin is expressed in all the layers of 
normal epidermis where might maintain the normal differentiation of epidermal 
keratinocytes 180. In the context of psoriasis activated neutrophils and mast cells can 
convert prochemerin into active chemerin through the release of CG, HLE, and tryptase 
contributing to P-DC influx to psoriatic skin 181, 182. Albanesi et al 182 have found that 
chemerin expression characterizes the early phases of evolving skin psoriatic lesions 
and is temporally strictly associated with P-DC, supporting a role for the 
chemerin/ChemR23 axis in the recruitment of P-DC in the early phases of psoriasis 
development. 
Parolini et al 69 found that chemerin is expressed by inflamed EC lining blood vessels 
in oral lichen planus (OLP), a pathologic condition characterized by the accumulation of 
NK cells and DC. Additionally they observed that ChemR23 + myeloid and 
plasmacytoid DC and NK cells colocalize in areas where chemerin was detected, 
suggesting a role for chemerin in NK cells and P-DC recruitment and colocalization in 
OLP lesions. 
LE is a complex disorder showing a broad spectrum of clinical manifestations, 
ranging from pure cutaneous form to a severe and progressive systemic disease. The 
hallmark of LE pathogenesis is represented by loss of tolerance to variable nuclear 
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antigen which leads to tissue deposition of immune complex followed by widespread 
inflammation and tissue damage. Recent evidences point to a potential role of P-DC in 
the pathogenesis of LE via production of type I IFN, a key protein in the pathogenesis 
of this disease 177, 183-185. P-DC blood content resulted decreased in systemic LE 
patients; however, these cells have been found to infiltrate extra-lymphoid lesional 
tissues and to locally produce type I IFN 186-188. Vermi et al 71 have reported a 
significant induction in chemerin expression in LE skin biopsies (this positivity was 
restricted to EC of dermal blood vessels and in the granular layer keratinocytes) with 
the concomitant presence in close proximity of ChemR23+ P-DC. This finding sustains 
the role of chemerin as cutaneous P-DC chemoattractant in LE. 
 
1.2. Dendritic cells. 
Dendritic cells (DC) are a heterogeneous population with unique properties in 
antigen presentation, and play a crucial role in inducing T and B cell responses as well 
as immune tolerance 135. DC are bone marrow derived and migrate through the blood 
stream to peripheral tissues throughout the body, where they reside as immature DC 
with high ability to capture antigens. Immunological as well as inflammatory danger 
signals induce a functional maturation process into DC, transforming them from poor 
immunostimulatory cells that function as sentinels of the surrounding environment into 
potent T cell stimulators. The current paradigm of DC immunobiology states that 
maturation is associated with DC mobilization from the periphery to the T cell rich 
areas of lymphoid organs 189. There, DC present the processed antigens in the context of 
MHC class I and class II molecules and elicit specific T cell responses 190, 191. Recent 
evidences indicate that migration of DC into the lymph nodes also occurs in normal 
conditions and may serve to tolerize T cells against self and non-dangerous antigens 192. 
However, the mechanisms involved in the mobilization of DC in the steady-state need 
to be better elucidated. 
DC are very rare cells both in tissues and in biological fluids, and this aspect has 
made difficult the study of their functional properties, since the first description of this 
cells by Steinman and Cohn in 1973 193. However, in the last 15 years several 
procedures have been developed to generate large numbers of fully functional pure 
human and mouse DC from circulating and bone marrow precursors, including 
peripheral blood CD14+ monocytes and CD34+ stem cells. Using these in vitro 
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cytokine-driven populations, much work has been accumulated in the understanding of 
DC immunobiology. 
DC constitute a heterogeneous population in terms of origin, morphology, 
phenotype, function and homing properties 189, 194, 195. Since the nomenclature of 
circulating DC has become quite confusing because of the use of different antibodies for 
their identification, very recently, a group of experts drafted a nomenclature proposal 
under the auspices of the International Union of Immunological Societies and the World 
Health Organization 196. In blood a subdivision into 3 subsets is suggested, that is, P-DC 
and 2 types of myeloid DC (M-DC). 
P-DC in tissues were originally described as T-associated plasma cells, plasmacytoid T 
cells, or plasmacytoid monocytes. P-DC were found to have the capacity to produce 
high levels of interferon α (IFNα) in response to viruses, and these cells were named 
natural type 1 IFN-producing cells 197. In human the CD68 marker can discriminate the 
P-DC from the 2 types of M-DC, but this requires combination with additional markers 
because CD68 is also strongly expressed on monocytes 198. While CD123 expression is 
only incrementally higher on P-DC compared with monocytes, CD303 is a marker with 
good signal-to-noise ratio for the P-DC 199. In mice P-DC selectively express Siglec-H 
(Sialic acid-binding immunoglobulin-like lectin H) 200 and bone marrow stromal antigen 
(BST2) 201. However, expression of the BST2 antigen on plasma cells under steady state 
conditions and on many other cells after induction by type I IFN needs to be considered 
196
. P-DC are mainly found in blood in the steady-state, from where they can enter into 
the lymph nodes upon inflammatory stimuli. P-DC are poor antigen presenting cells 
(APC) but upon activation they produce large amounts of cytokines, particularly type I 
IFN, that affect NK, B and T cell activity, and in this way can regulate inflammation 
and link innate and adaptive immunity 202. 
In human blood, both the CD1c+ and CD141+ M-DC express myeloid markers 
CD13 and CD33, suggesting their direct derivation from the myeloid lineage. For 
proper identification of the CD1c+ DC in blood, CD19+CD20+B cells need to be 
excluded, because the latter cells also show strong expression of the CD1c molecule. A 
fraction of the CD1c+ blood DC expresses low-level CD14 203. No comparative data 
between CD14+ and CD14- subsets are available, however, in support to their 
uniqueness functional studies have shown a specific pattern of chemokines production 
in these cells. The CD141+DC represent a very minor subset of blood leukocytes. 
Costaining with CD14 is recommended to exclude low-level signals from monocytes. 
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These CLEC9A+CD141+ cells (but not CD1c+blood DC) are also major producers of 
IFN-β and cross-present antigen for CD8 class 1–restricted cytotoxic T lymphocyte 
responses in response to TLR-3/CD283 ligation. These and their other properties 
suggest that they are homologous to the mouse CD8α + DC subset 204. It is 
recommended that the CD1c+ and CD141+ blood DC are defined separately and are not 
addressed as one population of myeloid blood DC 196. Looking at M-DC the 
CD11c+CD11b+CD45RA- cells identified in mouse blood share features with the 
splenic CD8- DC subset 205, and they may be homologous to human CD1c+ myeloid 
blood DC 206. The CLEC9A+ DC in mouse blood also stain for CD24 and may thus be 
representative for the CD8+splenic DC subset. Because anti-CLEC9A also strongly 
stains the human blood CD141+ cells 207 and because human CD141+ blood DC and 
mouse CD8+ spleen DC share specific transcriptional signatures 206, the CLEC9A+ 
mouse blood DC are potential homologues of the human CD141+CLEC9A+ myeloid 
blood DC.  
M-DC constitute discrete population in tissues that play specific functions and 
express distinct markers depending on the anatomical location. Langerhans cells (LC), 
that were described more than a century ago and were later on recognized as the DC of 
the epidermis, express langerin and E-cadherin, which are down-regulated during 
maturation. However, LC do not express CD11b 208, 209. Dermal DC localize at the 
subepithelial tissues of the dermis and specifically express CD13, and similar to the DC 
of the epithelial mucosa and the interstitial DC present in the solid organs, they express 
CD11b, mannose receptor and DC-SIGN 195. All conventional DC express the β2 
integrin CD11c and CD1a, and except LC, also express the other CD1 isoforms 208. 
Furthermore, DC are also observed in the afferent lymphatic vessels, where are called 
veiled cells. They represent DC emigrating from peripheral organs into lymphoid 
tissues 210. 
Splenic DC are the best studied lymphoid organ DC. They are divided into different 
subpopulations based on the expression of classical lymphoid and myeloid markers. The 
main population is represented by  the CD8α-CD11b+F4/80+DEC205-/low33D1+ 
cells, which are located mainly within the marginal zone of the spleen, while the 
CD8α+CD11b-F4/80-DEC205+33D1- cells are located mainly in the T cell-rich 
paracortical areas of the spleen and are termed interdigitating DC 195. Regardless of the 
expression of myeloid or lymphoid surface markers, both populations can arise from a 
common precursor, revealing a high degree of plasticity that is a peculiar characteristic 
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of DC development 211, 212. Lymph nodes contain fairly similar DC populations. In 
addition, a distinct subset with phenotypical markers of interstitial DC has been 
described 213-215. This population most likely is represented by DC emigrated via the 
afferent lymphatics from their associated peripheral tissues. In fact, they display all the 
characteristics of a mature phenotype. Apart from this latter population, the majority of 
DC in the spleen and lymph nodes are in an immature state 216, a fact that apparently 
contradicts the current paradigm which states that DC migrate to secondary lymphoid 
organs upon maturation. Moreover, they have the capability to mature and acquire the 
phenotypic features of mature DC 216-218. Endovenous injection of LPS has been shown 
to promote phenotypical as well as functional DC maturation in the spleen, as assessed 
by down-regulation of antigen processing capacity and up-regulation of 
immunostimulatory properties, a process that is accompanied with the migration of 
most splenic DC from the marginal zone to the T cell areas 217. Unlike in vitro-
generated immature bone marrow-derived DC (BMDC), DC isolated from the spleen do 
not respond to inflammatory CC chemokines 219. Conversely, ex-vivo maturated DC 
subsets express CCR7 and migrate to its ligands CCL19 and CCL21 219. There is still 
not consensus about functional distinction of these two subsets 220. Splenic CD8α- DC 
seem to be the most immature DC cell population in this organ 221. CD8α- DC have a 
higher endocytic and phagocytic capacity than CD8α+ DC, which correlates with its 
preferential localization at the marginal zone and the subepithelial dome, which are 
typical antigen-uptake zones . On the other hand, CD8α+ DC are uniquely able to cross-
present antigens associated to MHC I 222. During in vivo T-cell responses, CD8α- DC 
mainly induce Th2 cell responses, whereas CD8α+ DC strongly elicit Th1 cell 
responses 223-226. However, in vitro studies and in vitro stimulation followed by in vivo 
transfer experiments have demonstrated that under appropriate conditions both subsets 
can mediate all DC effector functions with the same efficiency 227, 228. At present it is 
not known if this functional plasticity exists in vivo 220. 
The above findings suggest a fundamental similarity between resident lymphoid 
organ DC and peripheral tissue interstitial DC. Immature DC in lymphoid organs may 
also act as sentinels for soluble or shed antigens arriving via the blood or the lymph. 
The latter is further supported by the recent characterization of the conduit system that 
transports soluble antigens from the afferent lymph to the resident DC in the lymph 
nodes 229. Alternatively, lymphoid DC could receive antigens carried on by migratory 
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DC from the periphery resulting in amplification of the response 230. Moreover, they 
may contribute to peripheral tolerance 231, 232. Their unresponsiveness to inflammatory 
chemokines, although requiring further confirmation and extension of the studies to the 
known immature DC chemoattractants, may indicate that they have already achieved 
the proper tissue localization for these functions.  
 
1.2.1. Dendritic cell activation 
Maturation is a complex process that leads to differentiation of DC, by reducing their 
antigen uptake capability and transforming them into potent T cell stimulators. DC 
prime T cell responses in secondary lymphoid organs such as lymph nodes, spleen and 
mucosal-associated lymphoid tissues, where naïve T cells continuously recirculate 
seeking their cognate antigens. Functional maturation culminates with DC localization 
in T cell-rich areas of lymphoid tissues, where DC present peptide antigens acquired in 
the periphery in the context of MHC to circulating T cells. So, in order to mount an 
effective immune response, a coordinated regulation of DC migratory and functional 
properties must occur. 
Maturation is induced by microbial, tissue damage as well as immune signals. DC 
express a large array of receptors for pathogen-associated molecular patters (PAMPs) 
and damage- associated molecules patterns (DAMP). DAMPs include heat shock 
proteins (HSP), high mobility group box 1 (HMGB1) protein, uric acid and adenosine 
triphosphate (ATP), all mediators released upon damage to the tissues by pathogens, 
trauma, vascular damage, or necrosis 233, 234. 
The nature of an antigen can instruct the DC to influence the polarization of T cells 
by triggering specific receptors during uptake 235, 236. DC recognize a wide array of 
inhaled antigens through expression of ancient pattern-recognition receptors (PRR) such 
as toll like receptors (TLR), NOD-like receptors (NLR), and C-type lectin receptors that 
recognize motifs on virtually any inhaled pathogen, allergen, or substance 237. TLR 
ligands comprise a variety of microorganism-derived molecular structures, such as 
bacterial lipopolysaccharide (LPS), unmethylated cytosine-phosphate-guanosine (CpG) 
motifs in bacterial and viral deoxyribonucleic acid (DNA), and viral double-stranded 
ribonucleic acid (RNA). On the other hand, the binding of endogenous ligands such as 
heparan sulfate, hyaluronic acid and heat-shock protein 60 by TLR has been reported to 
be a signal of damage in case of abnormal release and accumulation of those products in 
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tissues 238. Distinct TLR ligands provide distinct activation status and cytokine 
production patterns, resulting in the induction of differential immune responses. 
In vitro-generated immature DC also express the inhibitory TLR family member 
SIGIRR (single immunoglobulin IL-1R)/TIR8, which is down-regulated during 
maturation 239. Bone marrow-derived DC from TIR8-/- mice show increased 
responsiveness in terms of cytokine production to some but not all TLR agonists. It 
would be interesting to evaluate if DC subpopulations in vivo differentially express 
TIR8 or if its expression is related to the local microenvironment where they are 
located. It could be hypothesized that immature DC present in mucosal tissues like the 
lung or the intestine, which are exposed to harmless antigens, would profit from 
inhibitory receptor expression that are turn off once the cells are activated by pathogens 
or inflammatory stimuli. 
Host-derived inflammatory stimuli able to induce DC maturation include molecules 
such as TNF-α, IL-1, IL-6, INF type I and II, and the T cell ligands CD40L and 
Receptor Activator for Nuclear Factor κ B Ligand (RANKL) 55-60. Multiple activating 
signals coexist in vivo, and their effects on DC activation and function are not merely 
additive. In this regard, TLR triggering and CD40-CD40L engagement have been 
reported to be necessary for fully DC capability to elicit effective T cell responses 240, 
241
. Simultaneous triggering of TLR can have synergistic effects. In addition, recent 
evidences suggest that non-TLR pattern-recognition receptors can also cooperate to 
optimize the outcome of the maturation process. DC-SIGN is a DC-specific C-type 
lectin that binds a broad panel of pathogens, including viruses, bacteria and Schistosoma 
mansoni parasite 242-244, and endogenous molecules like tumor glycoproteins 245. DC-
SIGN engagement of some pathogens, like Mycobacterium tuberculosis and 
Helicobacter pilori, appears to inhibit DC maturation as a strategy to favour pathogen 
survival 246, 247. Importantly, DC-SIGN is able to mediate cellular adhesion between DC 
and activated neutrophils through the specific binding to Mac-1, which would allow 
neutrophils to induce DC maturation through the paracrine production of pro-
inflammatory cytokines 248. Dectin-1 is a C-type lectin specific for β-glucan that is 
highly expressed on DC and macrophages. In addition to promote β-glucan-containing 
microbes phagocytosis, it synergizes with TLR2 to produce TNF-α, IL-12 and reactive 
oxygen species. Conversely, engagement of the endocytic mannose receptor by a 
specific mAb (monoclonal antibody) and by some natural ligands is able to elicit an 
anti-inflammatory secretory program characterized by high production of IL-10, IL-
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1Ra, IL-1R type II, and low level of IL-12 249, 250. It has been recently shown that 
scavenger receptors SREC-I (scavenger receptor expressed by EC) and LOX-1 (lectin-
like oxidized LDL receptor-1) collaborate with TLR2 in cell responsiveness to outer 
membrane protein (OmpA), a major component of the outer membrane of 
Enterobacteriaceae 63. SREC-I and LOX-1 bind OmpA while TLR2 transduces the 
signal. This mechanism may be functional in DC since they express LOX-I and 
probably SREC-I 251. TLR2-activated functional program includes the production of 
pentraxin 3 (PTX3), a soluble pattern recognition receptor that in turn binds OmpA and 
amplify the inflammatory response 252
 
253
. DC produce high amounts of PTX3 upon 
activation by different TLR agonists, which is further enhanced by IL-10 and INF type I 
and inhibited by INFγ and the anti-inflammatory agents dexamethasone, Vitamin D3 
and prostaglandin E2 (PGE2) 253. 
DC share most features of antigen processing and presentation with other APC 254. 
Exogenous protein antigens are processed in endosomes into peptides and loaded onto 
MHC class II that are displayed on the cell surface for recognition by antigen-specific T 
cells. Mature DC are ideally suited for presentation of the antigen they have captured at 
the time of activation. This is possible because maturation triggers the up-regulation of 
MHC II-complexes expression at cell membrane level while the overall antigen uptake 
capacity is inhibited, precluding the processing of antigens encountered after on. This 
property ensures that the antigens presented by a mature DC match with the 
environmental situation that triggers its maturation, and therefore is crucial for the 
effective transduction of information that DC undertake from the periphery to the 
lymphoid organs. Immature DC express significant levels of MHC II with a short half-
life. Maturation down-regulates MHC II endocytosis and, after a transient increase, 
down-regulates MHC II synthesis, thereby preventing turnover of MHC II- peptide 
complexes and promoting their stable expression at the cell surface 218, 255, 256. 
DC also express significant quantities of MHC I that is further up-regulated upon 
maturation 257 and therefore can present their own endogenous antigens after they have 
been degraded into peptides in the cytosol by the proteosome system. In addition, 
certain exogenous protein antigens may also be processed by DC in the context of MHC 
I, a unique DC process known as cross-presentation, that allows DC to cross-present 
antigens to cytotoxic CD8+ T cells 258-260. Moreover, DC can present in the surface lipid 
moieties associated with CD1 molecules, a family of receptors structurally related with 
MHC I 261.  
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In addition to MHC, mature DC strongly up regulate the expression of adhesion as 
well as co-stimulatory molecules that are involved in the formation of the 
immunological synapse, an area encompassing sites of contact between DC and T cells. 
Up-regulated molecules include the B7 family members CD80 and CD86, CD40 and 
OX40L. 135, 189, 262, 263. As mentioned before, maturation induces DC to secrete a distinct 
set of cytokines that help to determine the type of ensuing immune response, depending 
on the type of maturation stimulus 264, 265. In addition, TLR-agonist-, but not CD40L- 
activated DC produce reactive oxygen radicals that are important for intracellular 
microbe killing 266. Accumulating evidences indicate that the phenotypic and functional 
changes undergone by maturing DC are also associated with the specific population of 
activated DC 267, 268. 
P-DC express MHC II and the costimulatory molecules CD80 and CD86 and are able 
to present antigens to CD4+ T cells and cross-present antigens to CD8+ T cells, 
although less efficiently than classical DC 269. Besides producing type I IFNs, P-DC 
also secrete IL-12, IL-6, TNF- , and inflammatory chemokines. Through secretion of 
these cytokines and type I IFNs, P-DC may influence both innate and adaptive immune 
responses. Type I IFN and IL-12 promote multiple T-cell functions including long-term 
T-cell survival and memory 270, 271, Th1 polarization of CD4+ T cells 272, CD8+ T-cell 
cytolytic activity, and IFN-  production 271. Moreover, type I IFN and IL-12 increase 
NK cell-mediated cytotoxicity and IFN-  production in vitro and in vivo 273. IFN-  and 
IFN-β also promote the differentiation and maturation of DC allowing them to 
effectively present and cross-present antigen to naive T cells 274. By producing IL-6 and 
type I IFN, P-DC can also induce the differentiation of B cells into immunoglobulin-
secreting plasma cells 275 and instruct plasma cells to preferentially secrete IgG rather 
than IgM. By producing chemokines such as CXCL9 (MIG), CXCL10 (IP-10), CCL3 
(MIP-1 ), CCL4 (MIP-1β), and CCL5 (RANTES) 276, mouse and human P-DC can 
attract activated CD4+ and CD8+ T cells to sites of infection.  
 
1.2.2. Dendritic cell recruitment to peripheral tissues 
Classical DC are present in non-lymphoid peripheral tissues in an immature state. 
Immature DC are the immunological sentries of peripheral tissues and their recruitment 
at sites of inflammation in response to chemotactic stimuli is critical for optimal 
immune response. The expression and regulation of functional chemotactic receptors 
account for the different distribution of DC subsets in vivo. Immature DC express a 
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unique repertoire of inflammatory chemokine receptors (e.g. CCR1, CCR2, CCR5, 
CCR6) 132, 277-279. These receptors bind a pattern of "inflammatory" chemokines, 
including CCL2, CCL3, CCL4, CCL5, and CCL20 that are produced at peripheral sites 
of infection and immune reaction. In addition, immature DC also express functional 
CXCR4 280. Since CXCL12, the CXCR4 ligand, is constitutively expressed in both 
lymphoid and non-lymphoid tissues, this chemokine may play a role in the recruitment 
of DC in such tissues. Similarly, myeloid blood DC can migrate in response to a wide 
array of inflammatory chemotactic agonists 281, 282.  
It is generally believed that DC precursors in the peripheral blood migrate into 
peripheral tissues and differentiate to become immature DC. Although it is conceivable 
that the same classes of molecules that regulate DC migration in inflammatory 
situations also direct the migration of these cells under normal conditions (e.g. adhesion 
molecules and chemoattractants), the mechanisms that regulate the homing of DC or 
their precursors, in steady-state conditions need to be better elucidated 279, 283. The 
relevance of chemotactic receptors in DC travelling in vivo has been clearly documented 
in mice lacking PI3Kγ. PI3Kγ is located downstream seven-transmembrane chemotactic 
receptors and plays a non-redundant role in cell migration in response to chemotactic 
agonists 284. DC generated from PI3Kγ-null mice show a profound defect in the 
migration in response to both inflammatory and constitutive chemokines. A defect of 
DC migration was also observed in vivo in PI3Kγ-/- and most importantly, this defect 
was associated with a defective ability of PI3Kγ-/- mice to generate a specific immune 
response 285. Therefore, PI3Kγ may represent a new valuable target to control 
inappropriate activation of specific immune responses.  
A number of studies have established a role for CCR2 in the localization of LC 
precursors. It is of note that transgenic mice overexpressing CCL2, under the keratin 
promoter, have local accumulation of cells with DC morphology in the basal layer of 
the epidermis 286. However, LC in the skin of CCR2-/- mice is normal and CCL2 
expression has only been demonstrated in inflamed skin, indicating that it may not play 
a role in steady-state conditions. Following differentiation, LC precursors start to 
express CCR6 and respond to the cognate ligand CCL20 287-289. Since CCR6-/- mice 
have a normal numbers of skin DC 290, and CCL20 is principally up-regulated in 
inflammation, it is likely that the CCR6/CCL20 axis plays a role mainly in 
inflammatory skin disorders that are characterized by the expression of CCL20 by 
inflamed keratinocytes. CCL20 plays also a role for the homing of DC to mucosal 
Introduction                                                  46 
surfaces. In particular, CCL20 is constitutively expressed in murine intestinal Peyer’s 
patches, and CCR6-/- mice lack for DC in the subepithelial dome of Peyer’s patches 
within the intestinal mucosa, which correlates with a defect in humoral immune 
response to oral antigens in these mice 290, 291. Recently, Shaerli and colleagues have 
proposed that CXCL14, may be involved in the homeostasis of CD14+ LC precursors 
292
. CXCL14 is expressed in the superficial dermal plexus as well as within epidermis in 
normal human skin. It vitro, CXCL14 has a restricted chemoattractant ability for 
CD14+ DC precursors and not other myeloid or lymphoid cell subpopulations. Using an 
artificial epidermal model that closely resembles normal human skin and spontaneously 
expresses CXCL14 , they demonstrated that CD14+ DC precursors migrate into the 
suprabasal layer of keratinocytes, where they indeed acquired LC phenotype and 
function 292. Further work with gene deficient mice is needed to mechanistically 
demonstrate its involvement in the recruitment of LC precursors. It had been previously 
reported that CXCL14 is chemotactic for monocytes 293 and immature DC 294. CXCL14 
is also express in other epithelial tissues, such as intestinal tract and the airways 293, 295, 
suggesting a broader role for this chemokine in mucosal DC homeostasis 
Under inflammatory conditions an array of chemokines are expressed by resident 
cells and presented by activated EC, these include CCL2, CCL5, CCL7 CCL13, CCL20 
and CCL22 15, 296. DC near the site of immune reaction represent also an important 
source of inflammatory chemokines. Pro-inflammatory mediators, such as TNF-α and 
IL-1 produced by tissue macrophages further contribute to the expression of inducible 
chemokines by virtually all cells resident in the area. As previously mentioned, 
immature DC express a repertoire of chemokine receptors that can interact with 
inflammatory chemokines. Interestingly, immature DC constitutively produce high 
levels and respond to the orphan human chemokine CCL18 297. CCL18 levels are high 
in human plasma and may contribute to the physiological homing of DC. In addition, 
CCL18 production has been demonstrated in several diseases, including various 
malignancies and inflammatory disorders, and may have a role in immature DC 
retention at the tissues in these conditions 298.  
Immature DC express a wide variety of receptors for chemotactic agonists different 
from chemokines. These chemotactic stimuli are rapidly produced (within minutes) at 
the site of inflammation and represent an early signal for the recruitment of DC or their 
precursors, that can precede chemokines action. Early work documented that myeloid 
immature DC, but not mature DC, express functional receptors for fMLP and 
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chemotactic components of the complement cascade (e.g. C5a) 133. The expression of 
C5a receptors was also confirmed in vivo in LC 299. The formyl peptide receptor family 
includes multiple proteins, two of them FPR and FPR3 were found to be expressed by 
immature DC 300. FPR is the fMLP receptor, whereas FPR3 is activated by the 
WKYMVM hexapeptide originally identified from a combinatorial peptide library for 
its ability to stimulate phophoinositide hydrolysis in lymphocytes 301. Recently, F2L an 
endogenous high affinity ligand for FPR3 was isolated from porcine spleen 302. F2L is a 
highly conserved acetylated 21-aminoacid peptide derived from the cleavage of the N-
terminus of the intracellular heme-binding protein that activates FPR3 in the low 
nanomolar range. The acetylation of the N-terminal methionine of F2L is a modification 
that is reminiscent of the formylated methionine of bacterial and mitochondrial peptides 
active on FPR. F2L is able to induce calcium mobilization and chemotaxis of 
monocytes and immature DC. Therefore, F2L could be involved in the response of these 
cells to infection, inflammation or cell death. Recent evidences indicate that DC are 
attracted by dead or dying cells 303. The first self-molecules shown to represent danger 
signals were the HSP gp96 or hsp70. These proteins are released from necrotic cells and 
are able to potently activate antigen-presenting cells 304. Intracellular nucleotides 
released under conditions of hypoxia, ischemia, inflammation or mechanical stress, and 
crystalline uric acid derived from dead cells, were also shown to stimulate DC 305, 306.  
Human and mouse DC express functional receptors for platelet activating factor 
(PAF) 64, 65. Since PAF is synthesized at the site of inflammation following PLA2 
activity, it is conceivable that it functions to recruit DC to the pathological site. Using a 
FITC (fluorescein isothiocyanate) skin painting assay, it was recently reported that the 
migration of LC to skin draining lymph nodes is increased in PAFR-/- mice and in WT 
animals administered with a PAFR antagonist. Similarly, the PAFR antagonist 
promoted the egression of LC from human skin explants, in vitro 307. These results 
suggest that PAF normally acts as a negative regulator of DC mobilization from skin to 
lymph nodes. The retention ability of PAF into peripheral tissues may be relevant in the 
retention of DC at pathological sites, such as atherosclerotic plaques 307. 
One of the effector’s mechanisms of innate immunity relies on the generation of 
antimicrobial substances; these include inorganic cytotoxic molecules (e.g. hydrogen 
peroxide and nitric oxide) and antimicrobial peptides, like defensins and cathelicidins. 
The latter, in addition to their antimicrobial function, possess chemotactic activity for 
immature DC. Human α-defensins and β-defensins are chemotactic for immature, but 
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not mature DC 308. The chemotactic activity of β-defensins is mediated by the 
interaction with CCR6, the receptor for CCL20. Although the migration in response to 
α-defensins is inhibited by PTX, the identity of the receptor for these proteins has not 
yet been identified 308. Sharing a receptor with chemotactic factors is not unique to β-
defensins, because LL-37, an antimicrobial peptide, promotes the migration of human 
neutrophils, monocytes and T lymphocytes through the interaction with FPRL1 309. 
Eosinophil-derived neurotoxin (EDN), a protein belonging to the ribonuclease A 
superfamily was found to be a selective chemotactic agonist for DC. Its effect is 
sensitive to the action of PTX; however, the nature of the chemotactic receptor engaged 
on DC membrane is still unknown 310. 
P-DC are confined to primary and secondary lymphoid organs, a characteristic 
consistent with the fact that P-DC from human blood express an extensive profile of 
chemotatic receptors, however, with the exception of CXCR4 these receptors are 
apparently non functional 194. Although unable to directly induce P-DC migration, 
CXCR3 ligands increase P-DC chemotactic response to CXCL12 311. Furthermore, 
CXCR3 ligands are fully competent in inducing P-DC adhesion and migration when 
immobilized on heparan sulphates expressed by EC 312. Two recent reports showed that 
P-DC purified from patients with chronic hepatitis C, or exposed in vitro to IFN-α, 
acquire the ability to respond to CCR2, CCR5 and CXCR3 ligands 313, 314. These results 
suggest that under appropriate stimulatory conditions, additional chemokine receptors 
may be involved in human P-DC recruitment. P-DC infiltrate have been found in 
peripheral tissues associated with diverse pathologies such as autoimmune diseases (e.g. 
LE disease, psoriasis and rheumatoid arthritis) 187, 315-317 318, allergic diseases (e. g. 
contact dermatitis and nasal mucosa polyps) 318 and tumors 319, 320.  
In addition to chemokines, adenosine and F2L have the ability to induce P-DC 
migration through the engagement of the adenosine receptor A1 and FPR3 (the formyl 
peptide receptor formerly known as FPRL2), respectively 321, 322. It was also reported 
that like M-DC, P-DC have functional receptors for the anaphylatoxins C3a and C5a 323. 
Finally, IL-18 induces the migration of P-DC 324. All these data suggest that, in addition 
to chemotactic cytokines, signals associated with inflammation and tissue damage may 
contribute to recruitment of P-DC to pathological tissues. 
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1.2.3. Dendritic cell recruitment to secondary lymphoid organs 
In order to activate T lymphocytes, maturing DC migrate from the peripheral tissues 
to the draining lymphoid organs. As discussed before, inflammatory chemokines, acting 
through chemokine receptors such as CCR1, CCR2 and CCR5, function as signals to 
localize immature DC in inflammatory sites. Maturation is associated with 
downregulation of receptors for inflammatory chemokines and de novo expression of 
the chemokine receptor CCR7 that renders the cells responsive to CCL19 and CCL21, 
two chemokines that are expressed at the luminal side of high EC and in the T cell rich 
areas of secondary lymphoid organs, like tonsils, spleen and lymph nodes 325-327. Within 
the T cell area, CCL19 is expressed by mature interdigitating DC, whereas CCL21 is 
expressed by stromal cells 328. The “DC-chemokine receptor switch” paradigm is 
thought to be responsible for the migration of DC from the periphery to the draining 
lymph nodes. Crucially, the same signals that promote DC maturation virtually trigger 
the chemokine receptor switch, such as IL-1, TNF and LPS 132, 327, 329, 330. Remarkably, 
CCR7 can also bee induced in partially-matured DC, like DC exposed to apoptotic cells, 
or even in steady-state conditions, as  demonstrated for skin DC; this mechanism is 
thought to be important to allow DC to carry on self-antigens to the lymphoid organs for 
tolerance induction 331, 332. 
In vitro exposure of DC to LPS, IL-1,  TNF, and CD40 ligand, induce a rapid (< 1 h) 
inhibition of chemotactic response to CCL3, CCL4, CCL5, CCL7, C5a and fMLP 137, 
327, 329, 333, 334
. Receptor desensitization by endogenously produced chemokines is likely 
to be responsible for this effect, however, the reported desensitization to C5a and fMLP, 
two chemotactic factors that are not produced by activated DC, implicates additional 
agonist-independent mechanisms 137, 329. As previously observed in phagocytic cells335, 
336
, during maturation inhibition of chemotaxis is followed, with a slower kinetics, by 
the reduction of membrane receptors and by the down-regulation of mRNA receptor 
expression 327, 329. Concomitantly, the expression of CCR7 and the migration to CCL19 
and CCL21 is strongly upregulated, with a maximal effect at 24 h.  
CCR7 expression by DC was shown to be required for the entry of DC into 
lymphatic vessels at peripheral sites both in steady state and inflammatory conditions 
331, 337
. CCR7-/- mice are characterized by the absence of CD11c+MHCIIhigh DC, a 
subpopulation of DC that is postulated to migrate in a semimature state of activation, 
from the skin to the draining Lymph nodes to maintain tolerance under steady-state 
conditions 331. During inflammation, the entry of DC into lymphatic vessels is boosted 
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by the up-regulation of CCL21 on lymphatic EC. Therefore, inflammatory stimuli not 
only promote the recruitment of immature DC into tissues but also initiate their 
maturation process and boost the recruitment of maturing DC into lymphatics 337.  
The migration pathway that leads DC from periphery to secondary lymphoid organs 
is still poorly understood and may involve multiple signals in addition to CCR7. It has 
been reported that LC up-regulate CD44 and the integrin αVβ3 which are receptors for 
osteopontin, an important factor in LC migration to draining lymph nodes 338. More 
recently it was proposed that CCR8 and its cognate ligand CCL1 are involved in the 
migration of mouse monocyte-derived DC out of the skin 339. In vitro, the reverse 
transmigration of human monocyte-derived DC was significantly inhibited by the 
presence of blocking CCR8 antibodies. Since CCL1 is expressed in the subcapsule of 
the lymph nodes, it is possible that CCL1/CCR8 may function downstream the entry of 
DC into the lymphatics by regulating the entry of the afferent DC in the subcapsular 
sinus of the lymph nodes 339. Mature DC are also known to express chemotactic 
receptors other than CCR7, although their biological relevance is still unclear. Earlier 
studies have shown that the expression of CXCR4, the CXCL12 receptor, is retained 
during DC maturation and mature monocyte-derived DC were shown to migrate in 
response to CXCL12 137, 334. However, blood DC matured in vitro apparently do not 
express functional CXCR4 194.  
Mice defective in β2 or α6 integrin have showed a reduced ability in the migration of 
cutaneous DC to the draining lymph nodes, whereas β3 integrins appear to be not 
important 340, 341. Similarly, cutaneous DC from CD47 (integrin-associated protein)-
deficient mice show an impaired migration to draining lymph nodes 342. In vitro, mature 
BM-DC from these mice showed impaired migration to CCL19 despite normal 
expression of CCR7. CD47 is an ubiquitous G protein-coupled 5 transmembrane 
receptor that interacts in cis with β1 and β3 integrins and promotes cell activation 343. 
CD47 is also a ligand of SIRPα (signal regulatory protein α), a glycoprotein expressed 
in certain DC subsets. Interestingly, SIRPα-deficient mice showed reduced migration of 
LC to the draining lymph nodes 344. Conversely, DC generated from mice defective for 
JAM-A, showed a selective increase in their capacity to transmigrate across lymphatic 
EC monolayers in vitro. In vivo, JAM-A-/- mice have an enhanced migration of skin 
DC to lymph nodes and an increased response in a contact hypersensitivity model 345. In 
the same way, in vivo DC migration was increased in SPARC (secreted protein, acidic 
and rich in cysteine) null mice 346. SPARC is a calcium-binding matricellular 
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glycoprotein that binds a range of extracellular matrix components. The facilitated 
migration of DC in SPARC-/- mice was associated to an increased ability to mount an 
antigen specific immune response 346. Consistently with the notion that the interaction 
with extracellular matrix components may represent an obstacle for the migration of 
DC, MMP-9 and –2 are required for the migration of skin DC in vivo. MMP-9-/- mice 
present a severe defect in the egression of LC from skin ex-vivo and in vivo 347, and for 
the recruitment of DC into the airways of antigen-sensitized mice 348. CD44 is a 
heterogeneous multifunctional protein that functions as a major cell surface receptor for 
hyaluronate, an extracellular matrix component. CD44 isoforms are differentially 
modulated during DC maturation and participate in their migration out of the skin and 
in the induction of the sensitization phase of contact hypersensitivity response 349. 
Overall these findings provide a model for DC trafficking in which activation of 
inflammatory chemokine receptors and the regulation of adhesion molecules and 
protease secretion, function as signals to localize immature DC or their precursors to 
peripheral tissues. After antigen uptake, immune/inflammatory stimuli induce DC 
maturation and the loss of responsiveness to inducible chemokines locally produced. 
This unresponsiveness plays a permissive role for DC to leave peripheral tissues. 
Meanwhile the slower up-regulation of CCR7, and possibly other chemotactic 
receptors, prepare DC to respond to chemokines expressed in lymphoid organs, where 
priming of T lymphocytes takes place.  
In homeostatic conditions P-DC are not present in peripheral tissues, been present 
mainly in secondary lymphoid organs, where migrate directly from the blood 
compartment, across HEV 350. Indeed, P-DC express lymph node homing molecules 
such as L-selectin and PSGL1, the counter-ligand of P- and E-selectins 312. In addition, 
P-DC express CXCR4, the receptor for CXCL12, which is a homeostatic chemokine 
expressed by HEV 350, 351. L-selectin and CXCL12 are apparently central in inducing P-
DC migration, as shown by the reduced number of P-DC in the secondary lymphoid 
organs of mice defective for L-selectin and DOCK2 (dedicator of cytokinesis), a 
molecule involved in CXCR4 signalling in P-DC 352. Under reactive conditions, 
additional molecules are involved in mouse P-DC homing to lymph nodes, such as E-
selectin and the chemokine receptors CCR5 and CXCR3 351, 353. Consistent with in vivo 
data, mouse P-DC migrate in vitro in response to CCL3 and CCL5, and to CXCL9 and 
CXCL10, the respective CCR5 and CXCR3 ligands. CCR7 is upregulated following 
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activation, and it’s likely to be involved in mature P-DC migration through CCL19 and 
CCL21 presented by HEV. 
 
1.2.4. Regulation of dendritic cell migration 
Multiple evidences have shown that chemokine receptor expression is not predictive 
of DC migration suggesting that the coupling of chemokine receptors to chemotaxis is 
also regulated at the signalling level 194, 354. For instance, the simultaneous exposure of 
DC to maturation factors and anti-inflammatory cytokines (e.g. IL-10) uncouples 
inflammatory chemokine receptors from chemotaxis and converts them in scavenging 
chemokine receptors 354. Recent findings revealed that eicosanoids, such as cysteinyl 
leukotrienes (cysLT) and PGE2 regulate CCR7-dependent migration of DC to lymph 
nodes 355, 356. Experimental evidence on the role of cysLTs in DC migration emerged 
from studies in mice lacking the lipid transporter multidrug resistance protein 1 (MRP1) 
and by the use of MRP1 blocking antibodies 357, 358. In the absence of MRP1 the 
migration of epidermal DC to the draining  lymph nodes was impaired and the 
exogenous administration of LTC4 or LTD4 could rescue the defect. DC express the 
cysLT receptor CysLT1, and in vitro, cysLT promoted DC migration in response to the 
CCR7-ligands CCL19 and CCL21. Therefore, the MPR1-mediated efflux of cysLT and 
the autocrine or paracrine activation of cysLTR promote the migration of maturing DC. 
More recently, two studies have addressed the role of cysLT on DC functions, in 
particular the modulation of the cytokine profile and the antigen presentation capacity 
of DC 359, 360. They have shown that inhibition of cysLT signalling suppresses antigen-
inhalation-induced eosinophilic lung inflammation but did not explore the lymph nodes 
homing capacity of lung DC. However, Randolph GJ and colleagues have reported that 
airway DC migration to the mediastinal lymph nodes is not modulated in MRP1-
deficient mice, suggesting a tissue-specific regulation 361.  
FTY720 is a synthetic derivative from ISP-1 (sphingosine-like immunosuppressant 
1), a compound from traditional chinese medicine. FTY720 was recently shown to 
prolong allograft survival by increasing the migration of T lymphocytes to CCR7 
ligands and by promoting their sequestration in secondary lymphoid organs 362, 363.  
FTY720 is phosphorylated in vivo to its active metabolite FTY720-P that is analogous 
to S1P and acts through the S1P (1-5) receptors 364. SP1 was shown to induce the 
selective migration of human immature DC 365 and to inhibit the production of Th1 
cytokines 366, 367. Conversely, in the mouse system, both immature and mature DC were 
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reported to migrate to S1P 368, while in another study only mature DC were responsive
 
369
. However, more systematic studies are needed to demonstrate that these differences 
are not simply due to the DC tissue origin or culture conditions  
PGE2 modulates multiple aspects of DC biology, such as maturation, cytokine 
production, T cell activation and apoptosis 356. Furthermore, PGE2 promotes the 
migration of mature human monocyte-derived DC to the CCR7 ligands CCL19 and 
CCL21 370, 371. The effect of PGE2 on these cells is mediated by two of the four PGE2 
receptors, namely prostaglandin E receptor (EP) 2 and 4 and the cAMP (cyclic 
adenosine monophosphate) pathway. Interestingly, blood M-DC, matured in vitro, did 
not require PGE2 for an optimal migration in response to CCR7 ligands 371. These 
results suggest that the coupling of CCR7 to chemotaxis is regulated by the state of 
activation/maturation of DC. The importance of PGE2 for DC migration has been 
highlightened in vivo by the use of mice that are genetically defective for EP4 372. EP 4 -
/- mice displayed a reduced migration of skin LC to regional lymph nodes after FITC 
sensitization, in vivo, and a reduced spontaneous emigration from skin explants, ex-
vivo. The nonredundant role of EP4 in LC migration was further confirmed in WT mice 
by the use of an EP4 antagonist, and correlated with an impaired induction of contact-
type hypersensitivity responses 372. PGE2 is secreted by monocytes, macrophages, 
fibroblasts activated by inflammatory stimuli 373. This suggests that immature DC are 
exposed to PGE2 in situ at the site of inflammation. Recently, it has been reported that 
nitric oxide can also give a second signal to promote mature DC migration to the CCR7 
chemokine CCL19 374.  
PGD2 is released by mast cells during allergic response that interact with two 
different receptors, the D prostanoid receptor 1 and 2 375. Opposite to PGE2, PGD2 was 
shown to inhibit LC migration to the skin draining lymph nodes during percutaneous 
infection with the helminth parasite Schistosoma mansoni 375 and the migration of lung 
DC in vivo 376.  
New anti-inflammatory lipid mediators were recently identified during the resolution 
of inflammation and following aspirin treatment 377. These compounds were shown to 
inhibit leukocyte migration by interacting with chemotactic receptors. Among them, 
lipoxin A4, an autacoid generated from arachidonic acid, was found to inhibit DC 
mobilization in the spleen through the interaction with FPRL1 378. Similarly, resolvin 
E1, a new bioactive oxygenated product of eicosapentaenoic acid, a component of fish 
oils, reduced dermal inflammation, IL-12 production and DC migration through the 
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interaction with ChemR23, the chemerin receptor 73. Therefore, the engagement of the 
same receptor by alternative ligands may result in an opposite biological output.  
CD38 is an ectoenzyme that catalyses the synthesis of cyclic adenosine biphospate 
ribose, a potent second messenger for calcium release, as well as a receptor that initiates 
transmembrane signalling upon engagement with its counter-receptor CD31. CD38 was 
found to be upregulated during DC maturation and to promote a DC membrane and 
functional phenotype in vitro 379. CD38 apparently controls DC migration, since mice 
lacking CD38 have a defect in the recruitment of DC precursors to peripheral tissues 
and in DC mobilization of mature DC to the draining lymph nodes 380. In human 
monocyte-derived DC, CD38 is closely associated with CD11b and CCR7 at the 
membrane, and its engagement is necessary for efficient in vitro chemotaxis and trans-
endothelial migration to CCL21 381.  
The lipid mediator LTB4 is involved in the regulation of DC traffic, attracting immature 
and maturing DC to the sites of inflammation and to the draining lymph node via the 
LTB4 receptor BLT1. It controls DC traffic also indirectly by inducing CCR7 
expression and function 382 
 
1.3. Asthma. General characteristics 
Asthma is a chronic inflammatory disorder of the airways arising as a result result of 
a dysregulated immune response to commonly encountered antigens in genetically 
predisposed individuals. It is characterized by the clinic pathologic symptoms of 
intermittent and reversible airway obstruction, attacks of wheezing and breathless due to 
broncocostriction, mucus hypersecretion, infiltration of Th2 cells, eosinophils and mast 
cells in the airway wall, airway hyperresponsiveness (AHR) to non specific stimuli and 
thickening of submucosa, eventually leading to impaired epithelial repair and airway 
remodelling 383. 
Under physiological conditions, activated Th2 cells are able to induce an immune 
response against extracellular or parasitic infections. In allergic asthma, genetically 
susceptible individuals mount a chronic Th2 cell type immune response to common 
allergens, like house dust mite (HDM), plant pollen, molds and animal dander by 
secreting cytokines like IL-4, IL-5, IL-9, IL-10, IL-13 and granulocyte macrophage-
colony stimulating factor (GM-CSF), whereas mast cells and eosinophils exert 
important effector functions 384 (Fig. 9). Individually, these cytokines can already 
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explain many of the salient features of asthma as IgE synthesis, growth and activation of 
eosinophils and mast cells and expression of EC-adhesion molecules 385. 
IL-4 and IL-13 induce the expression of cell adhesion molecules on inflamed 
endothelium and epithelial production of chemokines, leading to the recruitment of 
inflammatory cells, and act on epithelia inducing globet cell metaplasia. IL-4 stimulate 
the production of IgE by B cells and IL-13 acts on bronchial smooth muscle cells 
causing bronchial hyper-reactivity (BHR). IL-5 is important for the growth, 
differentiation and activation of tissue eosinophils while IL-9 is important for mast cell 
growth and activation. GM-CSF stimulates the growth of eosinophils and the activation 
of APCs 386. Moreover, cytokines produced by Th2 cells and inflammatory cells can 
affect the airway epithelium, subepithelial (myo-) fibroblasts and smooth muscle cells 
in the lungs, thus leading to structural abnormalities 385.  
Mast cells play a key role in asthma through the release of several 
bronchoconstrictors, including histamine, which is preformed and stored in granules, 
and the lipid mediators leukotriene C4, leukotriene D4, leukotriene E4 and prostaglandin 
D2 (PGD2}, which are synthesized following mast-cell activation. The release of these 
mediators may account for the variable bronchoconstriction observed in asthma, as 
these mediators are released by various environmental triggers, such as allergens, and 
an increase in plasma osmolality as a result of increased ventilation during exercise. 
Mucosal mast cells are recruited to the surface of the airways by stem-cell factor (SCF; 
also known as KIT ligand} released from epithelial cells, which acts on KIT receptors 
expressed by the mast cells 387. Mast cells also release cytokines that are linked to 
allergic inflammation, including interleukin IL- 4, IL- 5 and IL- 13 388.  
The inflammation that occurs in asthma is often described as eosinophilic. The 
functional role of eosinophils in asthma is not clear and the evidence that links their 
presence to airway hyper-responsiveness has been questioned by the finding that the 
administration of IL-5-specific blocking antibodies that markedly reduce the number of 
eosinophils in the blood and sputum does not reduce airway hyper-responsiveness or 
asthma symptoms 389. Eosinophilic bronchitis is not associated with AHR, but 
subepithelial fibrosis does occur, which suggests a role for eosinophils in airway 
fibrosis. Interestingly, the presence of eosinophils seems to be a good marker of steroid 
responsiveness 390. 
B cells have an important role in asthma, through the release of allergen-specific IgE 
which binds to high-affinity Fc receptors for IgE (FcεRI) expressed by mast cells and 
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basophils, and to low-affinity Fc receptors for IgE (FcεRII) expressed by other 
inflammatory cells, including B cells, macrophages and possibly eosinophils 391. The 
Th2-type cytokines IL-4 and IL-13 induce B cells to undergo immunoglobulin class 
switching to produce IgE. 
Th2 cells do not react directly to inhaled antigens, as their T cell receptor can only 
recognize antigens that are processed into peptides for presentation in the context of 
MHC molecules 392. Like in other epithelia and skin, the lung is equipped with an 
elaborate network of DC that can be found throughout the conducting airways, lung 
interstitium, lung vasculature, pleura, and bronchial lymph nodes 393, 394 
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Figure. 9. Effector functions of Th2 cells. Effector Th2 cells produce several 
cytokines and chemokines that exert their effects on eosinophils, airway smooth muscle, 
epithelium and endothelium, resulting in several pathologic characteristics of asthma. 
(From Van Rijt and Lambrecht, 2005) 395 
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1.3.1. Chemokines in asthma 
Chemokines are key players in asthma because they promote the recruitment of both 
immune and structural cells to the lung and direct specific cell populations into different 
compartments within the lung tissue and control leukocyte activation 396, 397. Cellular 
sources of chemokines within the asthmatic airway include inflammatory cells and 
structural cells like epithelial cells, fibroblasts, and EC 398. 
Local Th2-cell dominance during allergic asthma is maintained, to a large degree, 
through production of the Th2 chemokines CCL17 and CCL22 399, although the 
mechanism initiating expression of these CCR4-binding chemokines is not yet fully 
understood 400. CCL17 is constitutively expressed in epithelial bronchial cells from 
healthy donors, but is overexpressed in subjects with asthma 401. Regarding CCL22, 
some studies report a weak constitutive expression in healthy donors, with no evidence 
of its regulation in patients with asthma 402, while other demonstrate a high 
concentration of CCL22 in broncheoalveolar lavage (BAL) from individuals with 
asthma 403. After activation and differentiation Th2 cells produce CCL1 and CCL22 15, 
both chemoattractants for Th2 cells, favoring a Th2 environment by a positive loop. 
Degranulated eosinophils release CCL5, CCL7, CCL11 and CCL13. Eosinophils are 
mainly recruited through the CCR3 receptor whose agonists: CCl1, CCL5, CCL7 and 
CCL13 present at high levels in asthma. This concentrated expression might 
preferentially target eosinophils to the airway. However other non-CCR3-binding 
chemokines can cause the migration and activation of eosinophils. CCL3, a 
CCR1/CCR5 ligand and CCL22, a CCR4 ligand, could induce chemotaxis of 
eosinophils through a CCR3 independent mechanism 404, 405. An increase in CCL3 
production has been observed in the lungs of patients with asthma 406 and in the nasal 
secretions of subjects with allergic rhinitis after allergen challenge 407. Blocking of 
CCL3 in several animal models suggests a role for this chemokine in mild eosinophils 
mobilization during the first stage of airways allergic and in BHR-associated disease 408. 
Mast cells release CCL2, CCL3 and CCL11, all of which are involved in leukocyte 
attraction during inflammation, thus connecting mast cell secretion with the late phase 
response in asthma 409, 410. CCL11 binding to CCR3 expressed on mast cells surface 
after Fc-receptor for IgE crosslinkage, provide a second signal, leading to amplification 
of Fc-receptor for IgE-dependent IL-13 production 411. CCL2 is able to recruit and 
activate mast cells. Instillation of CCL2 into the airways induces marked and prolonged 
airway hyper-response in mice, which is associated with mast cell degradation 412. 
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Macrophages in the lung insterstitium produce CCL3, CCL7 and CCL22 that address 
eosinophil migration out of the blood vessels and into the lung tissue 409, while DC 
produce the CCR4 ligands CCL17 and CCL22, suggesting that these cells are capable 
of selectively recruit Th2 cells and/or CD4+ CD25+ regulatory cells (Treg) at sites of 
inflammation 413. 
CXCL12 expressed in HEV contributes to the migration of naïve T cell to draining 
lymph nodes via CXCR4. Hoshino et al. suggested that CXCL12 could play a role in 
airway remodelling by promoting angiogenesis 414 
The two IFN-inducible chemokines, CXCL10 (IP-10) and CXCL9, have a role in 
modulating allergy phenotype 415, 416. Expression of CXCL9 is localized primarily to 
airway epithelial cells and functions by simultaneously diminishing IL-4 and enhancing 
IL-12 levels, suggesting that CXCL9 is able to direct activated T cells toward a Th1-cell 
phenotype significantly reducing AHR and eosinophil accumulation in allergen-
sensitized and challenged mice 417. CXCL10 has be shown to largely induce the 
opposite effect 415. CXCL10 can induce a degree of eosinophil chemotaxis through 
CXCR3, however CXCL9 has no chemotactic effect and actually exerts a blocking 
effect on eosinophil migration toward potent chemotactic stimuli such as CCL11 416. 
Both CXCL9 and CXCL10 bind to CXCR3, been capable of differentially regulating 
allergic asthmatic responses through a single receptor, indicating a mechanism by which 
Th1 and Th2 cytokine regulation can be implicated in this CXCL9/CXCL10 axis. 
There is little information on the role of CXCL13 in airways. Overexpression of 
CXCL3 has been detected by microarrays in an asthma mouse model 418 and in 
bronchial biopsies of patients with asthma 419. Neutralization of CXCL13 employing 
specific antibodies decreased the number of infiltrating cells, including lymphocytes, 
macrophages, eosinophils, and neutrophils, as well as the formation of cells surrounding 
inducible bronchus-associated lymphoid tissue suggesting some role in migration of 
leukocytes associated with asthma 397, 419 
As discussed above, the structural cells of the lung might be a significant source of 
chemokine mediators, allowing localization of specific leukocyte populations into and 
around the airway. Epithelial cells of asthmatic people strongly upregulate CCL5, 
CCL11 and CCL13 420, 421. CCL11 is beside the most potent degranulator agent. This 
concentrated expression might preferentially target eosinophils to the airway. In 
addition to recruiting and activating eosinophils, the same chemokines can affect other 
asthma-related leukocyte populations, such as basophils and Th2 cells 138, 143. Airway 
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EC are also a source of chemokines that contribute to the recruitment and the activation 
of basophils, eosinophils and lymphocytes into the airways during inflammatory 
responses. For instance, a combination of TNF-α and IFN-γ induced the production of 
CCL5 from EC isolated from nasal mucosa of subjects with allergic rhinitis. 
Interestingly, this cytokine-induced CCL5 production was higher in nasal mucosal EC 
recovered from atopic subjects as compared to non-atopic controls 422. In parallel with 
observations in epithelium, cytokines, generated in response to respiratory virus 
infection, which is frequently associated with asthma exacerbation, can increase 
vascular permeability and might provide a mechanism by which respiratory viral 
infection can lead to leukocyte migration out of the circulation, leading to airway 
inflammation and immune modulation in the lung 423.. The production of CX3CL1 
(fractalkine) by EC during inflammation also represents as a potential important 
initiator of CD4+ T-cell recruitment during allergic asthma. CX3CL1 is constitutively 
expressed by pulmonary EC of allergic asthmatics and in bronchoalveolar lavage after 
segmental allergen challenge accompanied by an increase in CX3CR1 function by 
CD4T cells in the peripheral blood in a manner that correlates positively with 
infiltrating cell numbers 424. 
Beside to contribute to the integrity of the lung tissue and the repair process during 
inflammation, lung fibroblasts participate in the local immune response by secreting an 
array of inflammatory cytokines and chemokines. For instance, after stimulation with 
TNF-α in vitro, fibroblasts stimulated the migration of eosinophils by the release of 
CCL5 and CCL11 425. In addition, both IL-4 and IL-13, strongly involved in allergic 
asthma, have been shown to upregulate CCL2 426, which recruits macrophages and 
basophils, hereby contributing to the asthmatic phenotype. Moreover, during airway 
inflammation, structural cells can also be activated by certain chemokines, which may 
contribute to the airway remodelling observed in asthma; e.g. chemokines might play a 
role in the peribronchial smooth muscle hypertrophy observed in asthmatics, as is 
illustrated by CCL1, which directly induces smooth muscle cell activation in vitro 427 
and CCL2, a competence factor for fibroblast activation 428. 
 
1.3.2. Dendritic cells in asthma 
The mouse lung is grossly divided into large conducting airways and lung 
interstitium containing alveloar septa and capillaries where gas exchange is taking place 
429
. Like in other epithelia and skin, the lung is equipped with an elaborate network of 
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DC that can be found throughout the conducting airways, lung interstitium, lung 
vasculature, pleura, and bronchial lymph nodes. At least five different subsets of DC 
can be found in the lungs (Fig. 10) 393, 430. In steady-state conditions, the conducting 
airways are lined with an intraepithelial highly dendritic network of 
MHCIIhighCD11chigh cells that are mostly CD11b- and, at least in the mouse and rat, 
express langerin and the mucosal integrin CD103 (αEβ7). These cells have the 
propensity to extend dendrites into the airway lumen through formation of tight 
junctions with bronchial epithelial cells 393, 431-433. Immediately below, the lamina 
propria of the conducting airways contains MHCIIhighCD11chigh cells that are highly 
expressing CD11b and are a rich source of proinflammatory chemokines 433, 434. The 
CD11b+CD103- subset also expresses the SIRPα molecule, a binding partner to CD47 
involved in DC migration 435. A similar broad division into CD11b+ and CD11b- can 
also be applied to lung interstitial CD11c+ DC 393, 436. Both CD11b+ and CD11b- 
subsets express high amounts of CD11c, so they can best be denominated as 
conventional DC, to contrast this with another population of CD11cint P-DC that express 
Siglec-H, and BST1 and some markers shared with granulocytes and B cells 223, 393, 437. 
The exact anatomical location of lung P-DC is unclear although they can be found to 
line alveolar septa in situ and have been recovered from digests of large conducting 
airways 223, 429. The alveolar space also contains CD11chighMHCIIhigh DC. At least in the 
rat and man, alveolar DC are highly enriched in CD103+ subsets that resemble LC in 
man. Under inflammatory conditions, such as viral infection, allergen challenge, or LPS 
administration, there is recruitment of additional subsets of CD11b+ monocyte-derived 
DC that rapidly upregulate CD11c and retain expression of Ly6c as a remnant of their 
monocytic descent, and are easily confused with resident CD11b+ conventional DC 393, 
438, 439
.
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Figure 10. Lung DC subsets. In steady-state conditions, conventional DC (CD11b+ 
and CD11b− subsets) line the conducting airways. They are also found in the interstitial 
compartments. P-DC are found in both compartments with a slight preference for the 
interstitial compartment. The alveolar space contains DC, autofluorescence has to be 
considered to differentiate them from macrophages. Under inflammatory conditions, 
there is recruitment of CD11b+ monocytes that rapidly become DC. During viral 
infections as well as in some cancers, there is also recruitment of IFN-producing killer 
DC, a subset of NK cells CD11c+B220+, can occur. To distinguish them from P-DC 
staining for NK1.1 is needed (From Lambrecht and Hammad, 2009)394 
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Based on the anatomical distribution of even the most exposed DC, it is clear that 
DC are basically always covered by a layer of epithelial cells that seal off the inhaled air 
by formation of tight junctions 440. Nevertheless, DC are able to sample the epithelium 
for inhaled antigens by forming long extensions throughout the epithelium to the airway 
lumen while maintaining the epithelial barrier function intact 441, 442. Recently, 
published results suggest that an activating signal is needed for the extension of 
dendrites by DC across epithelial barriers 439. Hammad et al 438 have identified airway 
epithelial cells as instructive in causing such DC sentinel behavior and activation in the 
lungs. Which epithelial signals are able to program this scanning response are largely 
unknown, but one possibility is the regulated expression or display of chemokines along 
the extracellular matrix of epithelial cells, followed by the secretion of DC-activating 
cytokines. Additionally, some clinically relevant allergens have the potential to cross 
the lung epithelium and gain access to DC 392. For example Derp1, a major allergen of 
HDM has been shown to increase the permeability of the bronchial epithelium by 
cleaving the tight junctional proteins laudin and occludin 443. 
Mucosal DC show an immature phenotype, meaning that they have exceptional 
allergen uptake and processing capability, but lack the power to stimulate naïve T cells 
444
. Local conditions contribute to maintain DC in a such immature state. After antigen 
uptake in the presence of a danger signal airway DC migrate to the T cell rich area of 
the draining mediastinal lymph nodes where naïve T lymphocytes continuously pass by 
445
. On their way to the mediastinal lymph nodes, DC process these captured antigens, 
display them as peptides in the context of MHC class II molecules and subsequently 
present them to naïve CD4 Th cells in the paracortex of the draining node 135. During 
this process, DC acquire a mature phenotype, meaning that they upregulate their 
expression of costimulatory molecules and chemokines necessary for optimal naïve T 
cell activation, and they acquire the capacity to stimulate an effector response 446. Upon 
encountering specific T cells, DC undergo a stable interaction with these cells, 
ultimately leading to the formation of an immunological synapse and T cell activation, 
division and differentiation 447. 
The DC therefore become a reporter of their earlier microenvironment and have the 
potential to influence polarization of T cells by specific expression and secretion 
cytokine pattern depending on their lineage 224, their maturation status and the 
consequent costimulatory molecule pattern 448 and the environment they are in 449 as the 
Introduction                                                  64 
type of antigen captured, the presence of microbial patterns or endogenous danger 
signals or the route of exposure and the genetic background of the host 450, 451. 
Airway is continuously exposed to airborne antigens. In order to prevent the 
continual induction of immune responses and stimulation of memory effector cells, 
which would support chronic inflammation in the airways and damage to the epithelial 
barrier and would impair gaseous exchange, a number of specialized control 
mechanisms exist. An absolute requirement is that these mechanisms discriminate 
harmless airborne antigens entering via the airways from pathogens 452, 453. Given these 
risks, it is not surprising that multiple interactions between leukocytes and cells of the 
lung stroma are central to this process of homeostatic pulmonary regulation. The 
epithelium plays a central role via the production of molecules such as mucins, 
surfactants, complement products, and antimicrobial peptides. In addition, a unique 
population of macrophages termed alveolar macrophages, which reside outside the body 
in the airway spaces, are likely to play an important role. These cells exhibit  
immunosuppressive properties, dampening down local DC and T cell activation by 
secreting different products (e.g. nitric oxide, that contribute to keep lung DC in an 
immature antigen-capturing mode (reviewed by Holt et al, 2008)453. 
Most inhaled particles do not have any intrinsic activating properties, and therefore 
the default immune response to the inhalation of inert antigens is tolerance (Fig. 11). 
Unresponsiveness to immunological inert antigens is regulated at different levels. 
In contrast with the gut mucosal immune system, where intestinal mucosa-derived 
DC continuously sample antigens and migrate into afferent lymphatics even in the 
steady state, conducting airway DC show very little migration to mediastinal lymph 
nodes. This difference might result from the fact that the gut is heavily colonized by 
microbes, whereas the (deeper) lung of unmanipulated animals is a relatively sterile 
environment. It follows that most of the lung DC migration to the mediastinal lymph 
nodes results from some form of insult to the lung, be it microbial, physical, or toxic in 
nature 439. 
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Figure 11. Immune regulation by DC in the lung. Under steady-state conditions 
(top), in the absence of danger signals, inhaled antigens are picked up by M-DC and P-
DC, which take the antigen to the mediastinal lymph nodes. Here partially mature M-
DC stimulate specific T cells, but these T cells fail to differentiate into effector cells and 
die. Some T cells might also differentiate into Tregs. P-DC in the draining lymph nodes 
give negative signals (IDO (indoleamine 2,3-dioxygenase) and PDL (programmed death 
ligand)-1)) to T cells and M-DC. At the same time, they also generate Tregs. Under 
inflammatory conditions (bottom), M-DC arrive in the draining node as fully mature 
cells. Antigen-specific T cells undergo proliferation, this time generating effector cells. 
On the other hand, P-DC also acquire a mature phenotype and prime antigen-specific T 
cells to become effector cells as well. (From Hammad and Lambrecht, 2006)450. 
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In the absence of inflammatory triggers, DC that take up these immunologically inert 
antigens do not properly express costimulatory molecules, and consequently fail to 
reach the threshold necessary to induce T cell activation (leading to anergic T cells or T 
cells that are not able to survive) inducing an abortive T cell response 454. Partially 
mature DC could stimulate the induction of IL-10- and/or transforming growth factor-β 
(TGF-β) producing Tregs in an IL-10 and/or inducible T cell costimulator ligand 
(ICOSL)-dependent manner 455. 
In another hand, it have been proposed a role of P-DC in respiratory tolerance 223, 456. 
The negative signal that is delivered by P-DC is mediated through programmed death 
(PD)-1-PD ligand 1 interactions 437 delivering a negative signal to T cells or to M-DC 
directly 223, 457. Additionally, P-DC can produce the tryptophan-metabolizing enzyme 
IDO, which has a strong inhibitory activity on T-cell proliferation 458 and inhibits 
inflammatory airway disease 459. In addition to IDO, the expression of transcription 
factors such as glucocorticoid-induced leucine zipper protein (TSC22 domain family 
protein 3, TSC-22R) is also considered a feature of tolerogenic DC. TSC-22R 
expression in DC, which is induced by glucocorticoids such as dexamethasone, leads to 
a decreased expression of costimulatory molecules such as CD80, CD83 and CD86, 
while the expression of “coinhibitory” molecules such as immunoglobulinlike transcript 
3 (ILT-3) and PD-L1 is increased 460. TSC-22R expressing DC produce IL-10 and elicit 
the development of Tregs 461. Another explanation for the tolerogenic properties of P-
DC is related to their immature phenotype 223, 456. 
It seems probable that primary functions of Treg cells in the airways are to limit the 
inflammatory consequences of infection and to maintain tolerance to harmless, inhaled 
aeroallergens. Treg cells represent a major mechanism of peripheral tolerance to ‘‘self’’ 
and in the regulation of the immune response to infectious organisms, both pathogens 
and commensals. Furthermore, Treg cells represent a major pathway proposed to 
contribute to the maintenance of immune homeostasis in the airways 462, 463. A number 
of different mechanisms by which antigen-specific Treg cells inhibit the function of 
effector T cells, antigen-presenting cells, and innate cells have been described (reviewed 
in Vignali et al. 464). A prominent inhibitory mechanism appears to be via the 
production of anti-inflammatory cytokines such as IL-10 and TGF-β 465, 466, but 
inhibitory molecules such as Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and PD1 
are also likely to contribute 464. IL-10 has broad immunosuppressive and anti-
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inflammatory actions relevant to the inhibition of asthma pathology 466. It is a potent 
inhibitor of proinflammatory cytokine production and acts on antigen-presenting cells to 
dampen T cell activation, including Th2 cells. The role of the cytokine TGF-β is more 
complex, with evidence for immune suppression and remodelling in the airways. Some 
of the functions of TGF-β that contribute to subepithelial fibrosis include amplification 
of fibroblast proliferation and differentiation as well as induction of the expression of 
collagen and other extracellular matrix proteins 467. TGF-β induces apoptosis of airway 
epithelial cells and is potentially involved in the regulation of the adhesion properties of 
epithelial cells leading to damage of the epithelial layer. TGF-β has been shown to play 
a role in enhancement of goblet cell proliferation and mucus secretion 467, 468. It also 
causes airway smooth muscle proliferation and contributes to increased airway smooth 
muscle cell mass 467. 
During generation of an efficient effector immune response, lung DC have to 
overcome suppression by Tregs, and the dominant way in they seem to do this is by 
producing the cytokine IL-6, which counteracts the suppression by naturally occurring 
CD41CD25 Tregs. Resistance to allergen- driven AHR is mediated in part by Treg 
suppression of DC activation and the absence of this regulatory pathway contributes to 
susceptibility 469. In human subjects with allergy, there is a reduction in the number and 
possibly function of Tregs 470 but it is unclear at present whether this would also lead to 
altered function of DC in these patients. 
For immunological inert antigens additional signals from environmental exposures 
(e.g. respiratory viruses, air pollution or cigarette smoke) or endogenous danger patterns 
might pull the trigger on DC activation 471, 472. 
DC will only start a T helper response if there is some sort of adjuvant activity on 
board at the time of exposure to the allergen. This activity is provided by the presence 
of PAMPs, DAMPs and cytokines released upon cell activation, necrosis or oxidative 
stress (e.g. cigarette smoking, ozone exposure, diesel particles). This adjuvant signal 
can also be found in the allergen itself. Indeed, Derp1, cockroach and many other 
allergens have proteolytic enzymes that can directly activate DC to promote Th2 cell 
responses through effects on polarizing cytokines, costimulatory molecules, and cell 
surface receptors 413, 473, 474. 
Additionally, lung DC express numerous receptors for PAMPs and DAMPs. DC 
express protease-activated receptors (PAR) which are activated by proteolytic proteins 
like tryptase and thrombin 235. Shortly after insult to the vascular compartment or after 
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pathogen entry in the mucosa, complement activation occurs, and lung DC can sense 
this ‘‘acute alert’’ through expression of the C5a and C3a anaphylatoxin receptors 457. 
They also express neuropeptide receptor that can respond to neurotransmittors released 
in response to axon reflexes or efferent neural responses, supported by the fact that lung 
DC synapse with unmyelinated nerve endings in and beneath the airway mucosa and 
produce neurotransmittors 475. Lung DC express receptors for prostaglandins and these 
acutely released inflammatory mediators can profoundly impact on the migration and 
maturation of the cell 476. Endogenously released metabolites like extracellular ATP 
trigger purinergic receptors on lung DC and in this way relay information about 
allergen-induced platelet aggregation or metabolic cell stress to the cells of the immune 
system through widely expressed purinergic receptors 233, 234. Eosinophil and mast cell 
degranulation can lead to the release of EDN and histamine that can feed back on DC 
and promotes further Th2 cell responses 477. Triggering of these receptors activates an 
intracellular signalling cascade that influences the phenotype and functions of DC 478, 479 
and lead to an inflammatory response 480, 481. 
Completely active DC upregulate the expression of costimulatory molecules (CD80 
and CD86, CD40 and PD-L1, and PD-L2) and produce pro-inflammatory cytokines 
involved in Th2 polarization (TNF-α, IL-1, IL-6, IL-10) 482-484. The up-regulation of 
PDL-1 can have pro-inflammatory effects providing a costimulatory signal to T cells 
485
. IL-6 produced by pulmonary DC blocks the development of Tregs. In addition IL-6 
downregulate IL-12 and thus polarize naïve cells into a Th2 phenotype in the lungs 486. 
The presence of IL-10 at the site of T cell differentiation diminishes the secretion of IL-
12, thereby indirectly attenuating the differentiation of Th1 cells driving the 
differentiation of naïve T cells toward a Th2 phenotype 228, 487. 
It is less clear whether airway DC are also required for the presentation of allergen to 
resting memory Th2 and/or effector Th2 cells during a secondary immune response but 
there are increasing findings that support a predominant role for DC in secondary 
immune responses in asthma. In favor of DC, it is known that the number and 
maturation state (expression of essential costimulatory molecules CD80, CD40, ICAM-
1, PDL-1, PDL-2) of CD11b+ inflammatory DC is increased in the conducting airways 
and lung interstitium of sensitized and challenged mice during the acute phase of the 
response, where they are seen to form clusters with primed CD4 T cells, at areas of 
nerve endings 475, 488. This accumulation of DC in the lung is supported by an almost 
threefold expansion of myeloid CD31high Ly-6c- haematopoietic precursor cells in the 
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bone marrow. Hu et al 444 have hypothesized that contact with primed T cells turns 
immature mucosal DC from an antigen uptake to an antigen presenting mode, leading to 
local antigen presentation to mucosal T cells. CCR2 is the predominant receptor for 
attracting Th2-cell-inducing DC to the lungs of mice after allergen exposure 489. CCR2+ 
monocytes are recruited to the lung, followed by rapid differentiation to monocyte-
derived inflammatory DC. Epithelial cells rapidly upregulate the expression of the 
CCR2 ligand CCL-2 (MCP-1) after challenge contributing to monocyte recruitment to 
the lung 438.  
Many inflammatory cell types such as mast cells, basophils and eosinophils are 
recruited to the airways in chronic asthma. These cells release many mediators such as 
cytokines, neuropeptides, enzymes and lipid mediators that may also profoundly 
influence DC function and in this way might perpetuate ongoing inflammation 490. As 
only one example, it is known that histamine and PGD2, both released by mast cells 
upon cross-linking, reduce the potential of DC to produce bioactive IL-12, and 
contribute to Th2 polarization in this way 366, 376. 
The presence of allergen specific IgE bound to the high-affinity receptor for IgE 
(Fc3RI) on DC can lead to a 1000-fold lowering of the threshold for allergen 
recognition and in this way IgE might sustain Th2 cell responses via effects on DC 491, 
492
. 
Although M-DC preferentially induce a Th2 sensitization to inhaled harmless 
antigens leading to asthmatic features 223, 445, 482, M-DC are equally able to induce a Th1 
response, under conditions of intense immune stimulation such as bacterial or viral 
infection 493, 494 or under environmental instruction by the presence of cytokines like IL-
12 495. 
Whereas the epithelium was initially considered solely as a physical barrier, it is now 
seen as a central player in controlling the function of lung DC through release of Th2 
cell-promoting cytokines. This situation by which stromal cells instruct the functional 
behavior of DC seems to be quite specific to the mucosal environment. 
Chemokines produced by airway epithelium after allergen exposure, promote the 
recruitment of specific inflammatory cell types to the airways probably contributing to 
Th2 sensitization Ex. In vitro and in vivo studies have shown that exposure of airway 
epithelium to HDM resulted in the rapid secretion of CCL20, a chemokine attractant for 
immature DC 496. Moreover, HDM exposure is also accompanied by an increased 
production of CCL2, a chemoattractant for monocytes, the precursors for inflammatory 
Introduction                                                  70 
DC 438. Epithelial cells also secrete a variety of cytokines like GM-CSF, IL-33, Thymic 
stromal lymphopoietin (TSLP), and IL-25 that activate DC, mast cells and basophils 438. 
GM-CSF has been shown to promote DC differentiation and maturation and to break 
inhalation tolerance 497. IL-33 inducess Th2 cell differentiation by programming the 
function of DC and goblet cell hyperplasia 498. TSLP is a 140 amino acid IL-7-like 4-
helix-bundle cytokine that has potent DC-modulating capacities, by binding its receptor 
complex, composed of the IL-7 receptor (IL-7R) and the TSLP receptor (TSLPR) 87, 88 
499
. Epithelia cells, mast cells and basophils secrete TSLP upon allergen challenge. 
TSLP can directly activate DC to prime naive CD4+ T cells to differentiate into 
proinflammatory Th2 cells by inducing the Th2 cell-prone costimulatory molecule 
OX40L 499  and the production of the Th2 cell-attractive chemokines CCL17 and 
CCL22 by DC 500, 501. In addition, TSLP might promote the production of Th2 cytokines 
by lymphocytes directly. The polarization of Th2 cells induced by TSLP-matured DC is 
further enhanced by IL-25, which is produced by epithelial cells, basophils, and 
eosinophils 502. Interestingly, TSLP also induces DC maturation without production of 
IL-12 (an important regulator of  Th1 cell development) 499 in contrast to most of the 
molecules known to cause DC maturation 189. In addition to its effects on DC, TSLP can 
also activate human mast cells to produce Th2 cell-associated effector cytokines in the 
absence of T cells or IgE crosslinking 503. Strikingly, IL-13 was shown to induce 
expression of TSLP, pointing out to an important feedback- loop acting via DC to 
enhance Th2 cell immunity 504. 
Most known environmental risk factors that are associated with development of 
allergy like cigarette smoking, exposure to ambient particulate matter like diesel 
exhaust, exposure to high ozone concentrations, or exposure to RSV (respiratory 
syncytial virus) have the potential to interfere  with the epithelial-DC crosstalk. For 
example, cigarette smoking enhances epithelial permeability and induces the production 
of TSLP by airway epithelial cells (reviewed in Robays et al, 2009)505, 506, whereas the 
Th2 cell adjuvant effects of diesel depend on epithelial production of GM-CSF 507. 
Epithelial-DC interactions are necessary for preventing overt Th2 cell responses. 
Epithelial cells modulate local DC differentiation (instruct DC to produce IL-12, IL-6, 
IL-10, and TNF-α), optimize antimicrobial defences in the airways and in the process 
downmodulate capacity for expression of potentially damaging Th2 cell immunity 508, 
509
. A defective innate immune response of epithelial cells might therefore be at the 
heart of allergic sensitization. 
Introduction                                                  71 
Many of the Th2 cell effector pathways of allergic inflammation maintain the DC 
network in an activated state. Allergen challenge leads to enhanced production of tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) in epithelial cells. Expression 
of TRAIL subsequently leads to enhanced production of CCL20, in this way attracting 
inflammatory CCR6+ DC and Th2 cells and perpetuating allergic inflammation 89. 
Prototypical Th2 cytokines like IL-4 and IL-13 also feed back on the function of the 
airway DC and epithelial cells to directly or indirectly (via DC-activating cytokines like 
TSLP) stimulate DC in a STAT- 6-dependent way 504, 510, 511. These feedback loops 
might be important in understanding the chronicity of allergic inflammation. 
Remodelling is a dynamic process that involves the laying down of extracellular matrix 
structures, which are also broken down by the action of tissue-degrading enzymes. How 
exactly collagen or extracellular disposition of matrix degradation products might 
influence DC function in remodelled airways is currently mainly unknown. 
 
1.3.3. Dendritic cell recruitment to the airways 
DC constantly migrate from the blood to the lungs and from the lungs to the draining 
lymph nodes. The migratory patterns of pulmonary DC are highly dependent upon 
inflammatory conditions in the lung. In steady-state, or non-inflammatory conditions, 
pulmonary DC undergo slow but constitutive migration to draining lymph nodes, where 
they remain for several days and confer antigen-specific tolerance. In the presence of 
inflammatory signals, airway DC trafficking increases dramatically, and these cells 
rapidly accumulate within draining lymph nodes. However, within a few days, the 
number of airway-derived DC in lymph nodes stabilizes or declines, even in the face of 
ongoing pulmonary inflammation. An important question for the understanding of 
airway DC biology is how DC populate the lung in the absence of inflammation, and 
how they are recruited there during inflammation. The understanding of the relative 
contribution of particular chemokines to the selective accumulation of leukocyte subsets 
to an organ site is made difficult by the simultaneous presence of multiple chemokines 
with partially overlapping functions as well as by the finding that chemokines often 
bind more than one receptor 57, 512. 
It is not clear yet whether lung DC are recruited from the blood in a differentiated 
form or as early precursors. It is important to note that GM-CSF, a key growth factor for 
“DC-poiesis,” is expressed in significant amounts in the lung. GM-CSF production in 
the airways is increased in an inflammatory context (e.g., respiratory viral infection or 
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exposure to environmental pollutants). DC can populate the lung through different 
mechanisms. DC present in the blood circulation could be directly recruited by means 
of appropriate pulmonary chemokine signals. Alternatively, monocytic DC precursors 
could first be chemoattracted from the blood into the lung and subsequently 
differentiate into DC under the influence of cytokines secreted by resident pulmonary 
cells (e.g., GM-CSF produced by respiratory epithelium). In addition, a hypothetical 
mechanism for maintaining lung DC homeostasis might be proliferation of putative 
intrapulmonary DC progenitors, induced by growth factors secreted by resident 
pulmonary cells (GM-CSF or Flt3L). Finally, indirect evidence points to the possibility 
of transdifferentation of pulmonary macrophages into DC under the influence of GM-
CSF 513, 514. 
In the absence of inflammatory signals, DC and their precursors are recruited from 
the bloodstream into the lung where they have a very rapid turnover of about 2–3 days 
515
. Under steady-state conditions, there are at least two pathways to recruit DC 
precursors: one that depends on CCR1 and/or CCR5, and one that does not  516. It is 
possible that the latter mechanism involves the chemokine receptor, CX3CR1, a receptor 
highly expressed on a population of monocytes that are recruited to noninflamed tissues, 
including the lung 517. Because monocytes can differentiate into DC, CX3CR1-directed 
monocyte recruitment might be important in maintaining DC homeostasis under steady-
state conditions. Steady state recruitment of DC into airway relies on constitutive 
chemokine production within the epithelium by one or more cell types which may 
include the resident DC 516. 
In the presence of inflammatory signals, DC can be recruited very rapidly to the 
lungs as a response to the increased requirement for surveillance at the local site. 
Studies in allergic asthmatics have shown that circulating M-DC are reduced between 4 
and 24 h after allergen inhalation 518, and start appearing in the airways 5–6 h after 
allergen 519. Because the wave of DC arrives in the airways before the neutrophils and 
other mononuclear cells, DC contribute to the very early phase of the immune responses 
in the airways. DC are also found in increased numbers in the lung during secondary 
immune responses. Indeed, the number of airway CD11c+ CD11b+ M-DC is strongly 
increased within the airway epithelium following allergen challenge in sensitized 
animals 513. This increase in the number of airway DC is accompanied with an increase 
in CD11c– CD11b+ MHCII+ monocytes that could be recruited to the airways and 
probably further differentiate into DC 520. 
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During bacteria-induced inflammation the rate of DC accumulation in the lung 
increases markedly 521. Unlike a wave of incoming neutrophils, which rapidly moves 
into the airway lumen, the DC precursors remain within the epithelium during the acute 
inflammatory response and assume the dendritic form morphology typical of mature 
airway DC. During the 48 h. period after bacterial challenge, many of these DC migrate 
to draining lymph nodes. As in steady state conditions, CCR1/CCR5 are involved in DC 
recruitment in this inflammatory conditions. It is not excluded a function for other 
chemokine receptors in recruiting DC precursors to the lung. DC precursor recruitment 
during allergen challenge depends on CCR2/CCR6, differing mechanistically from the 
recruitment after a bacterial stimulus 522. 
CCL20, the chemokine that acts on CCR6, is poorly expressed by bronchial 
epithelial cells and primary alveolar type 2 cells in steady state conditions; however is 
abundantly released in inflammatory conditions 523, 524. Pichavant el al 525 have shown 
that bronchial epithelial cells of asthmatic patients stimulated with Derp1 showed an 
increased production of CCL20. CCL2 and CCL7 (two of the known murine CCR2 
ligands) expression increases rapidly in lungs after antigen challenge in a antigen –
induced lung inflammation model 522. Hence ligands for both CCR2 and CCR6 are 
present in the lungs and could contribute to recruitment of DC. CCR2 ligands CCL2 and 
CCL7 are rapidly increase (peak at 1 day) after antigen stimulation, while CCL20 
production is delayed. Chemokine expression is spatially segregated in resected human 
tonsils, since a CCR2 ligand localize to vascular endothelium, whereas CCL20 
expression is restricted to epithelial cells bordering the exterior 90. Osterhoelzer et al 522 
suggest that an identical temporal and spatial pattern occur during antigen-driven lung 
inflammation with CCR2 mediating early DC precursors recruitment from the blood 
into lung interstitium, whereas CCR6 more centrally drives the later transit across 
epithelia into the airways (to enter the alveoli, the site where inhaled antigens first 
deposit). 
It is possible therefore, that during secondary immune responses in the lung, CCR2 
and CCR6 are important for DC recruitment, whereas CCR1 and CCR5 fulfil this 
function under steady-state conditions and after innate immune stimuli. Some of this 
difference might be due to the presence of antigen-specific T cells in the lung that can 
modify the responses of DC to antigen. During such secondary immune responses, the 
number of mature DC in the lung correlates with levels of inflammation, and with levels 
of various chemokines and cytokines 526, 527. However, it is difficult to determine 
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whether increased levels of pulmonary DC lead to increased inflammation or whether 
the converse is true.  
Monocyte chemokine-like protein, a new chemokine constitutively expressed in the 
lung, specifically attracts monocytes and DC in vitro; however, whether it has the same 
role in vivo remains to be elucidated 528. 
Besides chemokines, other molecules can also favour the migration of DC into the 
lungs. The airway epithelium can attract DC by means of defensins, cationic peptides 
with bactericidal activity engaging CCR6 on immature DC 64, 529. In this way, defensins 
may promote adaptive immune responses by recruiting DC to the site of microbial 
invasion. During inflammation, MMP-9-/- mice have been shown to have an impaired 
recruitment of DC into the airways, whereas the migration of DC to the draining lymph 
nodes was unaffected 213. In summary, DC are recruited to the lungs via different 
mechanisms, and it seems very likely that these chemotactic agents may act sequentially 
to attract recently transmigrated DC, and position them at the inflamed site. 
Whereas E- and P-selectin, VCAM-1, and L-selectin ligands have been extensively 
described in the transendothelial migration of skin DC, their involvement in the 
recruitment of precursors or DC to the lung has never been proven. 
P-DC can also be recruited to nonlymphoid organs in inflammatory conditions. In 
asthma, there is an increased expression of peripheral node addressin (PNAd), ICAM-1, 
and VCAM on the vessels of affected tissues. Interactions with these adhesion 
molecules are likely to be involved in DC migration into this site, as circulating P-DC 
express the appropriate ligands, namely CD62L, β2, and α4 integrins, respectively 350, 
530
. Moreover, P-DC express CXCR3, the receptor for CXCL10, which is upregulated 
under inflammatory conditions in the lung 415. 
DC not only are responsive to the action of chemokines, but they also produce a wide 
range of chemokines in order to direct their environment. Depending on the stimulus, 
human DC are able to produce CCL2, CCL3, CCL4, CCL17, CCL22 and CXCL8 281. 
Interestingly, production of CCR4 ligands (CCL17, CCL22) by M-DC cells suggests 
that these cells are capable of selectively recruit Th2 cells and/or Treg cells at sites of 
inflammation 413. This latter scenario may be especially important during chronic 
asthmatic responses that depend upon Th2 type cytokines. 
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1.3.4. Migration of airway dendritic cells to draining lymph nodes 
It has been proposed that under steady-state conditions, M-DC slowly but 
continuously migrate to draining lymph nodes and present either (self)-auto antigens or 
harmless antigen in a tolerogenic form 531. The mechanisms involved in the steady-state 
migration of airway DC to the mediastinal lymph nodes are unclear. Studies performed 
on skin DC suggest that semimature DC, which are immature DC with an intermediate 
phenotype, might use CCR7 to continuously migrate to the lymph nodes in the absence 
of inflammatory signals 331, 532. It is not clear whether this would also happen in the lung 
as some studies have reported the absence of functional CCR7 expression by DC at 
mucosal surfaces 533. 
The presence of ‘‘danger’’ signals in organs exposed to antigens is a strong stimulus 
for the migration of antigen-bearing DC toward lymph nodes. In a mouse model of 
allergic inflammation, ongoing airway inflammation was shown to cause a massive and 
accelerated flux of allergen-loaded DC from the airway mucosa to the mediastinal 
lymph nodes 444, 534. The mechanisms behind this increased migration to the lymph 
nodes are not clear, but some likely mechanisms are described. 
Factors driving DC migration from peripheral tissues to the T cell area of lymph 
nodes under inflammatory conditions is well documented in skin DC migration 535. 
However very little is known regarding the involvement of this molecule in the 
trafficking of lung DC. CCR7 expression has been described on a subset of lung DC 536 
and a series of experiments suggest that lung and skin DC use similar mechanism for 
their migration to the lymph nodes (e.g. in vivo neutralization of CCL21 prevents 
human DC migration to mediastinal lymph nodes of humanized severe combined 
immunodeficient (SCID) mice and the subsequent development of asthma features 537. 
Moreover, the intranasal injection of latex beads into mice led to a CCR7-dependent 
accumulation of DC in the mediastinal lymph nodes 361. DC migration from lung to 
lymph nodes is not only CCR7-dependent, but also involves another chemokine 
receptors, namely CCR8 which acts in concert with CCR7 361. CCL1, the chemokine 
that acts on CCR8 has been observed in the skin draining lymph nodes subcapsule. It is 
not known whether emigration of cells into the lymph nodes via afferent lymphatics 
requires chemokine signals to specifically enter the subcapsular sinus. If so, CCL1 is 
positioned to play a role at this point of entry during mobilization 33991. 
CCR7 requires additional extracellular signals to become functionally coupled 538. 
The responsiveness of CCR7 to CCL19 and CCL21 and the consequent  lymph nodes 
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migration of DC is controlled by lipid mediators, such as the leukotrienes and 
prostaglandins. PGE2 produced by epithelial cells after antigen exposure can stimulate 
DC emigration toward draining lymph nodes 372, 539. The latter response is dependent on 
the EP4 receptor 371, 372, 539, 540. In contrast, PGD2 exerts an opposite effect: through the 
ligation of DP1, a receptor expressed by lung DC, inhibits the emigration of airway DC 
toward mediastinal lymph nodes and consequently prevents the induction of a primary 
immune response and of eosinophilic airway inflammation 376. A stable analogue of 
PGI2, Iloprost, could inhibit the migration of lung DC to the mediastinal lymph nodes, 
thereby abolishing the induction of an allergen specific Th2 response in these nodes 541. 
The same effect was obtained with pharmacological agonists of the peroxisome 
proliferator-activated receptor-γ (PPAR-γ), an important intracellular mediator of 
prostaglandin signalling 542. S1P, can modulate many different functions including 
migration, cytokine, and chemokine release 543, 544. Inhalation of FTY720, a structural 
homologue of S1P, reduced the number of migrating M-DC in mediastinal lymph nodes 
of naive and allergen challenged mice and reduced asthma features 545. 
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Aim of the Thesis 
 
CCRL2, is an orphan  heptahelic serpentine receptor that shares high homology with 
the inflammatory chemokine receptors CCR5 and CCR1 121. It is rapidly induced during 
mouse DC maturation with a kinetics that precedes CCR7 induction 546. In order to 
evaluate the relevance of this receptor in DC biology, CCRL2 deficient mice 121, 546 
have been used in an established model of allergen-induced airway inflammation in 
which DC are known to play a crucial role 547. 
Chemerin has been identified as a natural non-signaling protein ligand for CCRL2. 
CCRL2 is able only to bind the chemoattractant and increase local concentrations of 
bioactive chemerin which then is available for interaction with ChemR23, the functional 
chemerin receptor expressed on adjacent cells 93. ChemR23 is expressed by human 
professional APC (monocyte/macrophages and DC) 70 and NK 69. DC positive for 
ChemR23 have been found in close proximity of chemerin-positive human EC 71, 
suggesting a key role of the ChemR23/chemerin axis in directing DC trafficking. 
However limited information are presently available on chemerin/ChemR23 system in 
mouse, especially in DC-EC interactions. 
Here we investigated the expression of functional ChemR23 in mouse bone marrow 
derived myeloid and plasmacytoid DC and its regulation during maturation. Moreover, 
since DC do transmigration and reverse-transmigration to cross the wall of vascular and 
lymphatic vessels, we investigated the possible presence and modulation of the 
ChemR23 functional ligand, chemerin, on lymphatic and vascular EC, taking 
advantages of specific cell mouse cell lines generated in the laboratory in the past.  
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2. Materials and Methods 
 
2.1. Reagents 
DMEM (high glucose), RPMI 1640 medium, heat-inactivated fetal bovine serum 
(FBS), ultraglutamine I, penicillin/streptomycin, non essential amino acids (NEAA) and 
sodium pyruvate were from Lonza (Verviers, Belgium). 1α,25 dihydroxyvitamin D3 
(calcitriol), all trans retinoic acid (RA), bovine serum albumin (BSA, low endotoxin), 
gelatine from bovine skin, type B, aluminium hydroxide gel (alum), OVA; grade V, 
LPS and heparin were from Sigma (St. Louis, MO. USA). Low-LPS OVA lots were 
used. Recombinant mouse chemerin was from R&D Systems (Minneapolis, MN. USA), 
endothelial cell growth supplement (ECGS) from Biomedical Technologies, 2-
βmercaptoetanol from Gibco (Scotland, UK), CpG from InvivoGen (San Diego, USA), 
mTNF-α, FMS-like tyrosine kinase 3 ligand (Flt3L), GM-CSF, CCl3, CCL5, CCL19, 
CXCL12 from Peprotech (Rocky Hill, NJ. USA). Sodium chromate Cr-51 (51Cr ) was 
from PerkinElmer. 
 
2.2. Cell preparations 
2.2.1. Isolation of mouse primary cells 
Mediastinal lymph nodes cells were smashed to a single cell suspension. Lung tissue 
cell suspension was obtained by incubation with 1 mg/ml collagenase (type D; Sigma, 
St. Louis, MO. USA) and 20 µg/ml DNase (type I; Roche, Mannheim, Germany) for 1h 
at 37ºC. For flow cytometric analysis lung cells were depleted of red blood cells.  
 
2.2.2. Endothelial cells 
The mouse lung capillary endothelial cell line 1G11 548 was grown in DMEM 
medium with 20% FBS, 1% NEAA, 1 mM Na pyruvate, penicillin (100 U/ml) and 
streptomycin (100 µg /ml), 1 mM ultraglutamine I, ECGS and heparin (100 µg/ml 
each). 
The mouse lymphatic endothelial cell line (MELC) 549 was cultured in DMEM 
medium with 10% FBS, NEAA, sodium pyruvate, penicillin, streptomycin, heparin and 
ECGS as above, and 10% supernatant from sarcoma 180 cells. 
In all cases cells at 6th-20th passage, grown to confluence on tissue culture plastic 
coated with 1% gelatine at 37°C in a humidified atmosphere with 5% CO2, were used. 
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2.2.3. Bone marrow derived (BM-DC) and peripheral blood dendritic cells 
Murine DC were generated from CD34+ bone marrow cells from C57Bl/6J, CCRL2-
/- and ChemR23-/- mice (Charles River Laboratories) as previous described 93. CD34+ 
cells were isolated from total bone marrow by positive immunoselection using the rat 
mAb MEC14.7 to mouse CD34 as a selecting agent. CD34+ cells were cultured in 
RPMI 1640 medium with penicillin/streptomycin, 5 % FBS and 2-βmercaptoetanol 
(5x10-5M). To generate M-DC 2x105/ml CD34+ cells were grown in medium with 
mGM-CSF (40 ng/ml) and Flt3L (100 ng/ml), while to generate P-DC 3x105/ml CD34+ 
cells were grown in medium with Flt3L (200ng/ml). Cells were diluted 1:2–1:3 every 2 
or 3 days and collected at day 8 (M-DC) or 9 (P-DC). DC were matured by incubation 
with TNF-α (20ng/ml) or LPS (100 ng/ml) (M-DC) or CpG (2µg/ml) (P-DC) for 
different times depending on the protocol. 
Peripheral blood mononuclear cells were isolated from buffy coats of normal donors 
by Ficoll gradient (Ficoll-Paque™ PREMIUM, GE Healthcare, Life Sciences) and were 
magnetically sorted with blood DC antigen BDCA-1 (M-DC) and BDCA-4 (P-DC) cell 
isolation kits (Miltenyi Biotec), as described previously 194. 
 
2.3. Generation of monoclonal antibody to CCRL2 
107 X-rayed CCRL2/L1.2 cells in PBS (phosphate buffered saline) were injected 
intraperitoneally (i.p) every other week for 6 weeks into CCRL2-deficient mice. Three 
days after the last challenge, spleen cells were fused following conventional protocols. 
Hybridomas recognizing CCRL2/CHO-K and CCRL2/L1.2 transfectants but not 
parental cells were cloned and tested for specificity on CCRL2, CCRs and CXCRs 
transfectants. One hybridoma (hybr 4, IgG2a) was selected for these studies, purified 
and biotinylated. 
 
2.4. Fluorescence activated cell sorting (FACS) analysis 
BM-DC, BAL, mediastinal lymph nodes and lung cell suspensions were obtained as 
indicated above. Cells were incubated with rat anti-mouse CD16/32 mAb 2.4G2 
hybridoma supernatant  for 30 min. on ice to prevent nonspecific binding of antibodies 
to Fc receptors. For CCRL2 staining cells were then incubated with biotinylated anti 
CCRL2 mAb (3 µg/ml) in PBS buffer containing 1% FBS for 30 min. on ice. After 
washing, cells were incubated with streptavidin-FITC or -PE (BD Pharmingen). For 
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analysis of cell subpopulations, cells were stained with directly conjugated Abs to CD3e 
(145-2C11), CD4 (A15.1.17), CD8α (53-6.7), CD11b (M1/70), Gr-1 (RB6-8C5), I-Ab 
(2G9), CD11c (HL3), CD 80 (16-10A1), CD86 (GL1) from BD (Franklin Lakes, NJ, 
USA), CD103 (2E7), ST2 (DJ8) and Siglec H (440c) from eBioscience (San Diego, CA, 
USA), PDCA-1 (JF05-1C2.4.1) from Miltenyi (Bergisch Gladbach, Germany) and DEC 
205 (hybridoma supernatant kindly provided by Dr A Vecchi) 
Staining was analyzed by a FACS Canto flow cytometer (BD Biosciences). Live 
cells were gated based on forward and side-scatter and no staining for propidium iodide. 
Flow cytometry analysis of lung single cell suspensions was performed as described by 
Jakubzick and Randolph 550. To obtain absolute numbers of each leukocyte subtype in 
BAL and lung tissue, percentages were multiplied by the total number of cells. Cell 
number in lung are referred to cell number/mg of tissue. All differential counts were 
performed in random order by the same observer 
 
2.5. Quantification of gene expression by Real-Time PCR (RT-PCR) 
Mouse EC lines (MELC and 1G11) were grown in 6 well culture plates (Becton 
Dickinson Labware) precoated with 1% gelatin. When confluent, serum and growth 
factors (ECGS, heparin, S180) supplemented medium was replaced by 0.2% BSA 
culture medium. Cells were stimulated with RA, 5 µM, 1α,25 dihydroxyvitamin D3 
(Calcitriol, 1 µM), mTNF-α (20 ng/ml) and LPS (100 ng/ml), for the times indicated in 
each experiment. Supernatants of culture were collected, centrifuged and stored at -
20°C until ELISA assays. The cells were used to determine the expression of different 
genes. 
Dendritic and EC total RNA was isolated using Trizol®reagent (Invitrogen) 
according to the manufacturer’s specifications. For real time PCR (RT- PCR) analysis, 
total RNA samples were treated with DNAse I (Invitrogen) in order to remove 
contaminating genomic DNA. Total RNA (1 µg) was reverse-transcribed using a High 
capacity cDNA (complementary DNA) reverse transcription kit from Applied 
Biosystems, following manufacturer’s instructions. RT-PCR was performed on cDNA 
samples using a 7900HT Fast Real-Time PCR System machine according to 
manufacturer’s guidelines (Applied Biosystems). The primers/fluorogenic (FAM) 
probes sets Mm 00503581_gH and Hs 99999901_s1 from Applied Biosystems were 
used to amplify chemerin and 18S respectively in a TaqMan gene expression assay. The 
other genes were amplified using a SYBR Green PCR master mix (Applied Biosystems, 
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Warrington, UK) and specific primers (Table 2). Human 18 S ribosomal and mouse β-
actin and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene were used to 
normalize PCR results. 
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Gene 
product 
Forward (5’-3’) Reverse (5’-3’) 
CCRL2 TGTGTTTCCTGCTTCCCCTG CGAGGAGTGGAGTCCGACAA 
ChemR23 CCATGTGCAAGATCAGCAAC GCAGGAAGACGCTGGTGTA 
CCR1 CTGCCCCCCCTGTATTCTCT GACATTGCCCACCACTCCA 
CCR2 CTACGATGATGGTGAGCCTTGT
C 
AGCTCCAATTTGCTTCACACTG 
CCR3 AGTGGGCACCACCCTGTG GCCATGACCCCAGCTCTTT 
CCR4 ACGAAAGCATGCCAAAGCC CCCCAAATGCCTTGATACCTT 
CCR5 TCAGCACCCTGCCAAAAAAT CAGGAGCTGAGCCGCAAT 
CCR6 GGCCTGTATCAGCATGGACC GATTTGGTTGCCTGGACGAT 
CCR7 TGGTGGTGGCTCTCCTTGTC CCTCATCTTGGCAGAGAAGCACA 
CCR8 ACCCTGATTTCTTCACCGCC TGCCCCTGAGGAGGAACTCT 
CCR9 TGATGCCCACAGAACTCACAA TGAAGTCATCAAACATGCCAGG 
CXCR1 TCCTGAGGTGACTTTGAGAAAG GGCAGCATTCCCGTGATATTT 
CXCR2 GTCATCTTCGCTGTCGTCCTT GTTGTAGGGCAGCCAGCAG 
CXCR3 TGGAAAACAGCACCTCTCCC AGAAGTCGCTCTCGTTTTCCC 
CXCR4 CCTGCTTCCGGGATGAAAA TGGTGGGCAGGAAGATCCTAT 
CXCR5 ACTCGGAGCTCAACCGAGAC AAGGTCGGCTACTGCGAGG 
CXCR6 TACGATGGGCACTACGAGGG ATCACTGGAATTGTTGAAGAGCC 
CXCR7 TGTAACAGCAGCGACTGCATT CATGGTGGGACACTGCACAG 
CX3CR CTGTCCGTCTTCTACGCCCT CAGATTTCCCACCAGACCGA 
XCR1 TCTTCACCGTCGTGGTAGCA TGAGGTTGTAGGGAGCCCAG 
CCL3 CATATGGAGCTGACACCCCG TCTTCCGGCTGTAGGAGAAGC 
CCL4 GCCCTCTCTCTCCTCTTGCT GAGGGTCAGAGCCCATTG 
CCL5 TGCTCCAATCTTGCAGTCGT ACACACTTGGCGGTTCCTTC 
CXCL10 CAACTGCATCCATATCGATGAC TTCATCGTGGCAATGATCTC 
CXCL12 CTGTGCCCTTCAGATTGTTG TAATTTCGGGTCAATGCACA 
β-Actin TCACCCACACTGTGCCCATCTA
CGA 
CAGCGGAACCGCTCATTGCCAATGG 
GAPDH CGTGTTCCTACCCCCAATGT TGTCATCATACTTGGCAGGTTTCT 
 
Table 2. Set of primers used for quantitative RT-PCR 
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2.6. ELISA 
Cytokines and chemokines were measured in 4x concentrated BAL fluids, lung 
homogenates and lymph nodes culture supernatants obtained as explained before by 
standard sandwich ELISA assays. Specific capture and detecting antibodies were from 
Pharmingen (IL-4, IL-5, INF-γ) and R&D (IL-13, IL-2, MCP-1/CCL2, 
CCL5/RANTES, eotaxin/CCL11, TARC/CCL17 and MDC/CCL22), and were used 
according to the manufacturer's protocol. 
Lung tissue was homogenized at 50 mg/ml in HBSS (Hanks' Balanced Salt Solution) 
(Invitrogen), centrifuged at 800 g for 10 min. and the supernatant was collected. 
Mediastinal lymph nodes were cultured in the conditions indicated in each experiment 
and the supernatants were collected at the indicated times. 
Total and OVA-specific IgE were detected in serum. Total IgE were measured by 
standard sandwich ELISA from Pharmingen. OVA-specific IgE were measured 
according to following protocol. Microtiter plastic plates were coated with anti-mouse 
IgE mAb (capture antibody) (Pharmingen, 2 µg/ml) O.N at 4°C, and afterward blocked 
with 3% BSA in PBS. Serum samples were diluted in PBS 5% FBS and then incubated 
O.N at 4°C. After washing with PBS-Tween 0.1%, 2 µg/ml of biotinylated OVA 
(detection reagent) was added to the wells for 1.5 h at room temperature (RT). Biotin 
was conjugated to OVA with the EZ-Link Sulfo-NHS-LC-Biotinylation Kit (Pierce 
Rockford, IL, USA), following manufacturer’s instructions. Plates were washed and, 
following the addition of streptavidin-HRP (horseradish peroxidase) (Pharmingen), 
incubated for 1 h at RT. OVA-specific IgE were detected by adding peroxidase 
substrate solution (colorimetric substrate) and reading in a microplate reader 
(VersaMax. Molecular Devices, Sunnyvale, CA. USA) to 450 nm. 
For chemerin determination EC supernatants were concentrated 10 times using a 
vivaspin concentrator unit (3000 MWCO (molecular weight cutoff) , Sartorius Stedim 
Biotech) and examined by ELISA according to manufacturers’ instructions (Mouse 
Chemerin Quantikine ELISA kit, R&D Systems). 
 
2.7. FITC-dextran uptake 
Endocytosis was measured as the cellular uptake of FITC-dextran (Sigma Chemical 
Co.) as described 95. Approximately 2x105 cells/sample were incubated in media 
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containing FITC-dextran (1 mg/ml)  for 60 min. Uptake of the label was determined by 
flow cytometry 
 
2.8. In vitro cell migration assays 
 
2.8.1. Chemotaxis 
Migration of BM-DC in response to different chemoattractants was evaluated using a 
chemotaxis chamber (Neuroprobe, Pleasanton, CA) and polycarbonate filter (5 µm pore 
size, Neuroprobe) as previously described 133, 551. 50 µl of 1.5 x 106 cell suspension were 
applied to the top wells and allowed to migrate to agonists for 90 min. at 37°C. Cells 
that migrated onto the underside of the filter were stained using Diff-Quik and counted 
in an average of 5 high-power fields. Each data point was performed in triplicate. 
 
2.8.2. Transendothelial migration assay 
EC were grown to confluence on 0.1% gelatine coated transwell inserts in 24-well 
costar chambers (5µm pore size, Corning Costar, Cambridge, MA). When indicated the 
EC were stimulated with RA (5µM) 18 h before the transmigration assays. For the 
transmigration assay, 100 µl of DC (0.5x106 cells/ml of 51Cr labelled mouse DC; 2x106 
cells/ml of human DC) were placed in the upper chamber and 600 µl of chemoattractant 
or control medium were added to the lower chamber. DC were allowed to migrate for 
90 min. (mouse DC) or 4 h (human DC) at 37 ºC in a 5% CO2 atmosphere. Serum free 
medium with 0.2% BSA (chemotaxis medium) was used in all migration experiments 
performed with chemerin. 
Mouse DC migration was evaluated as the percentage of radioactivity recovered in 
the lower compartment relative to input. Values are expressed as net migration (% 
radioactivity sample - % radioactivity control). 
Human DC were collected in the lower chamber and counted at microscopy using a 
Bürker chamber. The results were expressed as the percentage of cell input. 
In some experiments, human P-DC were preincubated (30 min. at 4°C) with anti-
ChemR23 mAb (clone 1H2 (IgG2a, 3 µg/ml) 70 and then added to the upper chamber. 
Chemerin (300 pM) added to EC for 90 min. at 37º C in the upper chamber was used as 
a control. Before addition of P-DC chemerin was removed, in order to eliminate the 
excess and leaving only chemerin bound to EC. 
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2.9. In vivo migration of murine dendritic cells 
 
2.9.1. FITC skin painting  
FITC (fluorescein isothiocyanate isomer I, Sigma, St Louis, MO) was dissolved in a 
50:50 (vol/vol) acetone–dibutylphthalate (BDH) mixture just before application. Mice 
were painted on the shaved abdomen with 0.2 ml/5 mg/ml FITC. After 24 h, inguinal 
lymph nodes were disaggregated and treated with collagenase A/DNase mixture for 30 
min. CD11c+FITC+ cells were analysed by FACS as described by 552. 
 
2.9.2. Migration of lung dendritic cells and dendritic cell adoptive transfer 
To address the migration of lung DC to mediastinal lymph nodes, mice were 
sensitized with OVA (day 0 and 11) and 80 µl of FITC-OVA 10 mg/ml (Sigma, St 
Louis, MO) was administered intratracheally at day 18, under direct vision, using a 18-
gauge polyurethane catheter connected to the outlet of a micropipette. CD11c+FITC+ 
DC were FACS counted in mediastinal lymph nodes as described by Jakubzick and 
Randolph 550. Mediastinal lymph nodes were sampled 8, 24, 48 and 72 h after FITC-
OVA administration 
For adoptive transfer of bone-marrow-derived DC, cells at the end of the culture 
were pulsed overnight (O.N) with 100 µg/ml OVA, washed and instilled intratracheally 
(106/mouse) as described above. 
 
2.10. Experimental protocol for induction of allergic airway inflammation 
WT and CCRL2-/- mice were sensitized with OVA (LPS depleted by centrifugation 
using a centricom with cutoff of 100000 KDa), at a concentration of 0.01 mg/mouse i.p 
in 0.2 ml alum on day 0 and 11. Control mice received the same volume of PBS in 
alum. All groups were challenged daily with 5% OVA aerosol (for 20 min.) from day 
18 to 23 (Fig. 12). The aerosol was generated by a PARI Master Nebulizer (Sapio Life) 
connected to the Plexiglas chamber. Mice were sacrificed by exsanguination under 
terminal anaesthesia at 24 h after the last aerosol.  
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OVA/OVA OVA OVA 
 
Figure 12. Allergic airway hyperresponsiveness model protocol. Mice were 
sensitized with an intraperitoneal application of LPS-depleted OVA (0.01mg/ mouse in 
0.2 ml alum) at day 0 and 11, and then challenged with 5% aerosolized OVA for 6 
consecutive days from day 18. Controls were treated with PBS during sensitization. 
Lung inflammation and clinical manifestations as AHR and mucus production were 
assessed at different times after the final allergen challenge. 
 
Sera were prepared by centrifugation and snap-frozen to –20°C until further use. 
Airways were washed three times with 1 ml of PBS via a tracheal cannula to obtain 
broncheoalveolar lavage (BAL). BAL was centrifuged (200 g, 5 min., 4˚C and then 
concentrated by using Vivaspin 2 concentrators (3000 MWCO, Sartorius Stedim 
Biotech), and stored at -200C for further analysis. 
BAL cells were counted, then pelleted onto glass slides by cytocentrifugation (5x104 
cells/slide). Differential cell counts were performed on Diff-Quik (Median Diagnostics 
AG, Bonnstrasse, Germany) stained cytospins. Percentages of eosinophils, 
lymphocyte/mononuclear cells, neutrophils and macrophages were determined by 
classifying at least 400 cells per slide under light microscopy visualization using 
standard morphological criteria. To obtain absolute numbers of each leukocyte subtype 
percentages were multiplied by the total number of cells obtained in the BAL fluid. All 
differential counts were performed in random order by the same observer. 
Lung tissue cell suspension was prepared as indicated before. Cytocentrifuge 
preparations were prepared and Wright-Giemsa stained, and differential counts were 
performed as for BAL. 
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For lung tissue histopathology, lungs were fixed in 10% normal buffed formalin. 4-
µm paraffin-embedded sections were stained with haematoxylin and eosin. For 
immunohistochemistry samples were snap frozen in dry ice and stored at -80 °C 
 
2.11. Measurement of airway hyperresponsiveness (AHR) 
AHR was measured in mice 24 h after the final OVA challenge by recording 
respiratory pressure curves by whole body plethysmography (Buxco Technologies) in 
response to inhaled methacholine (Sigma) at concentrations of 30 mg/ml for 1 min. 96 as 
previous described 553. Results are shown for Penh after allergen challenge. Penh results 
were confirmed by direct measurements of lung resistance and dynamic compliance in 
anaesthetized and tracheotomized mice in response to inhaled methacholine at 
concentrations of 30 mg/ml in a Buxco system (Buxco Technologies) as previous 
described 553. 
 
2.12. Assessment of mucus production 
After removal from the animal, one lobe of lung was inflated with PBS. Lungs were 
fixed in 10% normal buffered formalin. Paraffin embedded sections (4µm) were stained 
with Periodic Acid-Schiff (PAS). Globet cells were counted on PAS-stained sections 
and scored as previously described 553. Briefly, the lungs were scored in the following 
way: score 0: 5% goblet cells; score 1: 5 to 25%; score 2: 25 to 50%; score 3: 50 to 
75%; score 4: more than 75%. The sum of the airway scores from each lung was 
divided by the number of airways examined for the histologic goblet cell score 
(expressed as arbitrary units) 
 
2.13. Immunostaining of lungs 
For immunohistochemistry, sections were obtained from frozen lungs from three 
mice/experimental group. Immunostain was performed by using anti-CD11c (BD Franklin 
Lakes, NJ, USA), anti-Siglec H (rat anti-mouse, kindly provided by Prof. M. Colonna, 
Washington University, STL, MO, USA) and anti CD103 (eBioscience, San Diego, CA, 
USA). Primary antibodies were revealed using anti-hamster or anti-rat biotin-conjugated 
secondary antibodies (Vector, Burlingame, CA, USA) followed by HRP (for CD11c 
and Siglec H) or streptavidin-alkaline phosphatase for CD103) and 3,3’ 
Diaminobenzidine (all from Dako, Denmark) or Ferangi Blue (Biocare Medical, 
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Concord, CA, USA). As a negative control, primary antibodies were omitted or 
replaced with an irrelevant isotype-matched mAb. 
 
2.14. In vitro re-stimulation of draining lymph nodes  
Mediastinal lymph nodes cell suspension was prepared as previously described. 
5x105 cells in 200 µl were seeded in U-bottomed plastic plates and OVA was added at 
varying concentrations. Plates were incubated for 96 h at 37°C. Supernatants were 
harvested and used to measure cytokine levels. 
 
2.15. Dendritic cell-induced T cell proliferation 
For alloantigen T cell proliferation, CD4+ T cells were purified from spleens of 
Balb/c mice (Charles River laboratories) using CD4 immunoconjugated microbeads 
(Miltenyi Biotech). Isolated T cells were labelled with 5 µM CFSE (Carboxyfluorescein 
diacetate succi- nimidyl ester) in RPMI containing 5% FBS for 20 min., washed and 
seeded at 2x105 cells per well in U-bottom 96-well plates in RPMI 1640 supplemented 
with 2 mM L-glutamine, 10% FBS and 10 mM Hepes pH 7.4 and antibiotics. DC from 
WT or CCRL2-/- mice were matured with 20 ng/ml of TNF-α for 24 h, washed and 
added to T cells at different ratios, ranging from 0.1 to 10 % relative to T cells quantity. 
After 72 h of co-culture cells were stained with a CD4 antibody and T cell proliferation 
was monitored by FACS in terms of CFSE dilution. T cells with CFSE content lower 
than T cells cultured in the absence of DC (and hence did not dilute the CFSE) were 
considered as proliferated cells. Antigen-specific T cell proliferation was tested with a 
similar protocol, by using CD4+ T cells  purified from spleens of OT-II mice and by 
pulsing DC with 100 µg/ml OVA during maturation. Supernatants were frozen and the 
secreted cytokines were measured by ELISA in both cases. 
 
2.16. Statistics 
Statistic significance was calculated by Student T test, Mann-Whitney U test and 
one-way ANOVA as appropriate. Differences were considered significant at p< 0.05.
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3. Results 
 
3.1. Role of CCRL2 in lung leukocyte traffic 
 
3.1.1. CCRL2 participates to inflammatory infiltrate/Th2 cytokine production 
evaluated in broncheoalveolar lavages (BAL) in a model of airway 
hyperresponsiveness 
CCRL2 expression has been described during maturation of murine DC with kinetics 
that precedes CCR7 expression. To investigate the relevance of CCRL2 in DC biology, 
CCRL2 deficient mice (CCRL2-/-) 546 were used in an established model of allergen 
induced airway inflammation in which DC are known to play a crucial role in the 
transport of antigens to mediastinal lymph nodes 547. OVA-immunized CCRL2-/- mice, 
challenged by aerosol for six consecutive days, showed a dramatic reduction in the total 
number of leukocytes and in particular of eosinophils and lymphocyte/mononuclear 
cells, with respect to WT animals (Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Leukocyte population is reduced in BAL from CCRL2-/- mice. Mice 
were sensitized and challenged with OVA by aerosol. BAL was collected 24 h after the 
last aerosol; total cell numbers were counted and differential cell counts performed. 
Data are mean ± SEM of one representative experiment of the five performed with 6 to 
12 mice per group; *P<0.05; **P<0.01 
 
 
Results 90 
T cell population is composed by different subsets with different patterns of cytokine 
production to drive different types of immune responses 554, 555. To determine whether 
there was a selective deficiency of T subsets in BAL, cells were analyzed by FACS, 
using CD3 as a marker for T cell lineage in combination with CD4 (T helper cells) and 
CD8 (cytotoxic T cells). Since allergic asthma is characterized by a chronic immune 
response sustained by Th2 type cells, CD4+ST2+ Th2 subtype was also evaluated. A 
significant decrease in T cells was observed for all three subsets in CCRL2-/- mice 
compared to control ones (Fig. 14).  
 
 
Figure 14. CCRL2 deficiency is associated with a reduction in T cell subsets in 
BAL. Mice were sensitized as reported in Fig.13, challenged and sacrificed. T cell 
subsets (CD3+CD4+: T helper cells, CD4+ST2+: Th2 cells and CD3+CD8+: cytotoxic 
T cells,) were determined by FACS. Data are mean ± SEM of one representative 
experiment of the three performed with 6 to 12 mice per group; *P<0.05.  
 
However, a possible direct role for CCRL2 in the recruitment of eosinophils and T 
cells into the airways was ruled out by the lack of expression of CCRL2 in these two 
cell types; conversely BAL MHCII+ cells (macrophages and DC) expressed CCRL2 
(Fig. 15).  
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Figure 15. CCRL2 membrane expression on BAL leukocytes by FACS analysis. 
MHCII+ cells (macrophages and DC), eosinophils (Gr-1) and T lymphocytes (CD3) 
were analyzed. Histograms represent staining of cells from WT (open curves) and 
CCRL2-/- mice (filled curves) with anti-CCRL2 mAb. The data shown correspond to a 
representative experiment out of three performed with 6 to 12 mice per group  
 
In allergic asthma, genetically susceptible individuals mount a chronic Th2 cell type 
immune response to common allergens, by secreting cytokines like IL-4, IL-5, IL-9, IL-
10, IL-13 and GM-CSF 384. Individually, these cytokines can already explain many of 
the salient features of asthma as IgE synthesis, growth and activation of eosinophils and 
mast cells and expression of cytokines and EC-adhesion molecules 385. 
In parallel, Th2 and Th1 cytokines were measured in BAL from WT and CCRL2-/- 
mice. BAL of CCRL2-/- mice contained lower levels of the Th2 cytokines IL-4 and IL-
5, and similar levels of IL-13 and of the Th1 cytokine IFNγ (Fig. 16A). Of note, 
although Th2 cells and eosinophils represent an important source for Th2 cytokines, IL-
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13 can also be secreted by lung smooth muscle cells 556. This may explain the different 
regulation of IL-13 versus IL-4 and IL-5 here observed. 
 
 
 
 
Figure 16. Cytokine and chemokine levels in BAL. (A) Cytokines and (B) 
chemokines, were measured in BAL. Data are mean ± SEM of one representative 
experiment of three performed with 6 to 12 mice per group; *P<0.05; **P<0.01 
 
The development and maintenance of asthma correlates with the coordinated 
production of chemokines which guide leukocyte recruitment to different lung 
compartments 97. To further examine the mechanisms associated with the defective 
leukocyte recruitment observed in CCRL2-/- mice, the levels of some relevant 
chemokines in allergic lung inflammation were evaluated. The eosinophil-attracting 
chemokine CCL11/eotaxin and the Th2-attracting chemokine CCL17/TARC levels 
were significantly decreased in BAL, while there were no differences for CCL22, CCL2 
A 
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and CCL5 (Fig. 16B). This finding is consistent with the decreased number of 
eosinophils and Th2 cells observed in the airway lumen. 
 
3.1.2. Minor role of CCRL2 in lung parenchyma inflammation. 
The alterations observed in the BAL from CCRL2-/- mice were not paralleled by 
changes in the lung parenchyma, where normal degrees of infiltrating leukocytes (Fig. 
17A) and Th cells (Fig. 17B) were detected. 
 
 
Figure 17. Leukocyte composition of lung parenchyma. WT and CCRL2-/- mice 
were sensitized and challenged with OVA by aerosol. Lungs were collected twenty-four 
h after the last aerosol and a cell suspension was obtained after treatment with 
collagenase/DNase. (A) Differential cell count was carried out. (B) T cell subsets 
(CD3+CD8+: cytotoxic T cells, CD3+CD4+: T helper cells and CD4+ST2+: Th2 cells) 
Lymph Macr Eos Total 
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were determined by FACS. Data are mean ± SEM of one representative experiment of 
two performed with 12 mice per group. 
The levels of cytokines, IL-4, IL-5, IL-13 and IFNγ, measured in the BAL and 
expressed as pg/ml, resulted similar in CCRL2-/- mice compared to control ones (Fig. 
18A). Similarly, no difference was observed in the expression of CCL11, CCL17 and 
CCL22 chemokines between CCRL2-/- and WT mice, while CCL2 and CCL5 levels 
were decreased in CCRL2-/- mice (Fig. 18B). The fact that the levels of chemokines 
recruiting eosinophils and Th2 cells are similar in WT and CCRL2-/- mice is consistent 
with the equal amounts of infiltrating leukocytes observed in the lung parenchyma of 
WT and CCRL2-/- mice. 
 
 
Figure 18. Cytokine and chemokine levels in lung parenchyma. (A) Cytokines and 
(B) chemokines were measured in lung parenchyma Data are mean ± SEM of one 
representative experiment of two performed with 12 mice per group; *P<0.05 
B 
A 
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3.1.3. CCRL2 does not modify typical features of asthma 
Asthma is characterized by allergen specific IgE production by B cells 391. To 
determine whether CCRL2 deficiency was associated with a defective Th2 dependent 
humoral response, circulating levels of total and OVA specific IgE were determined in 
serum. OVA-sensitized CCRL2-/- mice showed normal levels of circulating total and 
OVA-specific IgE (Fig. 19). This finding is consistent with the ability of CCRL2-/- 
mice to mount a normal primary and secondary humoral response following i.p. 
immunization with OVA/Alum or OVA/complete Freund’s adjuvant (data not shown). 
 
 
 
Figure 19. Total and OVA specific IgE in serum. Total IgE and OVA specific IgE 
were measured in serum of WT and CCRL2-/- mice. Data are mean ± SEM of one 
representative experiment of three performed with 6 to 12 mice per group.  
 
Finally, the typical features of asthma, namely AHR and mucus hypersecretion were 
assessed in OVA-sensitized CCRL2-/- and WT mice. Both strains showed a significant 
increase in methacholine responsiveness evaluated as lung resistance (Fig. 20A, B) and 
dynamic compliance (Fig. 20C), that was however similar in the two mouse strains. 
Similarly, OVA-sensitized CCRL2-/- and WT mice displayed a comparable number of 
goblet cells (Fig. 20D). 
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Figure 20. Functional parameters measured in CCRL2-/- mice subject to an OVA-
induced airway inflammation model. (A) Penh (B) Resistance (C) Compliance and 
(D) mucus production. This last parameter was determined by scoring the samples 
according to the number of globet cells as described 553. Data are mean ± SEM of one 
representative experiment of three performed with 6 to 12 mice per group. 
 
3.1.4. CCRL2 dos not modify lung DC infiltrate after allergen challenge 
The migration of lung DC from periphery to regional lymph nodes is a key step for 
the induction of immune response and tolerance 132, 531, 557. Therefore, lung DC 
trafficking was investigated in OVA-challenged CCRL2-/- mice. Mice were sensitized 
with OVA at 0 and 11th day and then challenged with one 5% OVA aerosol at day 18. 
Lung tissue was collected at different time points after aerosol and tissue cell 
suspension was prepared as indicated in “Materials and Methods”. Lung DC were 
identified by FACS as CD11c+MHCII+ cells. The alveolar space is rich in macrophages 
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that can be confused with alveolar DC for their high expression of CD11c, however, 
unlike DC, alveolar macrophages show high autofluorescence, that lets discriminate 
them from DC population 558. In agreement with previous reports 213, 444, Figure 21 
shows that the influx of DC into the lung was already detectable after 2 h of OVA 
challenge and reached peak levels at 24 h. No significant difference in the absolute 
number of DC (Fig. 21), neither in their activation phenotype (evaluated as CD80, 
CD86, CD40 and MHCII surface expression, data not shown) was found between 
CCRL2-/- and WT mice at any of the time points investigated.  
 
 
Figure 21. Lung DC number after allergen challenge. Lung tissue and trachea were 
isolated from sensitized mice after one OVA-aerosol challenge. DC 
(CD11c+MHCII+low autofluorescence cells) were quantified by FACS analysis at 
different times points after aerosol Results are expressed as total number of DC per 
mouse. Data are mean ± SEM of one representative experiment of three performed with 
6 mice per group. 
 
Different subsets of DC can be found in the lungs. In steady-state conditions, 
conventional DC (CD11chighMHCIIhigh) are found lining the conducting airways and in 
the deeper interstitial compartments, subdivided into CD11b+ and CD11b− subsets. 
CD11b- express langerin and the mucosal integrin CD103 (aEb7) at least in mouse and 
rat 393. P-DC are found in both compartments with a slight preference for the interstitial 
Results 98 
compartment. P-DC are CD11cint and express Siglec-H, and BST-2 (recognized by 
PDCA1 antibody) and some markers shared with granulocytes and B cells 223, 437. Under 
inflammatory conditions, additional CD11b+ monocytes are recruited to the lungs 
where they rapidly become DC (CD11c+CD11b+) and can easily be confused with 
resident CD11b+ conventional DC 81, 101, 102. DC subsets show distinctive functions, 
thus an analysis of the subsets could be useful for the understanding of the differences 
seen between WT and CCRL2 -/- mice. Lungs of sensitized mice challenged by one 
OVA aerosol were thus analyzed by FACS Similarly to the results observed for total 
DC population in lung, no difference was observed in the relative proportion of the 
three major lung DC subsets, namely, myeloid CD103+ and CD11b+ DC and P-DC 
(Fig. 22).  
 
 
Figure 22. Lung DC subset composition after allergen challenge. Lung cell 
suspensions from OVA sensitized mice were obtained 24 h after one OVA-aerosol 
challenge. CD11c+MHCII+ cells, representing a mixture of lung macrophages and DC 
were initially gated. A further gate for the low autofluorescence population was drawn 
for pulmonary DC (left panel; results are expressed as the percentage of CD+/low 
autofluorescence DC in total lung CD11c+MHCII+ cells) and exclude lung 
macrophages. The three main pulmonary DC subsets (CD103+, CD11b+, and Siglec 
H+/PDCA1+ P-DC ) were discriminated inside the DC population (right panel). Data 
are mean ± SEM of one representative experiment of three performed with 6 mice per 
group. 
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Furthermore, the in vivo distribution of DC subsets was investigated by 
immunohistochemistry of lung frozen tissue sections. CD103+ cells were mainly 
identified in the peri-bronchiolar space lining the conducting airways. Siglec H+ and 
CD11c+ cells were localized in the peri-bronchiolar space admixed to other immune 
cells as well as in the interstitial space of the lung parenchyma. CD11c stain was also 
observed in large cells located in the alveolar space likely reflecting expression by 
alveolar macrophages. However, no difference was observed between WT and CCRL2-
/- mice in the distribution of these DC subsets in either resting or OVA-stimulated 
conditions (Fig. 23). 
 
 
Figure 23. Localization of lung DC. CCRL2-/- and WT mice were sensitized with 
OVA and subsequently challenged with one OVA aerosol. Lung tissue was isolated 24h 
after aerosol. Representative sections are from frozen mouse lungs. Experimental 
conditions and antibody used are in the panels. CD103+ cells are regularly found 
observed in the peribronchiolar space (a-d). Round to oval Siglec H+ and CD11c+ cells 
increase significantly in number upon OVA stimulation in both WT and KO and are 
located either in the peribronchiolar space as well as in the interstitium of lung 
parenchyma. Scale bars: 100 micron. 
 
 
Results 100 
3.1.5. CCRL2 affects the DC traffic to regional lymph nodes 
Migration of pulmonary DC to draining lymph nodes is a key step in the initiation of 
the allergic response in the lung 547. In order to study the migration of airway DC, 
OVA-sensitized animals were instilled intratracheally with a single administration of 
OVA conjugated with the fluorescent dye FITC. This treatment is known to induce lung 
DC maturation and mobilization 213. Mice were sacrificed 0, 8, 24, 48 or 72 h later and 
CD11c+FITC+ DC were enumerated in mediastinal draining lymph nodes. 
Figure 24A reports that the migration of FITC+ DC was already detectable after 8 h 
stimulation and reached a peak at 24 h, as previously reported 213. CCRL2-/- mice 
showed a statistical significant reduction in FITC+ DC trafficking to lymph nodes at 48 
and 72 h after antigen administration. Of note, airway-derived FITC+ DC expressed 
CCRL2, while FITC- DC, which correspond to resident mediastinal lymph nodes DC, 
did not (Fig. 24B). These results highlight a crucial role of CCRL2 in directing 
pulmonary DC migration to draining lymph nodes. 
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Figure 24. Lung DC migration to mediastinal lymph nodes. OVA-sensitized mice 
received i.t. 800 µg OVA FITC. (A) Representative FACS analysis of WT and CCRL2-
/- mediastinal lymph nodes cells obtained 48 h after FITC-OVA administration. (B) 
Kinetics of FITC+ DC in lymph nodes. (C) Surface expression of CCRL2 in lymph 
node FITC+ and FITC- WT DC after OVA-FITC administration. Data are mean ± SEM 
of three (B) or two (C) representative experiments with 4 to 15 mice per group; * P 
<0.05. 
 
3.1.6. CCRL2 does not affect generation and functions of bone-marrow in vitro 
derived DC. 
In order to investigate the molecular basis for the defective migration of lung DC, 
experiments were performed using BM-DC. In vitro, DC generated from CCRL2-/- and 
WT bone marrow progenitors were similar in terms of cell yield (number of harvested 
A B 
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DC/number of seeded CD34+ progenitor cells), expression of membrane markers 
(CD11c, CD11b, MHCII, DEC205) and costimulatory molecule (CD80, CD86) (Fig 
25A), and in their ability to take up antigens (Fig. 25B). These results postulate that 
CCRL2 deficiency does not interfere with DC development and maturation in vitro.  
 
 
Figure 25. Characterization of CCRL2-/- bone marrow derived DC (BM-DC). 
Immature DC and mature DC (20ng/ml of TNF-α for 24 h) were generated from WT 
and CCRL2-/- mice.(A) Expression level of six different cell surface markers was 
determined by FACS. (B) Antigen uptake capacity was evaluated by pinocytosis of 
FITC-dextran. Data are representative of at least three independent DC cultures.  
 
Considering the importance of chemokine/chemokine receptors in DC traffic and 
its consequent effect in the development of asthma, DC from CCRL2-/- mice were 
also tested for the expression and function of chemotactic receptors. 
When evaluated at the mRNA level, CCRL2-/-DC showed a normal expression of 
the chemokine receptors CCR1, CCR2, CCR5, CXCR4 and CXCR6 and CCR7 
(Fig.26). Expression of CCR-3, -4, -6, -8, -9, CXCR -1, -2, -3, -5, -7, CX3CR1 and 
XCR1 was low in both WT and CCRL2-/- DC (less than 500 mRNA molecules per 106 
β-actin molecules) and was not modulated during maturation (data not shown). 
A B 
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Figure 26. Expression of chemokine receptors by CCRL2-/- BM-DC. Bone marrow 
derived immature DC and mature DC (20ng/ml of TNF-α for 24 h) from CCRL2-/- and 
WT mice were evaluated for the expression of chemokine receptors by RT-PCR. Levels 
of β actin mRNA were used to normalize the measurements. Data are representative of 
at least three independent DC cultures. 
 
When tested in chemotaxis assays, immature CCRL2-/-DC showed a normal in vitro 
migration to CCL5 and chemerin, and a slightly reduced response to CCL3 and 
CXCL12, a chemokine constitutively expressed in many tissues 559, although it is 
preferentially expressed in lymph nodes, lung, liver, and bone marrow 560. Mature 
CCRL2-/- DC were competent in migrating to CCL19, a CCR7 ligand (Fig. 27)  
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Figure 27. Chemotaxis of bone marrow-derived DC. One experiment representative 
of six, each one performed with independent DC cultures. CCL3, CCL5, CXCL12 and 
chemerin migration are shown for immature DC. CCL19 migration is shown for mature 
DC (20 ng/ml). Results are at the net of basal migration (10±3 and 8±2 cells 
respectively). Data are mean ± SEM of one experiment representative of six, each one 
performed with independent cell cultures, * P <0.05. 
 
Finally, CCRL2-/- mice DC were also evaluated for their ability to migrate in vivo. 
Skin painting experiments did not reveal any alteration in the in vivo migration ability 
of endogenous CCRL2-/- DC (Fig. 28). Altogether, these results exclude the possibility 
that CCRL2 deletion may be associated to a major alteration in the expression and 
function of DC chemotactic receptors. 
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Figure 28. In vivo migration of CCLR-/- DC. WT and CCRL2-/- mice were sensitized 
with FITC on their shaved abdominal skin. Number of FITC+/CD11c+ DC in draining 
lymph nodes following FITC skin painting was determined by FACS at different times. 
Data are mean ± SEM of one representative experiments of three performed with 5 mice 
per group. 
 
3.1.7. Defective lymphocyte priming in mediastinal lymph node of CCRL2-/- mice  
The anti-OVA specific immune response was evaluated using cells collected from 
lung draining lymph nodes. For this purpose, lymph nodes from sensitized mice and 
challenged by treatment for 6 consecutively days with aerosolized OVA were collected 
24 h after the last aerosol challenge, homogenized, and cell suspensions analyzed. 
Consistently with the reduced migration of antigen-loaded DC, mediastinal lymph 
nodes from CCRL2-/- mice showed a 2-fold reduction in total cellularity (Fig. 29A) and 
a significant reduction in the percentage of CD11c+MHCII+ cells (Fig. 29B).  
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Figure 29. Impaired migration of CCRL2-/- DC to mediastinal lymph nodes. WT 
and CCRL2-/- mice were sensitized and challenged by treatment for 6 consecutively 
days with aerosolized OVA. Mediastinal lymph nodes were collected 24 h after the last 
aerosol. (A) Total cell and (B) Percentage of DC (CD11c+MHCII+) were determined. 
Data are mean ± SEM of 10 to 20 mice/group from 3 separate experiments. *, P <0.05; 
**, P <0.01. 
 
In allergic asthma, activated DC produce pro-inflammatory cytokines as TNF-α, IL-
1, IL-6, IL-10 482-484, 561 that drive to differentiation of naïve CD4 Th cells in the 
paracortex of the draining node toward a Th2 phenotype 487. The ability to prime naïve 
CD4+ T cells constitutes a unique and critical function of DC. The quality of T cell 
priming by DC is critical in asthma development since Th2 primed cells will secrete 
cytokines that will explain many of the salient features of asthma 385. We then asked 
whether deficient CCRL2-/- DC migration to mediastinal lymph node has an impact on 
local type-2 cytokine production by T cells. Mediastinal lymph node cell suspensions 
were restimulated with OVA and Th1/Th2 cytokine levels assessed in culture 
supernatants. As shown in Figure 30, at the end of 4-day culture, WT cells secreted IL-5 
and IL-13 at levels that were significantly higher than those detected using cells from 
CCRL2-/- lymph nodes. In the same experiments, IL-4 and IFNγ levels were below the 
assay detection limit. 
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Figure 30. Impaired cytokine production by restimulated lymph nodes from 
CCRL2-/- mice. WT and CCRL2-/- mice were treated as explained in Fig. 29. Lymph 
node cell suspension was obtained 24 h after last aereosol exposure and cells were 
restimulated ex vivo with OVA for 96 h. Expression of Th1/Th2 cytokines was assessed 
by ELISA. Data are mean ± SEM of 10 to 20 mice/group from 3 separate experiments. 
*, P <0.05; #: undetectable levels. 
 
To investigate the specific role of CCRL2 in elicitation of the Th2 response in vivo, 
WT mice were sensitized with OVA at days 0 and 11, and at days 18 and 20 received 
the i.t. injection of OVA-pulsed DC generated from either WT or CCRL2-/- mice. 48 h 
after the last DC instillation, mediastinal lymph node cells were collected and cultured 
in vitro in the presence of OVA for 96 h. As shown in Figure 31, cells obtained from 
mice that had received WT DC showed a strong Th2 response in terms of IL-5 and IL-
13 production that was not further stimulated by the in vitro addition of OVA. The lack 
of response to OVA in vitro is possibly due to the high concentration of the antigen 
used to load DC before adoptive transfer. On the contrary, lymph nodes cells from mice 
that had received CCRL2-/- DC showed very modest response, that could be elicited in 
a dose-dependent manner by the in vitro addition of OVA. Cells from lymph nodes of 
mice instilled with unpulsed WT or CCRL2-/- DC did not produce IL-5 or IL-13 both 
under basal conditions and in response to OVA (data not shown). 
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Figure 31. Impaired cytokine production by adopted transfer CCRL2-/- OVA-
pulsed DC. WT or CCRL2-/- OVA-pulsed bone marrow DC were injected 
intratracheally to WT-OVA sensitized mice at days 18 and 20. 48 h later, lymph nodes 
were excised and cytokine production determined after ex vivo stimulation with OVA. 
Data are mean ± SEM of 10 to 20 mice/group from 3 separate experiments. *, P <0.05; 
**, P <0.01. 
 
3.1.8. CCRL2 does not affect DC priming ability 
The defective ability of CCRL2-/- DC to prime a Th2 response could not be ascribed 
to an intrinsic defect of CCRL2-/- DC, since they were fully active when tested for their 
allostimulatory capacity in mixed leukocyte reactions (MLR). Indeed, similar levels of 
CFSE-labelled CD4+ cell proliferation was observed when CD4+ T cells were cultured 
with either allogenic WT or CCRL2-/- DC (Fig 32A).  
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Figure 32. Induction of T cell proliferation by DC from WT and CCRL2-/- mice. 
BM-DC were maturated by incubation with 20 ng/ml TNF-α. CD4+ T cells were 
purified from naïve Balb/c mice. (A) CD4+T cells were CFSE-labelled and cultured 
with different ratios of DC for 72 h. The mean fluorescence intensity (MFI) and % of 
proliferative cells were analyzed by FACS as indicated in “Materials and Methods”. (B) 
Th1/Th2 cytokines measurement in MLR supernatants. Data are mean ± SEM of 5 
mice/group from 2 separate experiments (two independent DC cultures).  
 
Similarly, CCRL2-/- DC induced a normal degree of OT-II OVA-specific TCR 
transgenic CD4+ T cell proliferation, in vitro (Fig. 33A). In agreement with these 
results, similar levels of cytokines (IL-2, IL-4 and IFN-γ) were detected in the 
supernatants of T cell cultures performed with WT and CCRL2-/- DC (Fig. 32B and 
33B). 
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These results demonstrate that the defective ability of CCRL2-/- DC to prime a Th2 
response could not be ascribed to an intrinsic defect of CCRL2-/- DC since they were 
fully able to induce T cell proliferation and cytokine production. 
 
 
Figure 33. Induction of OVA specific T cell proliferation by DC from WT and 
CCRL2-/- mice. BM-DC were maturated by incubation with 20 ng/ml TNF-α. CD4+ T 
cells were prurified from naïve OT-II mice. (A) CD4+T cells were CFSE-labelled and 
cultured with different ratios of DC for 72 h. The MFI and % of proliferative cells were 
analyzed by FACS as indicated in “Materials and Methods”. (B) Th1/Th2 cytokines 
measurement in MLR supernatants. IL-4 levels were below the detection limit. Data are 
mean ± SEM of 5 mice/group from 2 separate experiments (two independent DC 
cultures). 
A A 
B 
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3.2. Role of a putative non-signalling ligand of CCRL2 in DC migration  
Chemerin has been identified as a natural non-signaling protein ligand for CCRL2. 
Chemerin binding does not trigger ligand internalization, rather, CCRL2 is able to bind 
the chemoattractant and increase local concentrations of bioactive chemerin which then 
is available for interaction with ChemR23 on adjacent cells 93. 
Chemerin is active as chemotactic factor when it binds its specific receptor 
ChemR23, a chemotactic receptor expressed by human professional APC 
(monocyte/macrophages and DC) 70 and NK 69. DC positive for ChemR23 have been 
found in close proximity of chemerin-positive human EC 71. This evidence suggests a 
key role of the ChemR23/chemerin axis in directing DC trafficking. However limited 
information are presently available on chemerin/ChemR23 system in mouse, especially 
in DC-EC interactions. 
Here we investigated the expression of functional ChemR23 in immature mouse 
bone marrow derived myeloid and P-DC and its regulation during DC maturation. 
Moreover, since DC do transmigration and reverse-transmigration to cross the wall of 
vascular and lymphatic vessels, we investigated the possible presence and modulation 
of the ChemR23 functional ligand, chemerin, on lymphatic and vascular EC, taking 
advantages of specific cell mouse cell lines generated in the laboratory in the past.  
 
3.2.1. Expression of functional ChemR23 by mouse DC 
ChemR23 has been reported to be expressed by human M-DC and P-DC 71, while its 
presence in mouse DC is still controversial 68. Thus its expression was first investigated 
in mouse BM-DC (M-DC and P-DC) by RT-PCR. 
ChemR23 transcripts were found in immature M-DC and were downmodulated by 
O.N incubation with TNF-α or LPS (Fig. 34A). LPS induced a higher downregulation 
of ChemR23 than that caused by TNF-α. Maturation markers (downregulation of CCR1 
and CCR2, and upregulation of CCR7) measured in parallel were strongly regulated by 
LPS treatment (Fig. 34). It is not surprising that ChemR23 is only partially 
downregulated by TNF-α, since TNF-α has been reported to induce a partial DC 
maturation (high expression of MHCII and costimulatory molecules, but low capacity to 
produce proinflammatory chemokines), while complete maturation is achieved only by 
strong stimuli, such as LPS 562. 
To better understand the ChemR23 pattern of expression in M-DC, cells were 
exposed to the stimuli from 1 to 48 h. ChemR23 expression decreased progressively 
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during DC maturation, the lowest value being observed at 24 h. No further decrease was 
seen at 48 h (Fig. 34B). 
 
 
Figure 34. Expression of ChemR23 by mouse myeloid BM-DC. Mouse M-DC were 
generated from CD34+ bone marrow precursors as indicated in “Materials and 
Methods”. (A) M-DCs were maturated by incubation with TNF-α (20 ng/ml) or LPS 
(100 ng/ml). CCR1, CCR2 and CCR7 expression was measured as control of 
maturation. Data are representative of two independent DC cultures. (B) Time-course 
expression of ChemR23 in M-DC stimulated with TNF-α (20 ng/ml) or LPS (100 
ng/ml). Data are mean ± SEM of 2 experiments. ChemR23 and CCRs expression was 
determined by RT-PCR. Levels of βactin mRNA were used to normalize the 
measurements.  
 
ChemR23 mRNA was also found in immature P-DC. In contrast with M-DC, 
ChemR23 expression in P-DC was not affected by CpG-induced maturation (Fig. 35), 
while DC maturation markers (CCR1, CCR2 and CCR7) were modulated as expected. 
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Figure 35. Expression of ChemR23 by mouse plasmacytoid BM-DC. Mouse P-DC 
were generated from CD34+ bone marrow precursors as indicated in “Materials and 
Methods”. P-DC were maturated by O.N incubation with CpG (2µg/ml). ChemR23 
expression was determined by RT-PCR. Levels of actin mRNA were used to normalize 
the measurements. Data are representative of one experiment of two performed. 
 
To evaluated whether ChemR23 was functional, chemerin was used as chemotactic 
factor for mouse BM-DC. As shown in figure 36A and 36B mouse chemerin promoted 
a dose-dependent migration of immature M-DC (Fig. 36A) and P-DC (Fig. 36B) with 
an optimal dose of 100 pM for both DC subsets. P-DC did not migrate to chemerin 
when used bare filters (data not shown), however the interaction with an EC monolayer 
(MELC) favoured their migration. Mature DC did not migrated to chemerin but 
normally migrated in response to CCL19. The fact that mature mouse DC are 
unresponsive to chemerin, but still express some ChemR23 mRNA, might suggest that 
maturation provokes the uncoupling of ChemR23 from its signalling pathway. 
Alternatively, or in addition, M-DC might express on the membrane too few molecules 
of the receptor to bind enough chemerin to cause an effect. The percentage of M-DC 
migrated in response to chemerin was similar to that observed in response to an optimal 
concentration of CCL3, whereas for P-DC migration was half of that induced by 
CXCL12 (chemokines used as positive controls). Chemerin, being active in the pM 
range, showed a potency approximately 100 folds higher than that of most chemokines, 
which usually peak in the nM order. These results in mouse cells are in agreement with 
those described for human cells 71, indicating that also in the mouse chemerin represents 
a chemotactic factor for immature DC. 
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Figure 36. Mouse DC migration to chemerin. (A) M-DC and (B) P-DC were tested 
for their ability to migrate to recombinant mouse chemerin. Migration to an optimal 
concentration of CCL3 (immature M-DC), CXCL12 (immature P-DC) or CCL19 
(mature DC) (100 ng/ml) was evaluated as a positive control of the experiment. 51Cr 
labelled DC were allowed to migrate for 90 min. using transwell inserts. P-DC 
migration was assayed across a MELC monolayer. Values are expressed as net 
migration (% radioactivity sample - % radioactivity control). Data are mean ± SEM of 3 
(A) or 2 (B) separate experiments (independent DC cultures). *, P <0.05; **, P <0.01. 
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To verify the role of ChemR23 in mouse DC migration, BM-DC from ChemR23-/- 
mice were generated. These DC failed to migrate  in response to chemerin, but not to 
CCL3 (M-DC) and CXCL12 (P-DC) (data not shown), suggesting that the chemerin 
effect on DC migration is exclusively mediated by ChemR23. 
 
3.2.2. Expression of chemerin by mouse haematic (1G11) and lymphatic (MELC) 
EC 
Chemerin was found by immunohistochemistry in the interfollicular compartment of 
human secondary lymphoid organs close to HEV and in skin biopsies of LE patients on 
the EC lining dermal blood vessels 71. Some chemokines detected on the surface of 
HEVs are produced by cells different from HEV cells (e.g., CCL19, CXCL12, and 
CCL2) and subsequently transported through the fibroblastic reticular cell network to 
HEVs 563, 564. In vitro, human EC of different origin (e.g., cord blood, dermis, iliac 
artery, and bone marrow) did not show any production of chemerin in basal conditions 
and after cytokine stimulation (TNF-α, IL-1, LPS, IFNα, IFNγ and combinations of 
these agonists) 71. Therefore it is unknown at the moment whether chemerin production 
is a characteristic of a specialized endothelium of an anatomical compartment or if is 
produced by nearby cells and afterward transported to EC 
Using two mouse EC lines, MELC (a lymphatic EC line) and 1G11 (a lung capillary 
vascular EC line), a basal expression was observed at RNA level (data not shown). This 
result was confirmed at protein level by measuring the amount of chemerin in cell line 
supernatants by ELISA (Fig. 37C and 37D). 1G11 cells showed a basal production of 
chemerin higher than that produced by MELC. 
Chemerin has been reported as a transcriptionally regulated gene, induced by 
calcitriol and dexamethasone in the bone stromal cell line ST2 78 in psoriatic epidermis 
after topical application of tazarotene, an antipsoriatic synthetic retinoid 79, and in 
cultured fibroblasts by calcitriol 182. Regulation of chemerin production by mouse EC 
was investigated at RNA level. Both cell lines were stimulated with RA and calcitriol 
and with different inflammatory stimuli (TNF-α, LPS, IFNγ, Il-1β)for different times 
(from 8 to 36 h). Maximal expression of chemerin mRNA was observed at 18 h (data 
not shown), therefore this time was used for all subsequent experiments. 
As shown in figures 37A and 37B an up-regulation of chemerin mRNA was observed 
in both cell lines after 18 h of stimulation with RA. The up-regulation of chemerin 
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mRNA was paralleled by an increase of the protein detected in cell supernatants (Figs 
37C and 37D). All the other stimuli assayed did not modulate chemerin production.  
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Figure 37. Expression of chemerin by mouse lymphatic MELC and haematic 1G11 
EC. Confluent mouse EC, cultured as described in “Material and Methods”, were 
stimulated with 1α,25 dihydroxycholecalciferol (calcitriol, 1µM), RA (5µM) and 
mTNF-α (20 ng/ml) in serum free medium, supplemented with 0.2 % BSA for 18 h. 
MELC (A) and 1G11 (B) chemerin mRNA levels were evaluated by RT-PCR. 18S 
mRNA gene was used to normalize the data. Values are reported as folds of induction 
over unstimulated cell levels (MELC:4,035x10-6±1,01; 1G11:113,80x10-6±8,88). 
MELC (C) and 1G11(D) mouse chemerin secretion in the supernatants was analyzed by 
ELISA. Data are mean ± SEM of 4 separate experiments. *, P <0.05; **, P <0.01. 
 
  ** 
 
   * 
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3.2.3. Chemerin is involved in DC migration across EC  
The presence of DC positive for ChemR23 in close proximity of chemerin positive 
EC, as reported 71, suggests a key role of the ChemR23/chemerin axis in directing DC 
trafficking across HEV under steady-state conditions and to peripheral tissues in 
inflammatory conditions 71. 
To verify this hypothesis the ability of EC-derived chemerin to induce DC migration 
was evaluated in vitro in transmigration experiments. MELC and 1G11 EC were 
induced to produce chemerin by stimulation with RA for 18 h. Afterward, the stimulus 
was removed and BM-DC (M-DC and P-DC) migration in chemotaxis medium was 
assayed. Figures 38A-D show that unlike immature DCs, mature M-DC and P-DC were 
not able to migrate across RA stimulated EC lines or to chemerin, suggesting a specific 
role of chemerin in DC transmigration after EC exposure to RA. In line with this 
hypohtesis, DC from ChemR23-/- mice did not migrate in the same experimental 
conditions (Data not shown).  
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Figure 38. Transmigration of myeloid and plasmacytoid BM-DC across retinoic 
acid-activated EC. Panels (A) and (B) show M-DC migration across monolayers of 
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MELC (A) and 1G11 (B), stimulated with RA (5 µM) for 18 h. Migration in response to 
recombinant mouse chemerin (30 and 100 pM) or to an optimal concentration of CCL3 
(immature DCs), CCL19 (mature DCs) (100 ng/ml) was evaluated as a positive control. 
Panels (C) and (D) show mouse P-DC migration across RA stimulated MELC (C) and 
1G11 (D) monolayers. Migration in response to recombinant chemerin (10 and 100 pM) 
or to an optimal concentration of CXCL12 (immature DCs) or CCL19 (mature DCs) 
(100 ng/ml) was evaluated as a positive control. 51Cr labelled DC were allowed to 
migrate across EC for 90 min. using transwell inserts. Values are expressed as net 
migration (% radioactivity sample - % radioactivity control). Data are mean ± SEM of 2 
experiments. * p <0.05 versus immature DC. 
 
To exclude that BM-DC could have migrated in response to other chemokines 
produced by stimulated EC, chemokines known to be involved in immature DC 
migration (CCL3, CCL4, CCL5, CXCL10 and CXCL12) were measured by RT-PCR in 
RA stimulated 1G11 and MELC. No up-regulation of the mRNA for any of the 
chemokine tested was found (Fig. 39). 
 
 
Figure 39. Chemokine expression by RA stimulated EC. Confluent mouse EC were 
stimulated for 18 h with RA (5µM) in serum free medium, supplemented with 0.2 % 
BSA. (A) MELC and (B) 1G11 mRNA levels for different DC attracting chemokines 
were evaluated by RT-PCR. GAPDH mRNA gene was used to normalize the data. Data 
are mean ± SEM of 2 independent experiments.  
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To definitively probe that DC migration to RA stimulated EC was mediated by 
ChemR23/chemerin system, migration using an anti-ChemR23 mAb was assayed. No 
blocking antibodies are available for mouse ChemR23, thus human DC were used in 
this part of the study. Human DC from peripheral blood (M-DC and P-DC) 
preincubated with the anti-human ChemR23 mAb 1H2 were assayed for their migratory 
capacity across a monolayer of RA stimulated EC (1G11). As shown in figures 40A and 
40B, transmigration of both M-DC and P-DC across RA-stimulated endothelium was 
completely inhibited in the presence of antibody against ChemR23 (irrelevant antibody 
did not has such inhibitory effect) without affecting transmigration to CXCL12, 
demonstrating the specificity of ChemR23 in RA effects. Migration in response to 
chemerin pre-exposed 1G11 cells or to CXCL12, performed as controls, was also 
blocked by the antiChemR23 mAb (Fig. 40A and 40B). 
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Figure 40. Transmigration of myeloid and plasmacytoid human DC across retinoic 
acid-activated EC is ChemR23 dependent. Blood DC subsets were isolated as 
described in “Materials and Methods”. Migration of (A) M-DC and (B) P-DC across a 
monolayer of EC (1G11) stimulated with RA (5 µM) for 18 h was inhibited by the 
preincubation of DC with 3 µg/ml of the 1H2 anti-ChemR23 mAb for 30 min. at 4°C. 
Cells stimulation and transmigration were performed in serum free medium, 
supplemented with BSA 0.2%. Transmigration was evaluated after 4 h incubation in 
transwell inserts. Cells in the lower compartment of the transwell were recovered and 
microscopically counted. Migration in response to chemerin (300 pM) added to EC for 
90 min. at 37 ºC in the upper chamber and to an optimal concentration (100 ng/ml) of 
CXCL12 was used as positive controls. Before DC addition, chemerin was removed, 
leaving only chemerin bound to EC. Results are reported as the net of basal migration: 
9849±649 and 5062±919 for M-DC and P-DC respectively. Data are mean ± SEM of 2 
experiments for M-DC and 4 separate experiments for P-DC. *, P <0.05; **, P <0.01. 
 
Altogether, these data suggest that EC release biologically active chemerin, that 
remains partially membrane-bound, promoting DC migration in a chemerin/ChemR23 
dependent manner.  
Since chemerin has been indicated as the natural nonsignaling ligand for CCRL2 41, 
CCRL2 expression at basal level and after RA stimulation for 18h was determined both 
in MELC and in 1G11 EC by RT-PCR (Fig. 41). 
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Figure 41. CCRL2 expression by mouse haematic (1G11) and lymphatic (MELC) 
EC stimulated in vitro with RA. Confluent mouse EC were exposed for 18 h to RA 
(5µM) in serum free medium, supplemented with 0.2 % BSA. MELC and 1G11 CCRL2 
mRNA levels were evaluated by RT-PCR. Actin mRNA gene was used to normalize the 
data. Data are mean ± SEM of 2 separate experiments. 
 
Both cell lines showed a basal expression of CCRL2, although 1G11 presented 
higher level. After stimulation with RA, CCRL2 expression increased two folds in both 
cases. The expression of CCRL2 in the same conditions in which chemerin is induced 
suggests a possible role of this receptor in chemerin presentation by EC. 
To determine wether a reduced chemerin production in lymph nodes was the cause of 
the reduced CCRL2-/- DC migration observed, chemerin expression was determined in 
mediastinal lymph nodes of WT and CCRL2-/- mice after OVA immunization and 
challenge (Fig. 42). Chemerin expression was not modulated, excluding this possibility. 
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Figure 42. Chemerin expression in mouse mediastinal lymph nodes. CCRL2-/- and 
WT mice were subjected to the OVA-induced allergic airway inflammation model. 
Lymph nodes were obtained 24 h after the 6th aerosol challenge. Chemerin mRNA 
levels were evaluated by RT-PCR. 18S mRNA gene was used to normalize the data. 
Data are mean ± SEM of one representative experiment of 2 performed with 6 mice per 
group. 
.
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4. Discussion 
 
The migration of lung DC from periphery to mediastinal lymph nodes is a key step in 
the development of airway allergy and inflammation, including asthma 361, 392, 398, 513. 
DC rapidly induce CCRL2 during maturation with a kinetic that precedes the expression of 
CCR7, the main lymph nodes homing chemokine receptor 546. To investigate the potential 
role of CCRL2 in DC biology CCRL2-deficient mice were used in an established Th2 
model of OVA-induced airway inflammation in which DC migration was shown to play a 
prominent role 392, 557. 
In this experimental model antigen-loaded DC revealed an impaired capacity to 
traffic to regional lymph nodes and this defect was associated with reduced T cell 
priming. CCL11 and CCL17 were also significantly reduced in the airways of CCRL2 
deficient mice. CCL11 has been shown to be an important chemoattractant for 
eosinophils and Th2 cells whereas CCL17 is a chemoattractant for Th2 cells 565. 
Therefore the decreased production of these two cytokines likely accounts for the 
reduced number of these two cell types in the airway lumen of CCRL2-/- mice. Indeed, 
lung eosinophils and T cells do not express CCRL2, ruling out a direct involvement of 
this receptor in their recruitment. In the lung, CCL11 and CCL17 are produced by 
epithelial and EC, whereas smooth muscle cells and alveolar macrophages are 
responsible for the production of other chemokines, such as CCL2, CCL12 and CCL22 
398, 566
. CCRL2 is expressed by bronchial epithelial cells and lung macrophages 
following OVA challenge 123. Therefore it is possible that CCRL2 deficiency in these 
additional cell types might also contribute to the reduced airway inflammation observed 
in CCRL2-/- mice. On the contrary, the degree of leukocyte infiltration and the levels of 
CCL11 and CCL17 in lung tissue were not altered. 
The levels of the Th2 cytokines IL-4 and IL-5 were reduced in both the airway lumen 
and the lung interstitium, highlighting a defect of CCRL2-/-mice in generating Th2 
responses. Consistently with these results, T cell priming in mediastinal lymph nodes 
was almost abolished in CCRL2-/- mice. Since lung antigen-specific T cell response is 
initiated in the lymph nodes, these results suggest a critical role for CCRL2 in the 
generation of local primary immune responses. Indeed, adoptive transfer experiments of 
antigen-loaded CCRL2-/- DC into WT animals support the concept that the defective 
Th2 priming in mediastinal lymph nodes was strictly associated to a defect in DC 
trafficking. On the other hand, the recruitment of circulating DC to the lung of CCRL2-
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/- mice exposed to OVA was not different from that of WT animals. This result suggests 
that this receptor is not involved in the tissue recruitment of peripheral DC. BM-DC 
generated from CCRL2-/- mice were indistinguishable from WT mice in terms of 
antigen uptake, membrane phenotype and antigen presentation capacity. Furthermore, 
CCRL2-/-DC expressed normal mRNA levels of all the chemokine receptors 
investigated and normal in vitro and in vivo migration properties, excluding the 
possibility that CCRL2 deletion might be associated to a more general alteration of the 
chemotactic receptor functions. Finally, it should be noted that in vitro, DC obtained 
from CCRL2-/-mice were fully competent in promoting the proliferation of allogeneic 
or syngeneic OT-II cells and in inducing Th2 cytokines production. Taking together, 
these results exclude an intrinsic defect of CCRL2-/- DC to promote T cell activation 
and support a role for CCRL2 in lung DC migration and function. 
In spite of the reduced cell recruitment in BAL and of the reduced Th2 priming in 
lymph nodes, lung function, assessed as methacholine responsiveness, was only slightly 
decreased. These findings suggest that, in this model, lung function correlates better 
with the leukocyte content of lung parenchyma rather than the airway lumen. Indeed, 
previous studies have shown that blocking CCL12 or CCL22 reduces leukocyte 
recruitment to the lung interstitium but not to the airway lumen; this defect was 
associated to a decrease in AHR and mucus production 405, 567. 
In the past few years, it has been proposed that CCL2, CCL5, CCL7 and CCL8 could 
bind and activate CCRL2 129. However, we (data not shown) and others 41, 107 have not 
been able to confirm these data. Of note, it have been reported that maturation of mouse 
DC in vitro causes a marked decrease in the chemotactic response towards CCL2 and 
CCL5 330, whereas CCRL2 is induced during maturation 546. CCRL2 presents a non-
canonical DRYLAIV motif and the ability of this receptor to signal is still a matter of 
debate. It was recently shown that CCRL2 binds and presents chemerin in the absence 
of receptor internalization and signalling 93. Chemerin is a chemotactic protein that has 
been recently purified and characterized as the ChemR23 ligand 70, 72. This study reports 
that chemerin induces the in vitro migration of WT and CCRL2-/- M-DC and does not 
modify the migration to CCR7 ligands (data not shown). 
The migration of DC from peripheral tissues to draining lymph nodes relies on the 
functional  expression of CCR7 and CCR8 132, 557, 568. However, CCR7 proper 
functioning requires accessory signals. In particular, it was reported that CysLT and 
their transporter protein MRP1 were required for CCR7 activity 358. It has been recently 
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reported that also LTB4, through the activation of its high affinity receptor BLT1, 
promotes CCR7 expression and function in migrating DC 382. Recent work has proposed 
that DC trafficking from peripheral tissues is controlled in a tissue-specific manner, 
with lung DC egression being independent of the expression of MRP1 361. In this work 
we show that lung DC migration is impaired in CCRL2 deficient mice. However, we 
did not observe any defect in the migration of skin DC in a model of FITC-skin painting 
and using CCRL2/- bone marrow-derived DC injected in the footpad of WT mice (data 
not shown). Therefore, we propose that MRP1-independent lung DC trafficking to 
lymph nodes may require a still unknown accessory signal provided by CCRL2.  
Our studies on the expression and function of the specific chemerin receptor 
ChemR23 in mouse immature DC and its downregulation during maturation suggest a 
prominent role of ChemR23 in homeostatic conditions. On the other hand this study 
reports that CCRL2 is rapidly induced during DC maturation, suggesting a role for this 
receptor in inflammation. Since CCRL2 was reported to bind and present chemerin to 
ChemR23 expressing cells 93, we can hypothesize a function in DC – EC interactions, 
favouring the processes that lead to DC transmigration across the endothelia. Our in 
vitro data on the basal and inducible expression of chemerin by lymphatic and blood EC 
are in favour of this hypothesis. Chemerin expression in mediastinal lymph nodes was 
not modulated in vivo by OVA immunization and challenge, excluding that the reduced 
migration of CCRL2-/- DC was the consequence of a reduced production of chemerin in 
lymph node. These results are in agreement with the hypothesis that the interaction with 
chemerin on EC is a relevant step for DC entry in lymphatic vessels. It has been 
recently reported 569 that, in addition to gut DC, also lung DC express the aldehyde 
dehydrogenase enzyme, that converts retinal to RA, especially when they are migrating 
DC. The fact that mouse EC lines exposed in vitro to RA increase the production of the 
mature active form of chemerin also fits with the hypothesis of the relevance of 
chemerin in lung DC-EC interactions. 
In summary, this study reports that CCRL2 plays a nonredundant role in lung DC 
migration to peripheral lymph nodes and that this defective DC migration is responsible 
for the reduced Th2 response observed in CCRL2-/- mice. Our results on the expression 
and regulation of ChemR23 and chemerin in DC and EC suggest one possible 
mechanism, probably among others, of the defective migration of CCRL2-/- DC. 
Therefore, CCRL2 may represent a new target for the control of lung inflammatory 
responses. 
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1G11 Lung capillary endothelial cell line 
51Cr Sodium chromate Cr-51 
AHR Airway hyperresponsiveness 
Alum Aluminium hydroxide gel 
APC Antigen presenting cell 
ATP Adenosine triphosphate 
BAL Bronchoalveolar lavage  
BDH Dibutylphtalate 
BM-DC Bone marrow derived dendritic cells 
BSA Bovine serum albumin 
BST Bone marrow stromal antigen 
cAMP Cyclic adenosine monophosphate 
CCRL2 Chemokine CC motif receptor like 2 
CCX-CKR Chemo Centrix chemokine receptor 
cDNA Complementary DNA 
CFSE Carboxyfluorescein diacetate succi- nimidyl ester 
CG Cathepsin G 
ChemR23 Chemerin receptor 
CpG Unmethylated cytosine-phosphate-guanosine 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
CysLT Cysteinyl leukotriene 
DAG Diacylglycerol 
DAMP Damage associated molecular patterns 
DARC Duffy antigen receptor for chemokines 
DC Dendritic cell 
DNA Deoxyribonucleic acid 
DOCK Dedicator of cytokinesis 
EAE Experimental autoimmune encephalomyelitis 
EC Endothelial cell 
ECGS Endothelial cell growth supplement 
EDN Eosinophil derived neurotoxin 
List of Abbreviations 130 
ELR Tripeptide motif glutamic acid-leucine-arginine  
Eos Eosinophils 
EP Prostaglandin E receptor 
ERM Ezrin, radixin, moesin family 
ESAM Endothelium selective adhesion molecule 
FACS Fluorescence Activated Cell Sorting 
FBS Fetal bovine serum 
FcεR Fc receptor for IgE 
FITC Fluorescein isothiocyanate 
Flt3L FMS-like tyrosine kinase 3 ligand 
fMLP N-formilmetionil-leucil-fenilalanina 
FPR Formyl peptide receptor  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gly Glycine 
GM-CSF Granulocyte macrophage-colony stimulating factor 
GPCR G protein coupled receptor 
GPR1 G protein-coupled receptor 1 
GTP Guanosine-5'-triphosphate  
h Hour 
HBSS Hanks' Balanced Salt Solution 
HCR Human chemokine receptor 
HDM House dust mite 
HEV High endothelial venule 
HIV Human immunodeficiency virus 
HLE Human leukocyte elastase 
HMGB1 High mobility group box 1 
HRP Horseradish peroxidase 
HSP Heat shock proteins 
i.p Intraperitioneal 
ICAM Intercellular adhesion molecule 
ICOSL Inducible costimulator ligand 
IDO Indoleamine 2,3-dioxygenase 
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ILT-3 Immunoglonulinlike transcript 3 
IP3 Inositol triphosphate 
ISP-1 Sphingosine-like immunosuppressant 1 
JAM Junctional adhesion molecule 
LC Langerhans cells 
LE Lupus erythematosus 
LFA-1 Lymphocyte function-associated antigen 1 
LOX-1 Lectin-like oxidized LDL receptor-1 
LPS Lipopolysaccharide 
LTB4 Leukotriene B4 
Lymph Lymphocytes 
LYVE-1 Lymphatic vessel endothelial receptor 1 
mAb Monoclonal antibody 
Macr Macrophages 
MAPK Mitogen activated protein kinase 
M-DC Myeloid dendritic cell 
MELC Mouse lymphatic endothelial cell 
MFI Mean fluorescence intensity 
MHC Major histocompatibility complex 
Min. Minute 
MLR Mixed leukocyte reaction 
MMP Matrix metalloproteinase 
mRNA Messenger RNA 
MRP1 Multidrug resistance protein 1 
MS Multiple sclerosis 
MWCO Molecular weight cutoff 
NEAA Non essential aminoacids 
NK Natural killer 
NLR NOD like receptor 
O.N Overnight 
OLP Oral lichen planus 
OmPA Outer membrane protein 
OVA Ovalbumin 
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PAF Platelet activating factor 
PAMP Pathogen associated molecular pattern 
PAR Protease activated receptor 
PAS Periodic acid Schiff 
PBS Phosphate buffered saline 
P-DC Plasmacytoid dendritic cell 
PDL Programmed death ligand 
PGD2 Prostaglandin D2 
PGE2 Prostaglandin E2 
Phe Phenylalanine 
PI3Kγ Phosphatidilinositol-3 kinase γ 
PIP2 Phosphatydilinositol 4,5 biphosphate 
PIP3 Phosphatydilinositol 3,4,5 triphosphate 
PKC/B Protein kinase C/B 
PLC Phospholipase C  
PMN Polymorphonuclear 
PNAd peripheral node addressin 
PPAR-γ Peroxisome proliferator-activated receptor γ 
PR3 Proteinase 3 
PRR Pattern-recognition receptor 
PSGL1 P-selectin glycoprotein ligand-1 
PTEN phosphatase and tensin homolog 
PTX Pertussis toxin 
PTX3 Pentraxin 3 
R.T Room temperature 
RA Retinoic acid 
RANKL Receptor Activator for Nuclear Factor κ B Ligand 
RNA Ribonucleic acid 
RSV Respiratory syncytial virus 
RT-PCR Real time polymerase chain reaction 
S1P Sphingosine-1-phosphate 
SCC Skin squamous cell carcinoma 
SCID Severe Combined Immunodeficiency 
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SIGIRR Single immunoglobulin IL-1 receptor 
SIGLEC Sialic acid-binding immunoglobulin-like lectin 
SIRPα Signal-regulatory protein α 
SPARC Secreted protein, acidic and rich in cysteine 
SREC-I Scavenger receptor expressed by EC 
TGF-β Transforming growth factor β 
Th1 T helper type 1 cell 
Th2 T helper type 2 cell 
TIG 2 Tazarotene-induced gene 2 
TLR Toll like receptor 
TNF Tumor necrosis factor 
TRAIL Tumor necrosis factor-related apoptosis inducing ligand 
Tregs Regulatory T cell 
TSLP Thymic stromal lymphopoietin 
TSLPR TSLP receptor 
Tyr Tyrosine 
VCAM-1 Vascular cell adhesion molecule 
VLA-4 Very late antigen 4 
WT Wild type 
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